Sentence,class,file
"National Diabetes Factsheet, http://www.cdc.gov/diabetes/pubs/pdf/ ndfs_2007 .pdf;2007 .",Non-OADS,/arxiv_data1/oa_pdf/0f/b5/PM-12-475.PMC5068127.pdf
"The extracellular  space in the parenchyma is limited to 20% of the total CNS volume [ 2] and is filled with a  lattice-forming structure composed of hyaluronan, glycoproteins including tenascin C/R, and  This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/a8/48/nihms820043.PMC5068130.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/75/35/main.PMC5068141.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2015.11.019 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/75/35/main.PMC5068141.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 309 e310,Non-OADS,/arxiv_data1/oa_pdf/75/35/main.PMC5068141.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/86/82/main.PMC5068142.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2015.12.014 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/86/82/main.PMC5068142.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 302 e304,Non-OADS,/arxiv_data1/oa_pdf/86/82/main.PMC5068142.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b0/a3/main.PMC5068143.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2015.12.010 1008-1275/ ©2016 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universi ty.,Non-OADS,/arxiv_data1/oa_pdf/b0/a3/main.PMC5068143.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 305 e308,Non-OADS,/arxiv_data1/oa_pdf/b0/a3/main.PMC5068143.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7d/ab/main.PMC5068144.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2015.11.020 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/7d/ab/main.PMC5068144.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 298 e301,Non-OADS,/arxiv_data1/oa_pdf/7d/ab/main.PMC5068144.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fb/bc/main.PMC5068145.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.03.005 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/fb/bc/main.PMC5068145.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 290 e294,Non-OADS,/arxiv_data1/oa_pdf/fb/bc/main.PMC5068145.pdf
"5, e1212686 (2 pages)http://dx.doi.org/10.1080/23723556.2016.1212686",Non-OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
Adv Genomics Genet 2014; 4:95-106; http://dx.doi.org/10.2147/ AGG.S54184 2.,OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
Leuke-mia 2014; 28:241-7; PMID:24220272; http://dx.doi.org/10.1038/leu.2013.336 3.,OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
Mol Cell 2016; 62:479-90; PMID:27184077; http://dx.doi.org/ 10.1016/j.molcel.2016.04.011 4.,OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
Can- cer Cell 2015; 27:631-43; PMID:25965570; http://dx.doi.org/10.1016/j.ccell.2015.04.008 5.,OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
J Clin Invest 2015; 125:42-6; PMID:25654549; http://dx.doi.org/10.1172/JCI73941 6.,Non-OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
Free Radic Res 2015; 49:1081-94; PMID:25968944; http://dx.doi.org/10.3109/10715762.2015.1035268 7.,OADS,/arxiv_data1/oa_pdf/fd/70/kmco-03-05-1212686.PMC5068173.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which per- mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"1, e1228499 (4 pages)http://dx.doi.org/10.1080/19381980.2016.1228499",Non-OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"J Cell Biol 2004; 164:769-79; PMID:14993236; http://dx.doi.org/10.1083/jcb.200307137 [2] Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk.",OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"Cancer Sci 2006; 97:341-7; PMID:16630129; http://dx.doi.org/10.1111/j.1349-7006.2006.00188.x [ 4 ] K i v i s a a r iA K ,K a l l a j o k iM ,A l a - a h oR ,M c G r a t hJ A ,B a u e rJ W , K€onigov /C19a R, Medvecz M, Beckert W, Gr /C19enman R, K €ah€ari VM.",Non-OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"Eur J Cell Biol 2011; 90:527-35; PMID:21194787; http://dx.doi.org/10.1016/j.ejcb.2010.11.005 [6] Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M,Lemmon V, et al.",OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"J Cell Biol 2001; 155:661-73; PMID:11706054; http://dx.doi.org/10.1083/jcb.200101099 [ 7 ] R e i s sK ,M a r e t z k yT ,L u d w i gA ,T o u s s e y nT ,d eS t r o o p e rB , Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin andregulation of cell-cell adhesion and beta-catenin nuclear sig-nalling.",OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"EMBO J 2005; 24:742-52; PMID:15692570; http://dx.doi.org/10.1038/sj.emboj.7600548[8] Arima T, Enokida H, Kubo H, Kagara I, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Idesako T,et al.",OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"Cancer Sci 2007; 98:1720-6; PMID:17727679; http://dx.doi.org/10.1111/j.1349-7006.2007.00601.x [9] McCulloch DR, Akl P, Samaratunga H, Herington AC, Odorico DM.",Non-OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
Clin Cancer Res 2004; 10:314-23; PMID:14734484;http://dx.doi.org/10.1158/1078-0432.CCR-0846-3e1228499-4 S.-T. OH ET AL.,Non-OADS,/arxiv_data1/oa_pdf/f9/43/kder-08-01-1228499.PMC5068181.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
"5, e1199265 (3 pages)http://dx.doi.org/10.1080/23723556.2016.1199265",Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Nat Rev Mol Cell Biol 2009 Apr; 10(4):265-75 Erratum in: Nat Rev Mol Cell Biol 2009 May; 10(5):364; PMID:19305416; http://dx.doi.org/10.1038/ nrm2653 2.,Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Epub 2009 Apr 13; PMID:19364923; http://dx.doi.org/10.1083/jcb.200812045 3.,Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
J Cell Biol 2015 Mar 16; 208(6):661-9;PMID:25753036; http://dx.doi.org/10.1083/jcb.201408064 4.,OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Cell Rep 2016 Apr 19; 15(3):510-8;PMID:27068477; http://dx.doi.org/10.1016/j.celrep.2016.03.049 5.,OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Chem Bio Chem 2016 Apr 15; 17(8):650-6; PMID:2666 2918; http://dx.doi.org/10.1002/cbic.201500580 6.,OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Anti Cancer Drugs 2013 Nov; 24(10):999-1006; PMID:23949254; http://dx.doi.org/10.1097/CAD.0000000000000007 7.,Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Cell 2011 Mar 4; 144(5):646-74; PMID:21376230; http://dx.doi.org/ 10.1016/j.cell.2011.02.0138.,OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
J Clin Oncol 2016 Mar 1; 34(7):706-13; PMID:26755507; http://dx.doi.org/10.1200/JCO.2015.62.1474 9.,Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
Leukemia 2015 Jan; 29(1):11-9; PMID:25027517; http://dx.doi.org/10.1038/leu.2014.222 10.,Non-OADS,/arxiv_data1/oa_pdf/91/0d/kmco-03-05-1199265.PMC5068183.pdf
"The Data Supplement is available at http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.116.004940/-/DC1.Correspondence to Derek J. Hausenloy, PhD, Cardiovascular and Metabolic Diseases Program, Duke-NUS Graduate Medical School Singapore, 8  College Rd, Singapore 169857.",Non-OADS,/arxiv_data1/oa_pdf/ad/28/hci-9-e004940.PMC5068185.pdf
"E-mail derek.hausenloy@duke-nus.edu.sgResidual Myocardial Iron Following Intramyocardial  Hemorrhage During the Convalescent Phase of Reperfused  ST-Segment–Elevation Myocardial Infarction and Adverse  Left Ventricular Remodeling Heerajnarain Bulluck, MBBS; Stefania Rosmini, MD, PhD; Amna Abdel-Gadir, MBBS;   Steven K. White, MBChB; Anish N. Bhuva, MBBS; Thomas A. Treibel, MBBS;   Marianna Fontana, MD, PhD; Manish Ramlall, MBChB; Ashraf Hamarneh, MBBS;   Alex Sirker, PhD; Anna S. Herrey, MD, PhD; Charlotte Manisty, PhD;   Derek M. Yellon, MSc, PhD; Peter Kellman, PhD; James C. Moon, MD;   Derek J. Hausenloy, PhDMyocardial Infarction Circ Cardiovasc Imaging is available at http://circimaging.ahajournals.org DOI: 10.1161/CIRCIMAGING.116.004940© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/ad/28/hci-9-e004940.PMC5068185.pdf
Results of our approach can be found at http://cvri.ucsf.edu/~deo/TTNtruncationvariant.html.,Non-OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
"Key Words: alternative splicing ◼ confusion ◼ dilated cardiomyopathy ◼ human ◼ mutation Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.116.001513Received March 9, 2016; accepted August 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
"The Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.116.001513/-/DC1.Correspondence to Rahul C. Deo, MD, PhD, Cardiovascular Research Institute, UCSF School of Medicine, 555 Mission Bay Blvd.",Non-OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
"The exact location of Titin   truncation variants was obtained from supplementary tables of previ-ously published work 5,8,9,17 in the case of patients with DCM or from  control databases: Exome Variant Server (http://evs.gs.washington.edu), 1000 Genomes (http://browser.1000genomes.org/), and Exome Aggregation Consortium (http://exac.broadinstitute.org).",OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
Splicing estimates are in good  agreement with those reported at https://cardiodb.org/titin/.,Non-OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
"To assist in clinical variant interpretation, I have com- piled a categorization of TTN exons for the 5 major isoforms  (RefSeq and Ensembl identifiers) at http://cvri.ucsf.edu/~deo/ TTNtruncationvariant.html.",Non-OADS,/arxiv_data1/oa_pdf/df/12/hcg-9-419.PMC5068190.pdf
http://www.iarc.fr/en/media-centre/pr/2013/pdfs/ pr223_E.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/93/ncc-39-464.PMC5068191.pdf
<http://www.canceradvocacy.org/resources/ cancer-survival-toolbox/special-t opics/living-beyond-cancer/>:2013.,Non-OADS,/arxiv_data1/oa_pdf/21/93/ncc-39-464.PMC5068191.pdf
The MET receptor tyrosine kinase is a documented oncoprotein in human cancer (visual database avail- able here: http://www.vai.org/met/).,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at https://CRAN.R-project.org/package=beeswarm.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at https://CRAN.R-project.org/package=extrafont.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at https://CRAN.R-project.org/package=RColorBrewer.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at https://CRAN.R-project.org/package=scales.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
Available at https://CRAN.R-project.org/package=gplots.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
2015.Available at https://CRAN.R-project.org/package=cluster.,Non-OADS,/arxiv_data1/oa_pdf/33/1b/CJP2-2-210.PMC5068192.pdf
"Available at:http://apps.who.int/classifications/icd10/browse/2010/en.Accessed May 6, 2011.24.",OADS,/arxiv_data1/oa_pdf/c1/ee/pec-32-658.PMC5068196.pdf
Available at: http://www.aadnc-aandc.gc.ca/eng/1100100014642.,Non-OADS,/arxiv_data1/oa_pdf/c1/ee/pec-32-658.PMC5068196.pdf
http://www.mayo.edu/research/documents/vmatchsas-05- 14-14/doc-20094471.,Non-OADS,/arxiv_data1/oa_pdf/16/25/txd-2-e103.PMC5068199.pdf
Donor Selection Criteria: Sacramento; 2015 Available from http://www.ucdmc.ucdavis.edu/trans-plant/livingdonation/donor_criteria.html.,Non-OADS,/arxiv_data1/oa_pdf/f1/a9/txd-2-0e99.PMC5068205.pdf
"A trend toward increasedrisk for primary outcome in those assigned to sirolimus persisted in different subgroups of recipients (Figure S1, SDC, http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"Delayed graft function remained the only independent risk factor in weighted multivariable models to predict BPAR during the follow-up (Table S2,SDC, http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"The observed interac- tion with diabetes mellitus remained significant (interaction, P= 0.010) (Figure S2, SDC, http://links.lww.com/TXD/A23).",OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"Presence of periglomerular fibrosis or transplant glomerulopahty in the index biopsy significantly increased the risk of graft failure in the adjusted multivariable model (Table S3, SDC, http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"Analysis of GF in different sub- groups demonstrated no significant associations (Figure S3, SDC, http://links.lww.com/TXD/A23).",OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"As- signment to sirolimus was the only significant factor inthe multivariable model (Table S4, SDC, http://links.lww.",OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"Increased risk of DWFG persisted in all the subgroups treated with sirolimus (Figure S4, SDC,http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"Group treatment remained the only independent factor in the multivariable model (Table S5, SDC, http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
"All the subgroups studied had increased risk of death while on dialysis if exposed to sirolimus-based therapy rather than tacrolimus-based therapy before graft failure (Figure S5, SDC, http://links.lww.com/TXD/A23).",Non-OADS,/arxiv_data1/oa_pdf/f0/b8/txd-2-0e98.PMC5068206.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2015.03.007 1008-1275/ ©2016 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universi ty.,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 271 e274,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/ 10.1159/000338905 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/ 10.1161/STROKEAHA.110.579888 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/ 10.1161/STROKEAHA.111.633586 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/10.1212/WNL.0b013e3181c34b47 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/10.1159/000323867 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/10.1016/ j.apmr.2010.06.019 .,OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
http://dx.doi.org/ 10.1097/HTR.0b013e3181c133e9 .,Non-OADS,/arxiv_data1/oa_pdf/41/33/main.PMC5068208.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.04.005 1008-1275/ ©2016 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universi ty.,Non-OADS,/arxiv_data1/oa_pdf/88/f7/main.PMC5068209.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 249 e250,Non-OADS,/arxiv_data1/oa_pdf/88/f7/main.PMC5068209.pdf
http://dx.doi.org/10.1056/NEJMp1500523 .,OADS,/arxiv_data1/oa_pdf/88/f7/main.PMC5068209.pdf
"http://dx.doi.org/10.1056/ NEJMsb1503104 .Table 1 Examples of precision medicine application.9 Medical ﬁeld Disease Biomarker Intervention Cancer Chronic myeloid leukemiaBCR-ABL Imatinib Lung cancer EML4-ALK Crizotinib Hematology Thrombosis Factor V Leiden Avoid prothromboticdrugs Infectious diseaseHIV/AIDS CD4 þT cells, HIV viral loadHighly active antiretroviraltherapy Cardiovascular diseaseCoronary artery diseaseCYP2C19 Clopidogrel Pulmonary diseaseCystic ﬁbrosis G551D Ivacaftor Renal disease Transplant rejection Urinary gene signatureAntirejection drugs Hematology Hepatitis C Hepatitis C viral loadDirect-acting antiviral agents Endocrine diseaseMultiple endocrine neoplasia type 2RET Prophylactic thyroidectomy Metabolic diseaseHyperlipidemia LDL cholesterol Statins Neurology Autoimmune encephalitisCXCL13 Immunotherapy Psychiatry Alcohol-use disorder GRIK1 Topiramate Pharmacogenomics Smoking cessation CYP2A6 VareniclineOphthalmology Leber's congenital amaurosisRPE65 Gene therapyZ.-G. Wang et al.",Non-OADS,/arxiv_data1/oa_pdf/88/f7/main.PMC5068209.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/8d/main.PMC5068210.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.07.001 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/a3/8d/main.PMC5068210.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 259 e263,Non-OADS,/arxiv_data1/oa_pdf/a3/8d/main.PMC5068210.pdf
http://dx.doi.org/10.1007/s00774-011-0325-1 .,Non-OADS,/arxiv_data1/oa_pdf/a3/8d/main.PMC5068210.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cc/3f/main.PMC5068211.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.009 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/cc/3f/main.PMC5068211.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 255 e258,Non-OADS,/arxiv_data1/oa_pdf/cc/3f/main.PMC5068211.pdf
http://dx.doi.org/10.1007/s11999-011-1913-z .,Non-OADS,/arxiv_data1/oa_pdf/cc/3f/main.PMC5068211.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.003 1008-1275/ ©2016 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universi ty.,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 275 e277,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1007/ s00198-011-1588-z .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1359/ jbmr.081246 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1007/s00198-008- 0563-9 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1002/jbmr.2122 .,OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/ 10.5301/HIP.2012.9762 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1093/ndt/gfs412 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.5301/hipint.5000124 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.2215/CJN.05910809 .,Non-OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
http://dx.doi.org/10.1111/ j.1365-2265.2010.03792.x .P.-F. Li et al.,OADS,/arxiv_data1/oa_pdf/48/59/main.PMC5068212.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.004 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 251 e254,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
http://dx.doi.org/ 10.1016/j.aanat.2008.05.004 .,OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
"http://dx.doi.org/10.11637/kjpa.2013.26.3.125 .22.Lippert H, Pabst R. Arterial Variations in Man: Classi ﬁcation and Frequency .",OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
2012;2:105. http://dx.doi.org/10.4172/2161-0940.1000105 .,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
http://dx.doi.org/10.1016/j.jvir.2008.08.012 .,OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
http://dx.doi.org/10.1590/ S1807-59322009000900011 .,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
http://dx.doi.org/10.1097/TA.0b013e3182050613 .,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
http://dx.doi.org/10.1007/ s00192-011-1467-3 .,Non-OADS,/arxiv_data1/oa_pdf/27/ba/main.PMC5068213.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.002 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 278 e282,Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
http://dx.doi.org/10.1097/BOT.0b013 e31822fbdbe .3.,Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
http://dx.doi.org/10.1053/j.jfas.2011.10.034 .,OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
http://dx.doi.org/10.1111/os.12057 .,Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
"2010;33:873. http://dx.doi.org/10.3928/01477447-20101021-15 .Y.-C. Meng, X.-H. Zhou / Chinese Journal of Traumatology 19 (2016) 278 e282 282",Non-OADS,/arxiv_data1/oa_pdf/49/2c/main.PMC5068214.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.03.006 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 283 e285,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
2015;25:17 e27.http://dx.doi.org/10.1007/s00590-013-1291-1 .,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
http://dx.doi.org/10.1016/j.arcped.2012.08.022 .,OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
http://dx.doi.org/10.1007/ s00132-009-1412-z .,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
http://dx.doi.org/10.1007/s00167-014- 2985-6 .,Non-OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
http://dx.doi.org/10.1016/j.clinimag.2014.07.006 .,OADS,/arxiv_data1/oa_pdf/19/fb/main.PMC5068215.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier .com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.005 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 295 e297,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
2011;2011:656205. http://dx.doi.org/10.4061/ 2011/656205 .,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
2010;2:15. http://dx.doi.org/10.1186/1758-2555-2-15 .,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
http://dx.doi.org/10.1016/j.ocl.2010.03.004 .,OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
http://dx.doi.org/ 10.1007/s11999-013-3436-2 .,Non-OADS,/arxiv_data1/oa_pdf/55/c3/main.PMC5068216.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/30/42/main.PMC5068217.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.01.017 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/30/42/main.PMC5068217.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 286 e289,Non-OADS,/arxiv_data1/oa_pdf/30/42/main.PMC5068217.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.HOSTED BY Contents lists available at ScienceDirect Chinese Journal of Traumatology journal homepage: http://www.elsevier.com/locate/CJTEE http://dx.doi.org/10.1016/j.cjtee.2016.06.008 1008-1275/ ©2016 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
This is a n open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Journal of Traumatology 19 (2016) 264 e270,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/10.1016/ j.jsr.2012.09.002 .,OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/10.1542/peds.2012-2452 .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/10.1136/emermed-2012- 201781 .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/ 10.1097/QAI.0b013e3182928e2a .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
2013;13:109. http://dx.doi.org/10.1186/1472-6963-13-109 .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/10.3163/1536- 5050.101.2.008 .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
2013;13:52. http://dx.doi.org/ 10.1186/1472-6947-13-52 .,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/10.1016/j.enfcli.2013.03.006 .,OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
http://dx.doi.org/ 10.3857/roj.2011.29.3.164 .,OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
2011;4:85 e95.http://dx.doi.org/10.1111/j.1756-5391.2011.,Non-OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
"http://dx.doi.org/10.1016/ j.ijcard.2012.09.134 .17.Frank S, Coelho EB, Boing AF.",OADS,/arxiv_data1/oa_pdf/80/72/main.PMC5068218.pdf
11  2269–2279 https://doi.org/10.1084/jem.201519752269Introduct Ion Severe myeloid cytopenia is a serious complication of radia - tion or chemotherapy and leads to profound susceptibility to  a variety of opportunistic infections.,Non-OADS,/arxiv_data1/oa_pdf/33/a1/JEM_20151975.PMC5068229.pdf
"11  2259–2267 https://doi.org/10.1084/jem.201601682259Introduct Ion Age-induced alterations in hematopoiesis, including reduc - tion in functional B and T lymphocytes and expansion of  myeloid cells, are associated with numerous hematopoietic  pathologies (Wahlestedt et al., 2015).",OADS,/arxiv_data1/oa_pdf/3d/f3/JEM_20160168.PMC5068232.pdf
11  2503–2523 https://doi.org/10.1084/jem.201603972503INT ROD UCT ION Cancer metastases at distant organs require tumor cell adap - tion.,Non-OADS,/arxiv_data1/oa_pdf/21/e8/JEM_20160397.PMC5068235.pdf
"11  2229–2248 https://doi.org/10.1084/jem.201605252229Introduction The innate lymphoid cell (ILC) family consists of a variety of  innate immune cells that lack antigen specificity, are enriched  at mucosal and barrier surfaces, and regulate immune re - sponses and tissue homeostasis (Mebius, 2003; Tait Wojno and  Artis, 2012; Spits et al., 2013; Vosshenrich and Di Santo, 2013;  Diefenbach et al., 2014; McKenzie et al., 2014; Artis and Spits,  2015).",Non-OADS,/arxiv_data1/oa_pdf/1c/77/JEM_20160525.PMC5068238.pdf
"11  2293–2314 https://doi.org/10.1084/jem.201608002293Introduct Ion Monocytes arise from common monocyte progenitors  (cMoPs) in the BM (Hettinger et al., 2013) and develop into mature Ly6Chi monocytes before being released into the blood.",Non-OADS,/arxiv_data1/oa_pdf/27/9c/JEM_20160800.PMC5068243.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/85/ircmj-18-08-38198.PMC5068247.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/3e/ircmj-18-08-34961.PMC5068248.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/bc/ircmj-18-08-23827.PMC5068249.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/52/ircmj-18-08-35086.PMC5068250.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/44/ircmj-18-08-24384.PMC5068251.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/9a/ircmj-18-08-34270.PMC5068252.pdf
"The seasonal variation of Northern Hemisphere sea ice extent (upper curves) averaged into multiyear means, from NSIDC passive microwave satellite concentration (http://nsidc.org/data/nsidc-0051), where extent is deﬁned as the area covered by concentrations /C2115%.",OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
Sea ice concentration data from SSMI/SSMMIS are available from NSIDC: http://nsidc.org/data/nsidc-0051.html.,OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
Sea iceconcentration data from AMSR2 are available from the University of Hamburg: ftp://ftp-projects.zmaw.de/seaice/AMSR2/3.125km/.,OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
Sea icecoverage from the MASIE data set is available from NSIDC: http://nsidc.org/ data/masie/.,OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
Surface winds from the MERRA dataset are available from NASA-Goddard:http://disc.sci.gsfc.nasa.gov/daac-bin/ DataHoldings.pl.,OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
Surface wind speed data from Laptev Sea coastal stationsare available from NOAA/NCEI: http://www.ncdc.noaa.gov/isd.Journal of Geophysical Research: Oceans 10.1002/2015JC011182 STEELE AND ERMOLD LOITERING OF THE RETREATING SEA ICE EDGE 7720,OADS,/arxiv_data1/oa_pdf/8b/56/JGRC-120-7699.PMC5068453.pdf
"Selection of a 20 m threshold for bubble injection is also guided by the observation that wind speeds at Sta-tion ALOHA ( <12 m s 21, Woods Hole/HOT mooring meteorological data, http://www.soest.hawaii.edu/Table 1.",Non-OADS,/arxiv_data1/oa_pdf/de/ad/JGRC-120-7381.PMC5068454.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f2/c1/ndt-12-2649.PMC5068470.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2649–2657Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2649OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11206 9 Use of the hospital anxiety and Depression scale  and the Taiwanese Depression Questionnaire for  screening depression in head and neck cancer  patients in Taiwan Yu lee1 Yi-shan Wu1 chih-Yen chien2 Fu-Min Fang3 chi-Fa hung1 1Department of Psychiatry,   2Department of Otolaryngology,   3Department of radiation Oncology,   Kaohsiung chang gung Memorial  hospital and chang gung University  college of Medicine, Kaohsiung,   Taiwan, republic of chinaObjective:  The purposes of this study are 1) to estimate the prevalence of common mental  disorders including depressive disorder in patients with head and neck cancer (HNC) at baseline  and at the 6-month follow-up and 2) to test the validity of two self-reported questionnaires,  the Hospital Anxiety and Depression Scale (HADS) and the Taiwanese Depression Questionnaire  (TDQ), for screening depression in patients with HNC.",Non-OADS,/arxiv_data1/oa_pdf/f2/c1/ndt-12-2649.PMC5068470.pdf
"Previ - ous studies have shown that patients with HNC are often comorbid with depressive  disorders.5 The reported prevalence of depressive symptoms in HNC patients varied correspondence: chi-Fa hung Department of Psychiatry, Kaohsiung  chang gung Memorial hospital,  123 Ta-Pi road, Niao-sung District,  Kaohsiung city 833, Taiwan,  republic of china Tel +886 7 731 7123 ext 6316 Fax +886 7 732 6817 email chifa@cgmh.org.t w Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Lee et al Running head recto: HADS and TDQ for screening depression DOI: http://dx.doi.org/10.2147/NDT.S112069",Non-OADS,/arxiv_data1/oa_pdf/f2/c1/ndt-12-2649.PMC5068470.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/f2/c1/ndt-12-2649.PMC5068470.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f2/c1/ndt-12-2649.PMC5068470.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2627–2633Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2627OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11179 7 shortened questionnaires to assess anxiety and  depression during in-hospital rehabilitation: clinical  validation and cutoff scores giorgio Bertolotti1 loretta Moroni1 roberto Burro2 antonio spanevello3 roberto Fe Pedretti4 giandomenico giorgetti5 1Psychology Unit, salvatore Maugeri  Foundation, irccs , scientific  institute, Tradate, 2Department of  human sciences – University of  Verona, Verona, 3Department of  cardiology, 4Division of Pulmonary  Disease, 5Department of Neuromotor  rehabilitation, salvatore Maugeri  Foundation, irccs, scientific institute  of Tradate, italyBackground:  A postacute phase needs reliable routine screening instruments in order to identify  the patients to be referred for a clinical interview with a psychologist.",Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
"Appropriate outcome measures correspondence: giorgio Bertolotti Psychology Unit, salvatore Maugeri  Foundation, irccs, Via roncaccio 16,  21049, Tradate, italy Tel +39 0331 829630 email giorgio.bertolotti@fsm.i t Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Bertolotti et al Running head recto: Brief Anxiety and Depression: clinical validation and cutoff scores DOI: http://dx.doi.org/10.2147/NDT.S111797",Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
URL https://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
Available from: http://www.R-project.org /.,Non-OADS,/arxiv_data1/oa_pdf/41/c0/ndt-12-2627.PMC5068471.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8d/78/ndt-12-2635.PMC5068472.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2635–2647Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2635Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S11418 5 Changes in behavior as side effects in  methylphenidate treatment: review of the  literature Doris Susanne Konrad- Bindl1 Ursula Gresser1 Barbara Maria Richartz2 1Department of internal Medicine,   University of Munich, Munich,   2Clinic der Jägerwinkel, Bad wiessee,   GermanyBackground:  Our review of the scientific literature focused on an analysis of studies describing  instances of methylphenidate treatment leading (or not) to behavioral changes in the pediatric,  adolescent, and adult populations.",Non-OADS,/arxiv_data1/oa_pdf/8d/78/ndt-12-2635.PMC5068472.pdf
"In 2012, Britton  stated that until 2011, not a single study had been published on the long-term effects of  treatment with methylphenidate.1 Since then, preclinical research has identified possible  changes in brain structure and function, which suggest that “early pharmacotherapy can  produce neuroadaptations that can persist long after drug treatment has ended”.1Correspondence: Ursula Gresser Outpatient Clinic for internal Medicine,  University of Munich, 5 Blombergstrasse,  Sauerlach, Munich 82054, Germany Tel +49 8104 887 822 Fax +49 8104 887 824 email ursulagresser@email.d e Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Konrad-Bindl et al Running head recto: Behavior changes during and after methylphenidate treatment DOI: http://dx.doi.org/10.2147/NDT.S114185",Non-OADS,/arxiv_data1/oa_pdf/8d/78/ndt-12-2635.PMC5068472.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/8d/78/ndt-12-2635.PMC5068472.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8d/78/ndt-12-2635.PMC5068472.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9a/87/ndt-12-2605.PMC5068473.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2605–2616Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2605Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S8485 2 Managing drug-resistant epilepsy: challenges  and solutions Linda Dalic1 Mark J Cook2,3 1Department of Neurology, Austin  Health, 2St vincent’s Hospital, Centre  for Clinical Neurosciences and  Neurological Research, 3Department  of Medicine, The University of  Melbourne, Melbourne, AustraliaAbstract:  Despite the development of new antiepileptic drugs (AEDs), ~20%–30% of people  with epilepsy remain refractory to treatment and are said to have drug-resistant epilepsy (DRE).",Non-OADS,/arxiv_data1/oa_pdf/9a/87/ndt-12-2605.PMC5068473.pdf
"For example, some epilepsy patients have multiple Correspondence: Linda Dalic Austin Health, 145 Studley Road,  Heidelberg, Melbourne 3084,  viC, Australia Tel +61 3 9496 5000 Fax +61 3 9496 4065 email linda.dalic@austin.org.a u Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Dalic and Cook Running head recto: Managing drug-resistant epilepsy DOI: http://dx.doi.org/10.2147/NDT.S84852",Non-OADS,/arxiv_data1/oa_pdf/9a/87/ndt-12-2605.PMC5068473.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/9a/87/ndt-12-2605.PMC5068473.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9a/87/ndt-12-2605.PMC5068473.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1983–2020Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1983Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S8934 1 Management of noninfectious posterior uveitis  with intravitreal drug therapy Hui Yi Tan1 Aniruddha Agarwal2 Cecilia S Lee3 Jay Chhablani4 vishali Gupta5 Manoj Khatri6 Jayabalan Nirmal7 Carlos Pavesio8 Rupesh Agrawal1,7–9 1Y ong Loo Lin School of Medicine,   National University of Singapore,   Singapore; 2Department of  vitreoretina, Stanley M Truhlsen eye  institute, University of Nebraska  Medical Center, Omaha, N e,   3Department of Ophthalmology,   University of washington, Seattle, wA,   USA; 4Department of vitreoretina,   L v Prasad eye institute, Hyderabad,   T elangana, 5Department of Retina  and Uvea, Post Graduate institute  of Medical education and Research,   Chandigarh, 6Department of Retina,   Rajan eye Care Hospital, Chennai,   Tamil Nadu, india; 7School of  Material Science and engineering,   Nanyang T echnological University,   Singapore; 8Department of Medical  Retina, Moorfields eye Hospital,   NHS Foundation Trust, London, UK;   9Department of Ophthalmology,   National Healthcare Group eye  institute, Tan T ock Seng Hospital,   SingaporeAbstract:  Uveitis is an important cause of vision loss worldwide due to its sight-threatening  complications, especially cystoid macular edema, as well as choroidal neovascularization,  macular ischemia, cataract, and glaucoma.",Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
"Systemic steroid sparing immunomodulators  such as antimetabolites (methotrexate, azathioprine, and mycophenolate mofetil) and  calcineurin inhibitors (cyclosporine and tacrolimus), among others, are often included  in the treatment plan.5 Although oral corticosteroids and immunomodulatory therapy are able to effec - tively control inflammation in the eyes, a number of systemic and ocular side effects Correspondence: Rupesh Agrawal Department of Ophthalmology, National  Healthcare Group eye institute, Tan  Tock Seng Hospital, 11 Jalan Tan Tock  Seng, Singapore 308433 email rupesh_agrawal@ttsh.com.s g Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Tan et al Running head recto: Intravitreal drugs for uveitis DOI: http://dx.doi.org/10.2147/OPTH.S89341",Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
Available from: http://www.psivida.com/products-retisert.,Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/00/a7/opth-10-1983.PMC5068474.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/80/07/ijn-11-5041.PMC5068475.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 5041–5055International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  5041OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11599 9 Nanopatterned acellular valve conduits drive the  commitment of blood-derived multipotent cells rosa Di liddo1,2 Paola aguiari3 silvia Barbon1,2 Thomas Bertalot1 amit Mandoli1 alessia Tasso1 sandra schrenk1 laura Iop3 alessandro gandaglia3 Pier Paolo Parnigotto2 Maria T eresa conconi1,2 gino gerosa3 1Department of Pharmaceutical and  Pharmacological sciences, University  of Padova, 2Foundation for Biology  and regenerative Medicine, Tissue  engineering and signaling ON lUs,   3Department of cardiac, Thoracic  and Vascular sciences, University  of Padova, Padova, ItalyAbstract:  Considerable progress has been made in recent years toward elucidating the  correlation among nanoscale topography, mechanical properties, and biological behavior  of cardiac valve substitutes.",Non-OADS,/arxiv_data1/oa_pdf/80/07/ijn-11-5041.PMC5068475.pdf
"The heart valves are characterized by a  highly compartmentalized structure enforcing mechanical adaptation to environmental  changes.13 The architectural pattern is complex and comprises 1) valvular endothelial  cells (VECs) at the blood-contacting surfaces and valvular interstitial cells (VICs) in correspondence: rosa Di liddo Department of Pharmaceutical and  Pharmacological sciences, University  of Padova, Via Marzolo 5, I-35131  Padova, Italy Tel +39 049 8275636 Fax +39 049 8275366 email rosa.diliddo@unipd.i t Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Di Liddo et al Running head recto: Differential stem cell commitment on heart valve matrices DOI: http://dx.doi.org/10.2147/IJN.S115999",Non-OADS,/arxiv_data1/oa_pdf/80/07/ijn-11-5041.PMC5068475.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/80/07/ijn-11-5041.PMC5068475.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/80/07/ijn-11-5041.PMC5068475.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/90/7e/ijn-11-5335.PMC5068476.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 5335–5347International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  5335OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11628 8 real-time colorimetric detection of DNa  methylation of the PAX1  gene in cervical scrapings  for cervical cancer screening with thiol-labeled  Pcr primers and gold nanoparticles Jin huang1,2 Yu-ligh liou1,2 Ya-Nan Kang3 Zhi-rong Tan1,2 Ming-Jing Peng1,2 hong-hao Zhou1,2 1Department of clinical Pharmacology,   Xiangya hospital, central south  University, 2Institute of clinical  Pharmacology, hunan Key laboratory  of Pharmacogenetics, central south  University, 3Department of Obstetrics  and gynecology, Xiangya hospital,   central south University, changsha,   hunan, People’s republic of chinaBackground:  DNA methylation can induce carcinogenesis by silencing key tumor suppressor  genes.",Non-OADS,/arxiv_data1/oa_pdf/90/7e/ijn-11-5335.PMC5068476.pdf
"Keywords:  colorimetric detection, gold nanoparticles, DNA methylation, cervical cancer screen - ing, UV -vis, high sensitivity, quantitative detection Introduction Cervical cancer is the second most common cancer in women worldwide and the  major cause of death in developing countries.1,2 Approximately 500,000 new cases correspondence: hong-hao Zhou Institute of clinical Pharmacology,  central south University, 110 Xiang  Ya road, changsha, hunan 410078,  People’s republic of china Tel +86 731 8480 5380 Fax +86 731 8235 4476 email hhzhou2003@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Huang et al Running head recto: Real-time colorimetric detection of DNA methylation of the PAX1  gene DOI: http://dx.doi.org/10.2147/IJN.S116288",Non-OADS,/arxiv_data1/oa_pdf/90/7e/ijn-11-5335.PMC5068476.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/90/7e/ijn-11-5335.PMC5068476.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/90/7e/ijn-11-5335.PMC5068476.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/84/c6/ijn-11-5311.PMC5068477.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 5311–5321International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  5311OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10919 9 Increased survival rate by local release of  diclofenac in a murine model of recurrent oral  carcinoma Olga Maria Will1,* Nicolai Purcz2,* athena chalaris3 carola heneweer4,5 susann Boretius1 larissa Purcz2 lila Nikkola6 Nureddin ashammakhi6 holger Kalthoff7 claus-christian glüer1 Jörg Wiltfang2 Yahya açil2 sanjay Tiwari1 1section Biomedical Imaging, clinic  for radiology and Neuroradiology,   MOIN cc, 2Department of Oral  and Maxillofacial surgery, University  hospital schleswig-holstein,   3Institute of Biochemistry, christian- albrechts-Universität zu Kiel, 4clinic  for radiology and Neuroradiology,   University hospital schleswig- holstein, Kiel, 5Institute for Diagnostic  and Interventional radiology,   University hospital cologne,   cologne, germany; 6Department  of Biomedical engineering, Tampere  University of T echnology, Tampere,   Finland; 7Institute for experimental  cancer research, University hospital  schleswig-holstein, Kiel, germany *These authors contributed equally  to this workAbstract:  Despite aggressive treatment with radiation and combination chemotherapy following  tumor resection, the 5-year survival rate for patients with head and neck cancer is at best only  50%.",Non-OADS,/arxiv_data1/oa_pdf/84/c6/ijn-11-5311.PMC5068477.pdf
"In some cases, a second primary tumor  arises in which the tumor does not share any genetic similarity to the original tumor.3 correspondence: sanjay Tiwari section Biomedical Imaging, clinic for  radiology and Neuroradiology, MOIN cc,  University hospital schleswig- holstein,  campus Kiel, am Botanischen garten 14,  24118 Kiel, germany Tel +49 431 880 5836 email stiwari@email.uni-kiel.d e Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Will et al Running head recto: Localized release of diclofenac reduces tumor recurrence DOI: http://dx.doi.org/10.2147/IJN.S109199",Non-OADS,/arxiv_data1/oa_pdf/84/c6/ijn-11-5311.PMC5068477.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/84/c6/ijn-11-5311.PMC5068477.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/84/c6/ijn-11-5311.PMC5068477.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5e/23/ndt-12-2617.PMC5068479.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 2617–2625Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  2617OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11681 1 Physical activity and self-esteem: testing direct  and indirect relationships associated with  psychological and physical mechanisms seyed hojjat Zamani sani1 Zahra Fathirezaie1 serge Brand2 Uwe Pühse3 edith holsboer-Trachsler2 Markus gerber3 siavash Talepasand4 1Department of Motor Behavior,   Faculty of Physical education and  sport science, University of Tabriz,   Tabriz, iran; 2Psychiatric clinics  of the University of Basel, center  for affective, stress and sleep  Disorders (Zass), 3Department of  sport, exercise and health, sport  science section, University of Basel,   Basel, switzerland; 4Department of  Psychology and educational sciences,   semnan University, semnan, iranAbstract:  In the present study, we investigated the relationship between physical activity  (PA) and self-esteem (SE), while introducing body mass index (BMI), perceived physical fit - ness (PPF), and body image (BI) in adults (N =264, M =38.10 years).",Non-OADS,/arxiv_data1/oa_pdf/5e/23/ndt-12-2617.PMC5068479.pdf
"SE can be defined as a person’s evalua - tive judgment of the self4 and is best understood within the framework of theoretical  models of the self.5 SE is important for a successful and satisfying life and constitutes a  fundamental aspect of psychological well-being.6 Sonstroem and Morgan’s framework  of PA and SE suggests that exercising is associated with global SE through percep - tions of self-efficacy, physical competence, and physical acceptance.7 In line with this  notion, PA has been found to be associated with higher SE among middle-aged and  healthy adults.8,9 Recently, change in SE has been shown to be significantly associ - ated with perceived athletic competence and moderate-to-vigorous PA in children.10  Moreover, two studies identified significant increases in SE following exercise correspondence: seyed hojjat  Zamani sani Department of Motor Behavior, Faculty  of Physical education and sport science,  University of Tabriz, 51666-14766,  29 Bahman Blvd, Tabriz, iran Tel +98 41 3339 3247 Fax +98 41 3339 3258 email hojjatzamani8@gmail.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Zamani Sani et al Running head recto: Relationship of PA and self-esteem  DOI: http://dx.doi.org/10.2147/NDT.S116811",Non-OADS,/arxiv_data1/oa_pdf/5e/23/ndt-12-2617.PMC5068479.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/5e/23/ndt-12-2617.PMC5068479.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5e/23/ndt-12-2617.PMC5068479.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4f/07/ijn-11-5323.PMC5068480.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 5323–5333International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  5323OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9754 1 Increased radiosensitivity of colorectal tumors  with intra-tumoral injection of low dose of gold  nanoparticles Minghan shi1 Benoit Paquette1 Thititip Thippayamontri1 louis gendron2 Brigitte guérin1 léon sanche1 1Department of Nuclear Medicine and  radiobiology, center for research  in radiotherapy, 2Department of  Pharmacology-Physiology, University  of sherbrooke, sherbrooke,   Qc, canadaAbstract:  The potential of gold nanoparticles (GNPs) as radiosensitizers for the treatment of  malignant tumors has been limited by the large quantities of GNPs that must be administered  and the requirement for low-energy X-ray irradiation to optimize radiosensitization.",Non-OADS,/arxiv_data1/oa_pdf/4f/07/ijn-11-5323.PMC5068480.pdf
"Moreover, since GNPs are expensive, correspondence: Benoit Paquette Department of Nuclear Medicine and  radiobiology, center for research  in radiobiology, Faculty of Medicine  and health science, Université de  sherbrooke, 3001, 12e avenue North,  sherbrooke, Qc, canada, J1h 5N4 Tel +1 819 346 1110x74767 Fax +1 819 564 5442 email benoit.paquette@usherbrooke.c a Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Shi et al Running head recto: Tiopronin GNPs radiosensitize colorectal cancer DOI: http://dx.doi.org/10.2147/IJN.S97541",Non-OADS,/arxiv_data1/oa_pdf/4f/07/ijn-11-5323.PMC5068480.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/4f/07/ijn-11-5323.PMC5068480.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4f/07/ijn-11-5323.PMC5068480.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/48/e1/ijn-11-5287.PMC5068481.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 5287–5310International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  5287RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S11690 2 RNA interference-based nanosystems for  inflammatory bowel disease therapy Jian Guo1 Xiaojing Jiang1 Shuangying Gui1,2 1Department of Pharmaceutics,   College of Pharmacy, Anhui University  of Chinese Medicine, 2Institute of  Pharmaceutics, Anhui Academy   of Chinese Medicine, Hefei, Anhui,   People’s Republic of ChinaAbstract:  Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s  disease, is a chronic, recrudescent disease that invades the gastrointestinal tract, and it requires  surgery or lifelong medicinal therapy.",Non-OADS,/arxiv_data1/oa_pdf/48/e1/ijn-11-5287.PMC5068481.pdf
"The mean cost for patients with UC was $5,066, and  the corresponding proportion spent on pharmaceutical therapy was ∼27%.7 The primary goal of IBD treatment is to maintain clinical remission and mucosal  concrescence.5 Conventional medicinal therapeutics for IBD can be divided into three  categories: 1) non-steroidal anti-inflammatory drugs of classic agents (eg, sulfasalazine, Correspondence: Shuangying Gui College of Pharmacy, Anhui University   of Chinese Medicine, No 1 Qianjiang  Road, Hefei 230012, Anhui,  People’s Republic of China Tel/fax +86 551 6812 9123 email guishy0520@126.co m Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Guo et al Running head recto: RNAi nanosystems in IBD therapy DOI: http://dx.doi.org/10.2147/IJN.S116902",Non-OADS,/arxiv_data1/oa_pdf/48/e1/ijn-11-5287.PMC5068481.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/48/e1/ijn-11-5287.PMC5068481.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/48/e1/ijn-11-5287.PMC5068481.pdf
"REFERENCES  [1] World Health Organization (WHO): World Malaria Report 2014  http://www.who.int/malar ia/publications/world_malaria_report_20 14/en/   [2] Ridley, R.G.",Non-OADS,/arxiv_data1/oa_pdf/c7/9f/CTMC-16-3048.PMC5068492.pdf
"[73] PlasmoDB ( Plasmodium falciparum  genomic database)  [http://www.plas modb.org]  [74] Horng, Y.C.",OADS,/arxiv_data1/oa_pdf/c7/9f/CTMC-16-3048.PMC5068492.pdf
"Given these promising results, the efficacy of polyphenols in cancer therapies are under investigation  in different clinical trials (http://www.clinicaltrials.gov/).",Non-OADS,/arxiv_data1/oa_pdf/2d/b1/ACAMC-16-1385.PMC5068501.pdf
Genetic ancestry was used as a covariate in the regression model as differences in rs1344706 allele frequencies have been observed between populations (http://www.ncbi.nlm.nih.gov/projects/ SNP/snp_ref.cgi?rs = 1344706).,OADS,/arxiv_data1/oa_pdf/7f/58/tp2015198a.PMC5068593.pdf
"Prefrontal region-of-interest delineation : The PFC was divided into ﬁve sub-regions (SFC, MFC, IFC, OFC and RG) for both left and right hemispheres by using MNIDisplay, which is a visualization tool developed by McConnel Brain Imaging Center (http://noodles.bic.mni.mcgill.ca/ServicesSoftware/HomePage) employing methods described previously.32 Each individual ’s three-dimensional cortical surface object and all three planes of their brain images were used to trace all anatomical delineations.This is to identify sulcal line markers for each sub-region.",OADS,/arxiv_data1/oa_pdf/00/ef/tp2015162a.PMC5068757.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)Schizotypy and antisocial behavior BYH Lam et al 7 Translational Psychiatry (2015), 1 –7",Non-OADS,/arxiv_data1/oa_pdf/00/ef/tp2015162a.PMC5068757.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)Chromatin remodeling properties of antipsychotic drugs E Dong et al 11 Translational Psychiatry (2016), 1 –11",Non-OADS,/arxiv_data1/oa_pdf/c7/1f/tp2015191a.PMC5068871.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Trends in Hearing 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/43/50/10.1177_2331216516670388.PMC5068923.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).T rends in Hearing 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/09/db/10.1177_2331216516673833.PMC5068924.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d0/28/40262_2016_Article_403.PMC5069300.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.novo-pi.com/ saxenda.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.novonordisk.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://ec.europa.eu/health/ documents/community-register/2015/20150323131125/anx_131125_ en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://fmdiabetes.org/ aprueba-la-cofepris-primer-tratamiento-para-el-manejo-cronico-de-la-obesidad-en-mexico/ .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.fda.gov/downl oads/Drugs/Guidances/ UCM072137.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientiﬁc_guideline/2012/07/WC500129606.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.wma.net/en/30publications/10policies/ b3/.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.ich.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/001026/WC500050017.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
Available at: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2010/022341lbl.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/64/40262_2016_Article_410.PMC5069304.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Population model to quantify everolimus PK 1455",Non-OADS,/arxiv_data1/oa_pdf/f8/8f/40262_2016_Article_414.PMC5069307.pdf
29 May 2009. http://www.ema.europa.eu/docs/e n_GB/document_library/EPAR_-_ Public_assessment_repor t/human/001038/WC500022817.pdf .,Non-OADS,/arxiv_data1/oa_pdf/f8/8f/40262_2016_Article_414.PMC5069307.pdf
2008. http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2009/022334s000_ClinPharmR.pdf .,OADS,/arxiv_data1/oa_pdf/f8/8f/40262_2016_Article_414.PMC5069307.pdf
http://www.fda.gov/ohrms/dockets/ac/05/brieﬁng/ 2005-4183B1_02_08-FDA-Clin-Pharm-Original.pdf .,Non-OADS,/arxiv_data1/oa_pdf/f8/8f/40262_2016_Article_414.PMC5069307.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/81/c9/40262_2016_Article_413.PMC5069309.pdf
"1663 version 2.2.064 (Biostat Inc. Englewood NJ USA) and  MetaXL version 5.1 (EpiGear International, http://www.epigear.com).",OADS,/arxiv_data1/oa_pdf/2c/68/134_2016_Article_4549.PMC5069310.pdf
http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort.,Non-OADS,/arxiv_data1/oa_pdf/2c/68/134_2016_Article_4549.PMC5069310.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgGemigliptin: An Update of Its Clinical Use in the  Management of Type 2 Diabetes Mellitus Sung-Ho Kim1, Jung-Hwa Y oo1, Woo Je Lee2, Cheol-Y oung Park3 1LG Life Sciences Ltd., R&D Park, Daejeon,  2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul,  3 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine,  Seoul, Korea Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Keywords:  Diabetes mellitus, type 2; Dipeptidyl-peptidase IV inhibitors; LC15-0444 Corresponding author: Cheol-Y oung Park    http://orcid.org/0000-0002-9415-9965   Division of Endocrinology and Metabolism, Department of Internal  Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of  Medicine, 29, Saemunan-ro, Jongno-gu, Seoul 03181, Korea   E-mail: cydoctor@chol.com Received: Jun.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Various studies have shown that gemi - gliptin is an optimized DPP-4 inhibitor in terms of efficacy, Review Clinical Care/Education http://dx.doi.org/10.4093/dmj.2016.40.5.339 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:339-353",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.340 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgsafety, and patient compliance for treatment of T2DM.",OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin341 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgTable 1.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.342 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgrelated to fibrosis, inflammation, and oxidative damage [19].",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin343 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgpharmacokinetic profiles of gemigliptin between dialysis and  non-dialysis periods.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.344 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgtients with an HbA1c greater than 7.5% were randomized to  gemigliptin 50 mg qd+metformin SR qd ( n=141), gemigliptin  50 mg qd ( n=142), or metformin SR qd ( n=150).",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin345 Diabetes Metab J 2016;40:339-353 http://e-dmj.orggroup) were −0.011% in gemigliptin 25 mg bid and 0.004% in  gemigliptin 50 mg qd.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.346 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgduring the 40-week extension period.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Review of efficacy and safety of gemigliptin347 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgas mono- and combination therapy slightly decreased mean  total cholesterol, low density lipoprotein cholesterol, and tri - glycerides.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.348 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgDPCL011, and LG-DPCL012.",OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin349 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgpendent of its glucose lowering effect.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.350 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgAbsorption, metabolism and excretion of [14C]gemigliptin, a  novel dipeptidyl peptidase 4 inhibitor, in humans.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Available from: https://ezdrug.mfds.go.kr (cited 2016  Aug 3).,OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin351 Diabetes Metab J 2016;40:339-353 http://e-dmj.org2014;14:165-76.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"Kim SH, et al.352 Diabetes Metab J 2016;40:339-353 http://e-dmj.org48.",Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
Review of efficacy and safety of gemigliptin353 Diabetes Metab J 2016;40:339-353 http://e-dmj.orgthe efficacy and safety of saxagliptin as add-on therapy in pa - tients with type 2 diabetes and inadequate glycaemic control  on metformin plus a sulphonylurea.,Non-OADS,/arxiv_data1/oa_pdf/26/02/dmj-40-339.PMC5069390.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgThe Effect of Bariatric Surgery on Diabetic Retinopathy:  Good, Bad, or Both?",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Keywords:  Bariatric surgery; Diabetes mellitus; Diabetic retinopathy; Microvascular complications; Obesity Corresponding author: Neil G. Docherty    http://orcid.org/0000-0002-0961-2607   Diabetes Complications Research Centre, Conway Institute of Biomolecular  and Biomedical Research, University College Dublin School of Medicine and  Medical Sciences, Belfield, Dublin 4, Ireland   E-mail: neil.docherty@ucd.ie Received: Jun.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
DR is classified as Review Complications http://dx.doi.org/10.4093/dmj.2016.40.5.354 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:354-364,Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
Bariatric surgery and diabetic retinopathy 355 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgnon-proliferative diabetic retinopathy (NPDR) and prolifera - tive diabetic retinopathy (PDR) disease with reference to  events occurring in the retinal capillary bed.,Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Gorman DM, et al.356 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgcontrol to standard treatment for T2DM have included sec - ondary endpoints that focus on ophthalmic outcomes.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Bariatric surgery and diabetic retinopathy 357 Diabetes Metab J 2016;40:354-364 http://e-dmj.orglong-term, initial worsening of DR has been reported as a con - sequence of rapid improvement of hyperglycemia.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Gorman DM, et al.358 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgfunction, improved significantly in obese patients with cardio - vascular risk factors at 9 months postbariatric surgery [41].",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
Bariatric surgery and diabetic retinopathy 359 Diabetes Metab J 2016;40:354-364 http://e-dmj.org(PPDR).,Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Gorman DM, et al.360 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgcrovascular complications compared to medical treatment.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
Bariatric surgery and diabetic retinopathy 361 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgHbA1c.,Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Gorman DM, et al.362 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgdiabetes.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
Bariatric surgery and diabetic retinopathy 363 Diabetes Metab J 2016;40:354-364 http://e-dmj.orgpairs retinal oxygen autoregulation in normal and diabetic  dogs.,Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"Gorman DM, et al.364 Diabetes Metab J 2016;40:354-364 http://e-dmj.org498-502.",Non-OADS,/arxiv_data1/oa_pdf/b8/23/dmj-40-354.PMC5069391.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/89/dmj-40-365.PMC5069392.pdf
Copyright © 2016 Korean Diabetes Association http://e-dmj.orgBlood Glucose Measurement: Is Serum Equal to  Plasma?,Non-OADS,/arxiv_data1/oa_pdf/9a/89/dmj-40-365.PMC5069392.pdf
"Hye Soon Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea Corresponding author: Hye Soon Kim    http://orcid.org/0000-0001-6298-3506 Division of Endocrinology and Metabolism, Department of Internal Medicine,  Keimyung University School of Medicine, 56, Dalseong-ro, Jung-gu, Daegu  41931, Korea E-mail: hsk12@dsmc.or.krIn 2002, the National Academy of Clinical Biochemistry  (NACB) published “Guidelines and recommendations for lab - oratory analysis in the diagnosis and management of diabetes  mellitus” [1].",Non-OADS,/arxiv_data1/oa_pdf/9a/89/dmj-40-365.PMC5069392.pdf
"Among 1,254 participants, mean glucose  concentrations for plasma and serum were 119.4±9.9 and Editorial Others http://dx.doi.org/10.4093/dmj.2016.40.5.365 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:365-366",Non-OADS,/arxiv_data1/oa_pdf/9a/89/dmj-40-365.PMC5069392.pdf
"366Kim HS Diabetes Metab J 2016;40:365-366 http://e-dmj.org108.5±6.5 mg/dL, respectively.",Non-OADS,/arxiv_data1/oa_pdf/9a/89/dmj-40-365.PMC5069392.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgSerum 25-Hydroxyvitamin D Concentration Is  Independently Inversely Associated with Insulin  Resistance in the Healthy, Non-Obese Korean  Population So Y oung Ock1, Kyoung Hwa Ha2,3, Bu Kyung Kim1, Hyeon Chang Kim4,5, Jee-Seon Shim5, Myung Ha Lee4,5, Y oung Me Y oon5,  Dae Jung Kim2,3 1Department of Endocrinology and Metabolism, Kosin University College of Medicine, Busan,  2Department of Endocrinology and Metabolism, 3Cardiovascular and Metabolic Disease Etiology Research Center, Ajou University School of Medicine, Suwon,  4Department of Preventive Medicine, 5Cardiovascular and Metabolic Diseases Etiology Research Center, Y onsei University College of Medicine, Seoul, Korea Background:  We evaluated the associations between 25-hydroxyvitamin D (25(OH)D) concentrations in serum and insulin re - sistance in the healthy Korean population.",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Keywords:  Insulin resistance; Obesity; Vitamin D Corresponding author: Dae Jung Kim    http://orcid.org/0000-0003-1025-2044 Department of Endocrinology and Metabolism, Ajou University School of  Medicine, 164, World cup-ro, Y eongtong-gu, Suwon 16499, Korea E-mail: djkim@ajou.ac.kr Received: Sep. 10, 2015; Accepted: Jan. 26, 2016INTRODUCTION Vitamin D is not only a regulator of calcium-phosphorus me - tabolism, but it also influences the onset of diseases, including  diabetes, cardiovascular disease, and cancer [1,2].",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
Original Article Epidemiology http://dx.doi.org/10.4093/dmj.2016.40.5.367 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:367-375,Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Ock SY , et al.368 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgHowever, few studies have examined the relationship between  25(OH)D concentration and insulin resistance in a healthy  Asian population.",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Vitamin D and insulin resistance369 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgvided into three categories: never smokers (if the subjects had  smoked <100 cigarettes), former smokers (≥100 cigarettes in  one’s lifetime but not currently a smoker), and current smok - ers (≥100 cigarettes and reported “currently smoking” in the  questionnaire).",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Ock SY , et al.370 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgdependently associated with high insulin resistance even after  adjustments.",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
Vitamin D and insulin resistance371 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgTable 3.,Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Ock SY , et al.372 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgWith regard to the Korean population, the Korean Genome  Epidemiology Study (KoGES)-Kangwha study reported an  inverse relationship between 25(OH)D concentrations and  HOMA-IR score, but the association was no longer present  after adjusting for sex, age, BMI, smoking status, alcohol in - take, and regular exercise [19].",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
Vitamin D and insulin resistance373 Diabetes Metab J 2016;40:367-375 http://e-dmj.orgtain more precise results.,Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"Ock SY , et al.374 Diabetes Metab J 2016;40:367-375 http://e-dmj.org17.",Non-OADS,/arxiv_data1/oa_pdf/8f/ac/dmj-40-367.PMC5069393.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgStatins Increase Mitochondrial and Peroxisomal Fatty  Acid Oxidation in the Liver and Prevent Non-Alcoholic  Steatohepatitis in Mice Han-Sol Park1,*, Jung Eun Jang2,*, Myoung Seok Ko1, Sung Hoon Woo1, Bum Joong Kim1,2, Hyun Sik Kim1, Hye Sun Park1,   In-Sun Park3, Eun Hee Koh2, Ki-Up Lee2 1Asan Institute for Life Sciences, 2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul,  3Department of Anatomy, Inha University School of Medicine, Incheon, Korea Background:  Non-alcoholic fatty liver disease is the most common form of chronic liver disease in industrialized countries.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Keywords:  Fatty acid oxidation; Non-alcoholic fatty liver disease; Peroxisomes; Statins Corresponding author: Ki-Up Lee    http://orcid.org/0000-0001-6233-6093   Department of Internal Medicine, Asan Medical Center, University of Ulsan  College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea E-mail: kulee@amc.seoul.kr * Han-Sol Park and Jung Eun Jang contributed equally to this study as first  authors.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
The overall benefits of statins seem to be  greater than what might be expected from an alteration in the Original Article Obesity and metabolic syndrome  http://dx.doi.org/10.4093/dmj.2016.40.5.376 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:376-385,Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Statins prevent NASH377 Diabetes Metab J 2016;40:376-385 http://e-dmj.orglipid profile alone, suggesting that statins have cholesterol-in - dependent pleiotropic effects [6].",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Park HS, et al.378 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgMeasurement of FAO The rate of FAO was measured as 14CO 2 generation from 14C  palmitate (NEN Life Sciences, Boston, MA, USA), as previ - ously described [19].",OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Statins prevent NASH379 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgone-way analysis of variance with the Bonferroni correction  using SPSS version 18 (SPSS Inc., Chicago, IL, USA).",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Park HS, et al.380 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgTable 2.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Statins prevent NASH381 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgbody weight, liver weight, and plasma levels of cholesterol, free  fatty acid, and TG in each experimental group.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Park HS, et al.382 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgthe gene expression of anti-oxidant enzymes: catalase, a major  peroxisomal anti-oxidant; manganese superoxide dismutase,  which exists in both mitochondria and peroxisomes; and glu - tathione peroxidase (GPx)-1, a cytosolic anti-oxidant.",Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
Statins prevent NASH383 Diabetes Metab J 2016;40:376-385 http://e-dmj.org The two-hit hypothesis is a well-known theory to explain  the pathogenesis of NAFLD and its progression from steatosis  to NASH [26].,Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"Park HS, et al.384 Diabetes Metab J 2016;40:376-385 http://e-dmj.orggenes.",OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
Statins prevent NASH385 Diabetes Metab J 2016;40:376-385 http://e-dmj.orgof a histological scoring system for nonalcoholic fatty liver dis - ease.,Non-OADS,/arxiv_data1/oa_pdf/2c/0e/dmj-40-376.PMC5069394.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgEffects of Body Weight Reduction on Serum Irisin and  Metabolic Parameters in Obese Subjects Y aeko Fukushima1, Satoshi Kurose1,2, Hiromi Shinno1, Ha Cao Thi Thu1, Nana Takao1, Hiromi Tsutsumi1, Takaaki Hasegawa3,  Toshiaki Nakajima3, Yutaka Kimura1,4 1Department of Health Science, Kansai Medical University Graduate School of Medicine, Hirakata,  2Disease Prevention Center, Ijinkai Takeda General Hospital, Kyoto,  3Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi,  4Health Science Center, Kansai Medical University, Hirakata, Japan Background:  Irisin is a myokine implicated in lipid and glucose metabolism.",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Keywords:  Body composition; Insulin resistance; Irisin; Lean muscle mass; Obesity Corresponding author: Y aeko Fukushima    http://orcid.org/0000-0001-9677-8762   Department of Health Science, Kansai Medical University Graduate School of Medicine,  2-3-1, Shinmachi, Hirakata 573-1191, Japan   E-mail: bsk-80@outlook.com Received: Mar.",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
[7] in Original Article Obesity and metabolic syndrome http://dx.doi.org/10.4093/dmj.2016.40.5.386 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:386-395,Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
Effects of body weight reduction on serum irisin387 Diabetes Metab J 2016;40:386-395 http://e-dmj.org740 healthy adults and by Hecksteden et al.,Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Fukushima Y , et al.388 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgMeasurement of lower limb muscle strength The lower limb muscle strength was measured twice based on  the uniform rotation leg strength using a recumbent ergometer  (Strength Ergo; Mitsubishi Electric Corp., Tokyo, Japan).",OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Effects of body weight reduction on serum irisin389 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgsignificant decreases in % body fat (46.3%±9.9% to 44.0%±  7.8%), SMI (7.7±1.2 to 7.6±1.2 kg/m2), TG (142.6±50.1 to 135.0±  52.8 mg/dL), fasting insulin (13.8±8.2 to 12.5±7.1 μU/mL),  and HOMA-IR (3.3±1.8 to 2.8±1.5); and non-significant in - creases in low density lipoprotein (LDL) cholesterol (106.9± 29.1  to 113.8±25.3 mg/dL) and serum irisin (1.20±0.20 to 1.25±  0.18 ng/mL) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Fukushima Y , et al.390 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgsignificantly.",OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Effects of body weight reduction on serum irisin391 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgwith body weight reduction [10,26,27].",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Fukushima Y , et al.392 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgtion.",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
Effects of body weight reduction on serum irisin393 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgIR was independently related to the irisin level in stepwise  multiple linear regression analysis [13].,OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"Fukushima Y , et al.394 Diabetes Metab J 2016;40:386-395 http://e-dmj.org14.",Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
Effects of body weight reduction on serum irisin395 Diabetes Metab J 2016;40:386-395 http://e-dmj.orgpredicted by muscle oxidative potential than adiposity in non- diabetic men.,Non-OADS,/arxiv_data1/oa_pdf/f4/87/dmj-40-386.PMC5069395.pdf
"DIABETES  & METABOLISM JOURNAL Copyright © 2016 Korean Diabetes Association http://e-dmj.orgDIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Repeated Glucose Deprivation/Reperfusion Induced  PC-12 Cell Death through the Involvement of FOXO  Transcription Factor Na Han1, Y ou Jeong Kim2, Su Min Park2, Seung Man Kim2, Ji Suk Lee3, Hye Sook Jung3, Eun Ju Lee2, Tae Kyoon Kim2,   Tae Nyun Kim2, Min Jeong Kwon2, Soon Hee Lee2, Mi-kyung Kim2,3, Byoung Doo Rhee2, Jeong Hyun Park2,3 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Onhospital, Busan,  2Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University College of Medicine, Busan,  3Paik Institute for Clinical Research, Molecular Therapy Lab, Inje University, Busan, Korea Background:  Cognitive impairment and brain damage in diabetes is suggested to be associated with hypoglycemia.",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Keywords:  Apoptosis; Forkhead box O; PC-12 cell; Phosphatidylinositol 3-kinase/Akt pathway; Reperfusion Corresponding authors: Mi-kyung Kim    http://orcid.org/0000-0003-1111-9122 Division of Endocrinology and Metabolism, Department of Internal  Medicine, Inje University College of Medicine, 875, Haeun-daero, Haeundae- gu, Busan 48108, Korea E-mail: kmkdoc@hanmail.net Jeong Hyun Park    http://orcid.org/0000-0002-0045-4438 Division of Endocrinology and Metabolism, Department of Internal  Medicine, Inje University College of Medicine, 75, Bokji-ro, Busanjin-gu,  Busan 47392, Korea E-mail: pjhdoc@chol.net Received: Aug. 31, 2015; Accepted: Dec. 23, 2015INTRODUCTION Diabetes mellitus is a progressive disease which can result in complications of multiple organs.",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"In addition to classic chronic  diabetic complications, type 2 diabetes mellitus patients are  vulnerable to dementia, cognitive impairment, and Alzheimer’s Original Article Others http://dx.doi.org/10.4093/dmj.2016.40.5.396 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:396-405",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
Repeated hypoglycemia and PC-12 cell death through FOXO 397 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgdisease [1].,Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Han N, et al.398 Diabetes Metab J 2016;40:396-405 http://e-dmj.organd 31% increase in 0 mM glucose DMEM for 6 hours when  compared with the controls (data not shown).",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
Repeated hypoglycemia and PC-12 cell death through FOXO 399 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgincubated overnight at 4°C.,Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Han N, et al.400 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgProtein expressions of phospho-Akt, Bcl-2, caspase-3, and  cleaved caspase-3 in PC-12 cells exposed to repeated  glucose deprivation/reperfusion To evaluate whether the PI3K/Akt pathway regulates cell  apoptosis in repeated glucose deprivation/reperfusion condi - tions, the phospho-Akt and Akt protein levels were measured  using Western blot analysis in treated PC-12 cells.",OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Repeated hypoglycemia and PC-12 cell death through FOXO 401 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgThe neuronal death resulting from hypoglycemia is not only  a result of energy failure, but also the sequence of events initiat - ed by hypoglycemia.",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Han N, et al.402 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgcemic condition.",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
Repeated hypoglycemia and PC-12 cell death through FOXO 403 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgOne of limitations of this study is that we did not apply  FOXO inhibitor or PI3K inhibitor to evaluate the causal rela - tionship between FOXO-related transcription factors and neu - ronal cell death.,Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"Han N, et al.404 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgstress oxidative state in healthy people.",Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
Repeated hypoglycemia and PC-12 cell death through FOXO 405 Diabetes Metab J 2016;40:396-405 http://e-dmj.orgProtective effect of Nigella sativa extract and thymoquinone on  serum/glucose deprivation-induced PC12 cells death.,Non-OADS,/arxiv_data1/oa_pdf/46/72/dmj-40-396.PMC5069396.pdf
"DIABETES  & METABOLISM JOURNAL Copyright © 2016 Korean Diabetes Association http://e-dmj.orgDIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Rg3 Improves Mitochondrial Function and the  Expression of Key Genes Involved in Mitochondrial  Biogenesis in C2C12 Myotubes Min Joo Kim1,2,*, Y oung Do Koo3,*, Min Kim3, Soo Lim4, Y oung Joo Park1, Sung Soo Chung1,5, Hak C. Jang4, Kyong Soo Park1 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul,  2Department of Internal Medicine, Korea Cancer Center Hospital, Seoul,  3Department of Biomedical Sciences, Seoul National University Graduate School, Seoul,  4Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam,  5 Biomedical Research Institute and Innovative Research Institute for Cell Therapy, Seoul National University Hospital, Seoul National University College of  Medicine, Seoul, Korea Background:  Panax ginseng  has glucose-lowering effects, some of which are associated with the improvement in insulin resis - tance in skeletal muscle.",Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Keywords:  Ginsenoside Rg3; Mitochondria; Panax Corresponding author: Kyong Soo Park    http://orcid.org/0000-0003-3597-342X Department of Internal Medicine, Seoul National University College of  Medicine, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: kspark@snu.ac.kr * Min Joo Kim and Y oung Do Koo contributed equally to this study as first  authors.",Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
Original Article Others http://dx.doi.org/10.4093/dmj.2016.40.5.406 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:406-413,Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
Rg3 and mitochondria 407 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgGinsenosides are biologically active components of P .,Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Kim MJ, et al.408 Diabetes Metab J 2016;40:406-413 http://e-dmj.orger’s protocol.",Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Rg3 and mitochondria 409 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgRg3 improves mitochondrial function Next, we assessed the effects of Rg3 on mitochondrial func - tion by measuring cellular adenosine triphosphate (ATP) lev - els or the OCR.",Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Kim MJ, et al.410 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgFig.",OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Rg3 and mitochondria 411 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgcreased after Rg3 treatment, regardless of the presence of anti - mycin A ( P<0.05) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"Kim MJ, et al.412 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgtion and ROS production based on the previous reports.",OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
Rg3 and mitochondria 413 Diabetes Metab J 2016;40:406-413 http://e-dmj.orgseng radix improves metabolic syndrome induced by a high  fat diet in ICR mice.,Non-OADS,/arxiv_data1/oa_pdf/d2/fd/dmj-40-406.PMC5069397.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgA Potential Issue with Screening Prediabetes or  Diabetes Using Serum Glucose: A Delay in Diagnosis Jun Goo Kang1, Cheol-Y oung Park2, Sung-Hee Ihm1, Sung Woo Park2 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of  Medicine, Anyang,  2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine,  Seoul, Korea The aim of this study was to compare the fasting serum glucose level with the fasting plasma glucose level for diagnosing hyper - glycemic states in real-life clinical situations.",Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"Keywords:  Diagnosing diabetes; Plasma glucose; Serum glucose Corresponding author: Cheol-Y oung Park    http://orcid.org/0000-0002-9415-9965 Division of Endocrinology and Metabolism, Department of Internal  Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of  Medicine, 29, Saemunan-ro, Jongno-gu, Seoul 03181, Korea E-mail: cydoctor@chol.com  Received: Jul.",Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"METHODS  We recruited 1,254 participants who were diagnosed with nor - moglycemia or IFG using the serum blood glucose level; these  were from 2,028 participants enrolled in Hallym University  Sacred Heart Hospital and Kangbuk Samsung Hospital for Brief Report Others http://dx.doi.org/10.4093/dmj.2016.40.5.414 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:414-417",Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"Serum glucose and hyperglycemic states 415 Diabetes Metab J 2016;40:414-417 http://e-dmj.orgevaluating metabolic abnormalities, including IFG or dyslipid - emia according to health examinations performed by the Na - tional Health Insurance Corp. or by personal medical checkup  between 2006 and 2009.",Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"Kang JG, et al.416 Diabetes Metab J 2016;40:414-417 http://e-dmj.orgwere examined over a period of 1 month.",OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
Serum glucose and hyperglycemic states 417 Diabetes Metab J 2016;40:414-417 http://e-dmj.org4.,Non-OADS,/arxiv_data1/oa_pdf/2d/52/dmj-40-414.PMC5069398.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ba/c5/dmj-40-418.PMC5069399.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgPrevalence and Risk Factors of Gastroesophageal  Reflux Disease in Patients with Type 2 Diabetes  Mellitus ( Diabetes Metab J  2016;40:297-307) Dongwon Yi Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Y angsan Hospital, Pusan National University School  of Medicine, Y angsan, Korea Corresponding author: Dongwon Yi    http://orcid.org/0000-0003-3574-036X Division of Endocrinology and Metabolism, Department of Internal  Medicine, Pusan National University Y angsan Hospital, Pusan National  University School of Medicine, 20, Geumo-ro, Mulgeum-eup, Y angsan 50612,  Korea E-mail: drwonny@gmail.comGastroesophageal reflux disease (GERD) is common in pa - tients with type 2 diabetes mellitus (T2DM), and the manifes - tations of GERD in diabetic patients may be more atypical  than those of the general population [1,2].",Non-OADS,/arxiv_data1/oa_pdf/ba/c5/dmj-40-418.PMC5069399.pdf
And the use of diabetes medications  such as metformin or glucagon-like peptide-1 receptor agonist  is associated with an increased risk of symptomatic GERD in Letter http://dx.doi.org/10.4093/dmj.2016.40.5.418 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:418-419,Non-OADS,/arxiv_data1/oa_pdf/ba/c5/dmj-40-418.PMC5069399.pdf
Gastroesophageal reflux disease and type 2 diabetes mellitus  419 Diabetes Metab J 2016;40:418-419 http://e-dmj.orgpatients with T2DM [7].,Non-OADS,/arxiv_data1/oa_pdf/ba/c5/dmj-40-418.PMC5069399.pdf
"DIABETES  & METABOLISM JOURNAL This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/7f/dmj-40-420.PMC5069400.pdf
"Copyright © 2016 Korean Diabetes Association http://e-dmj.orgPrevalence and Risk Factors of Gastroesophageal  Reflux Disease in Patients with Type 2 Diabetes  Mellitus ( Diabetes Metab J  2016;40:297-307)  Jun Ouk Ha1, Tae Hee Lee2, Chang Won Lee1 1Department of Internal Medicine, Busan St. Mary’s Hospital, Busan,  2Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea Corresponding author: Chang Won Lee     http://orcid.org/0000-0002-6184-7171 Department of Internal Medicine, Busan St. Mary’s Hospital, 25-14, Y ongho- ro 232beon-gil, Nam-gu, Busan 48575, Korea  E-mail: koje94@hanmail.netWe thank Dr. Yi for his comments in response to our study,  “Prevalence and risk factors of gastroesophageal reflux disease  in patients with type 2 diabetes mellitus” [1].",Non-OADS,/arxiv_data1/oa_pdf/81/7f/dmj-40-420.PMC5069400.pdf
Response http://dx.doi.org/10.4093/dmj.2016.40.5.420 pISSN 2233-6079 · eISSN 2233-6087Diabetes Metab J 2016;40:420-421,Non-OADS,/arxiv_data1/oa_pdf/81/7f/dmj-40-420.PMC5069400.pdf
Gastroesophageal reflux disease and type 2 diabetes mellitus 421 Diabetes Metab J 2016;40:420-421 http://e-dmj.orgCONFLICTS OF INTEREST  No potential conflict of interest relevant to this article was re - ported.,Non-OADS,/arxiv_data1/oa_pdf/81/7f/dmj-40-420.PMC5069400.pdf
"Additional Information Supplementary information accompanies this paper at http://www.nature.com/srep Competing financial interests: The authors declare no competing financial interests.How to cite this article: Ikebuchi, R. et al.",Non-OADS,/arxiv_data1/oa_pdf/a5/97/srep35002.PMC5069467.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/   © The Author(s) 2016",Non-OADS,/arxiv_data1/oa_pdf/a5/97/srep35002.PMC5069467.pdf
"In collaboration with members of the CCS Committee of the Japanese Society for  Pediatric Endocrinology (JSPE), we conducted  Received: March 28, 2016 Accepted: July 6, 2016 Corresponding author: Dr. Yoko Miyoshi, Department  of Pediatrics, Osaka University Graduate School of  Medicine, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan E-mail: miyoshi@ped.med.osaka-u.ac.jp This is an open-access article distributed under the terms  of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Clin Pediatr Endocrinol 2016; 25(4), 119–126 Copyright© 2016 by The Japanese Society for Pediatric Endocrinology",Non-OADS,/arxiv_data1/oa_pdf/16/c2/cpe-25-119.PMC5069540.pdf
"Available at: http://ganjoho.jp/en/professional/statistics/brochure/2014_en.html (accessed March 28, 2016).",OADS,/arxiv_data1/oa_pdf/16/c2/cpe-25-119.PMC5069540.pdf
"Available at: http://www.survivorshipguidelines.org (accessed March 28, 2016).",Non-OADS,/arxiv_data1/oa_pdf/16/c2/cpe-25-119.PMC5069540.pdf
"PHA type II (PHA II, also referred  to as Gordon syndrome(1)) is a heterogeneous syndrome inherited in an autosomal dominant Received: February 26, 2016 Accepted: May 24, 2016 Corresponding author: Dr. Seiji Sato, Department of  Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori- ku, Saitama-shi, Saitama 226-8522, Japan E-mail: hsp-shounika-b@city.saitama.lg.jp This is an open-access article distributed under the terms  of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Clin Pediatr Endocrinol 2016; 25(4), 127–134 Copyright© 2016 by The Japanese Society for Pediatric Endocrinology",Non-OADS,/arxiv_data1/oa_pdf/1a/52/cpe-25-127.PMC5069541.pdf
"Received: February 13, 2016 Accepted: July 1, 2016 Corresponding author: Dr. Keisuke Nagasaki, Division  of Pediatrics, Department of Homeostatic Regulation  and Development, Niigata University Graduate School  of Medical and Dental Sciences, 1-757 Asahimachi-Dori,  Chuo-Ku, Niigata city, Niigata 951-8510, Japan E-mail: nagasaki@med.niigata-u.ac.jp This is an open-access article distributed under the terms  of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Clin Pediatr Endocrinol 2016; 25(4), 135–138 Copyright© 2016 by The Japanese Society for Pediatric Endocrinology",Non-OADS,/arxiv_data1/oa_pdf/9b/e7/cpe-25-135.PMC5069542.pdf
"Blood examination showed hyperglycemia (serum glucose level was  753 mg/dL), metabolic acidosis (pH 7.26), and  Received: August 2, 2016 Accepted: August 27, 2016 Corresponding author: Tomonobu Hasegawa, Depart- ment of Pediatrics, Keio University School of Medicine,  35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan E-mail: thaseg@a6.keio.jp This is an open-access article distributed under the terms  of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Clin Pediatr Endocrinol 2016; 25(4), 139–141 Copyright© 2016 by The Japanese Society for Pediatric Endocrinology",Non-OADS,/arxiv_data1/oa_pdf/a6/a1/cpe-25-139.PMC5069543.pdf
Surfaces are colored by electrostaticpotential at neutral pH from /C02kT (red) to + 2kT (blue) using PyMOL (http://pymol.org/).,Non-OADS,/arxiv_data1/oa_pdf/94/ba/EMBJ-35-2170.PMC5069551.pdf
The figure was prepared using PyMOL (http://pymol.org/).,Non-OADS,/arxiv_data1/oa_pdf/94/ba/EMBJ-35-2170.PMC5069551.pdf
The resulting fluorescence intensity profile of the CENPCwas analyzed using the “Find Peak” plugin (http://fiji.sc/Find_Peaks) to automatically find the peaks.,OADS,/arxiv_data1/oa_pdf/6a/1e/EMBJ-35-2223.PMC5069552.pdf
"To explore whether FBW7 may be transcriptionally downregu- lated in primary medulloblastoma specimens, we used a largecombined set of gene expression profiles from primary medulloblas-tomas and analyzed overall FBW7 expression levels (using the R2 database: http://r2.amc.nl).",OADS,/arxiv_data1/oa_pdf/f1/5b/EMBJ-35-2192.PMC5069553.pdf
"Gene set overlap and gene set enrichment analysis Gene set overlap analyses (GSO) were performed using the respec- tive tool on the Gene Set Enrichment Analysis webpage (http://soft-ware.broadinstitute.org/gsea/index.jsp) using the predefined geneset databases (Subramanian et al, 2005).",OADS,/arxiv_data1/oa_pdf/f1/5b/EMBJ-35-2192.PMC5069553.pdf
"Comparison to putative SOX 9target genes Putative SOX9 target genes identified from three murine SOX9 transcription factor ChIP studies were downloaded (Kadaja et al, 2014; Oh et al, 2014; Larsimont et al, 2015) and matched to human orthologs using the BioMart software tool (http://www.ensembl.org/biomart/martview) and human gene names translatedusing the HUGO Gene Nomenclature Committee (Gray et al, 2015).",OADS,/arxiv_data1/oa_pdf/f1/5b/EMBJ-35-2192.PMC5069553.pdf
"Statistical analyses were performed using the statisticalpackage GraphPad Prism 5 (GraphPad Software, San Diego, CA,USA; http://www.graphpad.com) using either log-rank (Mantel – Cox) analysis, one-way analysis of variance (ANOVA), or two-wayanalysis of variance (ANOVA) with Bonferroni’s post hoc test when appropriate.",OADS,/arxiv_data1/oa_pdf/f1/5b/EMBJ-35-2192.PMC5069553.pdf
http://optn.transplant.hrsa.,Non-OADS,/arxiv_data1/oa_pdf/e2/44/HEP-63-1707.PMC5069561.pdf
http://optn.transplant.hrsa.gov/ resources/by-organ/liver-intestine/guidance-on-meld-peld-excep-tion-review/ .,Non-OADS,/arxiv_data1/oa_pdf/e2/44/HEP-63-1707.PMC5069561.pdf
"However, several target proteins pose a severe challenge even for BEVS because they are unable to be produced as soluble, correctlyThis is an open access article under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and nomodiﬁcations or adaptations are made.Correspondence to: J. van den Heuvel Contract grant sponsor: Helmholtz Protein Sample Production Facility Contract grant sponsor: Instruct part of the European Strategy Forum on ResearchInfrastructures (ESFRI)Contract grant sponsor: European Community’s Seventh Framework Programme (FP7/ 2007-2013) for the ComplexInc, Project under grant agreement N /C14270089 Received 14 September 2015; Revision received 19 January 2016; Accepted 17February 2016Accepted manuscript online 23 February 2016; Article ﬁrst published online 10 March 2016 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/bit.25956/abstract).DOI 10.1002/bit.25956ARTICLE /C2232016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/5a/45/BIT-113-1975.PMC5069567.pdf
Available from URL: http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM413317.pdf.Accessed21January2016.,Non-OADS,/arxiv_data1/oa_pdf/2b/d6/DOM-18-491.PMC5069568.pdf
Available from URL: http://www.fda.gov/downloads/Drugs/…/Guidances/UCM072137.pdf.Accessed21January2016.,Non-OADS,/arxiv_data1/oa_pdf/2b/d6/DOM-18-491.PMC5069568.pdf
Available from URL: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235671.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2b/d6/DOM-18-491.PMC5069568.pdf
Available from URL: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf.Accessed21January2016.,Non-OADS,/arxiv_data1/oa_pdf/2b/d6/DOM-18-491.PMC5069568.pdf
"[13]Tostart theproj- ectwith areason able num berofvariants, each mem berofthe librar ycontai ned between fiveand eight amino acids with one amin oacidbeing 4(Figure 2c,seeSuppo rting Infor mation for furth erdetails ).Rega rding theother amino acids, wedecid ed[a]Dr.F.Huber,Prof.Dr.S.F.Kirsch Organic Chemi stry Bergische Universi t(o22wtWupper tal Gaußstr .20,42119Wupper tal(Germany ) Fax:(+49)0202 -439-2648 E-mail :sfkirsc h@uni- wupperta l.de Supportin ginformat ionforthisarticle isavailab leontheWWW under http://dx.doi.or g/10.10 02/chem.20 1600790.",Non-OADS,/arxiv_data1/oa_pdf/b0/36/CHEM-22-5914.PMC5069569.pdf
Available from: https://www.nutritioncaremanual.org/.,Non-OADS,/arxiv_data1/oa_pdf/89/ea/OSP4-2-189.PMC5069570.pdf
"General Methods, Version 4.2 of 22 April 2015, IQWiG, Cologne, 2015 Available at: https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204-2.pdf (accessed 23 October 2015).",Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
Available at: http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/Guidelines/Efﬁcacy/E3/E3_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
Avail-able at: https://www.iqwig.de/download/A13-09_Vandetanib_Erneute-Nutzenbewertung-35a-SGB-V.pdf (accessed 29 December 2014).,Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
Available at: https://www.iqwig.de/download/A13-26_Addendum-zum-Auftrag-A13-09_Vandetanib.pdf (accessed 29 December 2014).,Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
Available at: https://www.iqwig.de/download/A13-06_ Abirateronacetat_neues_Anwendungsgebiet_Nutzenbewertung_35a_SGB_V.pdf (accessed 29 December 2014).,Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
"Addendum zum Auftrag A13-06 (Abirateronacetat [neues Anwendungsgebiet]), Auftrag A13-22, Version 1.0 vom 13.06.2013.Available at: https://www.iqwig.de/download/A13-22_Addendum-zum-Auftrag-A13-06_Abirateronacetat-neues-Anwendungsgebiet .pdf (accessed 29 December 2014).",Non-OADS,/arxiv_data1/oa_pdf/c7/b7/PST-15-292.PMC5069571.pdf
URL http://www.stat.go.jp/data/shakai/2011/h23kekka.htm (accessed 3 December 2015).Obesity Science & Practice Sleep duration and adiponectin level R. Sawamoto et al.,OADS,/arxiv_data1/oa_pdf/5f/87/OSP4-2-180.PMC5069573.pdf
"[*]T.Hering, B.M(o[z[hldorf, R.Wolf,B.Kçnig Universit (o[[wtRegensburg, Fakult(o[[wt f(o[z[rChemie undPharmazi e93040 Regensburg (Germany ) E-mail :robert.wolf @ur.de burkhard.ko enig@ur .de Supportin ginforma tionandtheORCID identifica tionnumber(s) for theauthor(s) ofthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016007 83.",Non-OADS,/arxiv_data1/oa_pdf/ac/05/ANIE-55-5342.PMC5069574.pdf
"United States Prescribing Information, November 2015. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/208462lbl.pdf.",Non-OADS,/arxiv_data1/oa_pdf/ad/58/JCPH-56-1288.PMC5069578.pdf
http://altweb.jhsph.edu/pubs/books/humane_exp/ addendum (accessed 13 November 2015).,Non-OADS,/arxiv_data1/oa_pdf/8a/13/JAT-36-1294.PMC5069579.pdf
es Supportin ginforma tionandtheORCID identifica tionnumber(s) for theauthor(s) ofthisarticle canbefound under http://dx.doi.org/ 10.,Non-OADS,/arxiv_data1/oa_pdf/9e/a6/ANIE-55-5019.PMC5069584.pdf
AllCNVs were visually inspected with Nexus copy number (http://www.biodiscovery.com).,Non-OADS,/arxiv_data1/oa_pdf/cc/ef/AJMG-171-777.PMC5069586.pdf
"[Color ﬁgure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/ajmgb].",Non-OADS,/arxiv_data1/oa_pdf/cc/ef/AJMG-171-777.PMC5069586.pdf
Available at: https://www.nice.org.uk/guidance/cg185.,Non-OADS,/arxiv_data1/oa_pdf/1b/29/DA-33-424.PMC5069590.pdf
Accessed at http://www.reginfo.gov/public/do/DownloadDocument?documentID ¼380559&version ¼0 on 1/26/2015.,Non-OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
"Accessed at https://www.dli.mn.gov/RS/PDF/wcclaims_ oshainitiatives.pdf on July 14, 2015.",Non-OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
Accessed at https://www.osha.gov/as/opa/whistleblowermemo.,OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
"Accessed at http://www.bls.gov/osmr/pdf/st080120.pdfon April 30, 2015.",Non-OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
"Accessed at http://www.gao.gov/assets/590/589961.pdf onMarch 20, 2013.",OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
Hidden tragedy: Under- reporting of workplace injuries and illnesses Accessed at http://www.gpo.gov/fdsys/pkg/CHRG-110hhrg42881/pdf/CHRG-110hhrg42881.pdf on 1/5/2015.,Non-OADS,/arxiv_data1/oa_pdf/50/4d/AJIM-59-343.PMC5069593.pdf
Availabl e at: http://media.wix.com/ ugd/dded87_29c5b002d99342f788c6ac670e49f274.pdf(accessed 13 August 2015).,Non-OADS,/arxiv_data1/oa_pdf/19/98/ADD-111-1096.PMC5069594.pdf
"Phone: +47 22 84 55 21, http://helseforskning.etikkom.no.",Non-OADS,/arxiv_data1/oa_pdf/86/46/AAS-60-1003.PMC5069596.pdf
Thetesting order of the techniques was randomizedusing an online randomization program (https://www.randomizer.org/).,OADS,/arxiv_data1/oa_pdf/86/46/AAS-60-1003.PMC5069596.pdf
"The static accuracy is0.08 mm and 0.3 °within the optimal operating range of 10 –70 cm, according to the manufacturer (http://polhemus.com/_assets/img/LIBERTY_Brochure.pdf).",Non-OADS,/arxiv_data1/oa_pdf/86/46/AAS-60-1003.PMC5069596.pdf
Available at: http://www.primarytraumacare.org/ (accessed 10October 2013).,Non-OADS,/arxiv_data1/oa_pdf/86/46/AAS-60-1003.PMC5069596.pdf
"The conditions for filtering variants include mutation type, genotype, quality, read depth, minor allele frequency (MAF), and presence in public databases; dbSNP137, 1000 Genomes project database (http://browser.1000genomes.org), and The Human Genetic Variation Database (HGVD) comprised of exome sequencing of 1,208 Japanese individuals (http://www.genome.med.kyoto- u.ac.jp/SnpDB/).",OADS,/arxiv_data1/oa_pdf/d7/d0/ANA-79-659.PMC5069600.pdf
"Briefly, a custom panel targeting 72 genes was designedusing the Ion AmpliSeq Designer tool (http://www.ampliseq.com).",Non-OADS,/arxiv_data1/oa_pdf/d7/d0/ANA-79-659.PMC5069600.pdf
Available:http://www.weedscience.org/[20October2015].,Non-OADS,/arxiv_data1/oa_pdf/7c/37/PS-72-864.PMC5069602.pdf
Available:http://www.weedscience.org/[25November2015].,Non-OADS,/arxiv_data1/oa_pdf/7c/37/PS-72-864.PMC5069602.pdf
South- east Farm Press [Online].Available:http://southeastfarmpress.com/ [22July2015].,Non-OADS,/arxiv_data1/oa_pdf/7c/37/PS-72-864.PMC5069602.pdf
http://www.R-project.org/ [Last Accessedon 11 January 2016].,Non-OADS,/arxiv_data1/oa_pdf/96/be/SIM-35-2669.PMC5069608.pdf
"mvtnorm:Multivariatenormalandtdistributions ,2014. http://CRAN.R-project.org/package=mvtnorm, rpackage version 0.9-9997 [LastAccessedon 11 January 2016].",OADS,/arxiv_data1/oa_pdf/96/be/SIM-35-2669.PMC5069608.pdf
12Ebers G. Ebers Papyrus http://web.archive.org/web/201309210551 14/http://oilib.uchicago.edu/books/bryan_the_papyrus_ebers_1930.pdf.,Non-OADS,/arxiv_data1/oa_pdf/16/ed/BJO-123-1481.PMC5069612.pdf
16WHO [http://www.who.int/medicines/publications/essentialmedicine s/EML2015_8-May-15.pdf].,Non-OADS,/arxiv_data1/oa_pdf/16/ed/BJO-123-1481.PMC5069612.pdf
"eMC, Leatherhead,Surrey, UK, Available from: https://www.medicines.org.uk/emc/medicine/23156 (accessed 01 October 2015).",Non-OADS,/arxiv_data1/oa_pdf/85/3e/EJP-20-861.PMC5069616.pdf
Available from: http://www.versorgungsleitlinien.de/themen/kreuzschme rz/pdf/nvl-kreuzschmerz-kurz-engl-4.pdf (accessed 01 October 2015).,Non-OADS,/arxiv_data1/oa_pdf/85/3e/EJP-20-861.PMC5069616.pdf
Availablefrom: http://www.who.int/medicines/areas/priority_medicines/Master DocJune28_FINAL_Web.pdf?ua=1 (accessed 01 October 2015).,Non-OADS,/arxiv_data1/oa_pdf/85/3e/EJP-20-861.PMC5069616.pdf
Available from:http://www.nice.org.uk/guidance/CG88 (accessed 01 October 2015).,Non-OADS,/arxiv_data1/oa_pdf/85/3e/EJP-20-861.PMC5069616.pdf
Available from:http://www.nice.org.uk/guidance/cg173 (accessed 01 October 2015).,Non-OADS,/arxiv_data1/oa_pdf/85/3e/EJP-20-861.PMC5069616.pdf
"The full-length translated sequence of the SMP precursor, based on the cloned cDNA nucleotide sequence, wasaligned by BLAST (http://blast.ncbi.nlm.nih.gov/blast.cgi) and the sequence was submitted to the GenBank database (Accession number: KT870152).",OADS,/arxiv_data1/oa_pdf/7f/36/JNC-137-33.PMC5069636.pdf
pectinifera SMP precursor and related proteins in other species was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/ msa/clustalo/).,OADS,/arxiv_data1/oa_pdf/7f/36/JNC-137-33.PMC5069636.pdf
2015); http://www.echi- nobase.org/Echinobase/Blasts] was analysed and non-overlappingcontigs encoding the 5 0region (GAUS01027726.1) and the 30region (GAUS01027727.1) of a SMP-type precursor transcript was iden- tiﬁed from the star ﬁsh species Asterias forbesi.,OADS,/arxiv_data1/oa_pdf/7f/36/JNC-137-33.PMC5069636.pdf
The sequence obtained (GenBank accession number KT870153) was translated into protein sequence using ExPASy (http://web.expasy.org/translate/) and Sig-nalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) was used to predict the signal peptide of the translated protein sequence.,OADS,/arxiv_data1/oa_pdf/7f/36/JNC-137-33.PMC5069636.pdf
"The open reading frame of the SMP precursor encodes a 426 amino acid residue protein thatcontains four regions: a signal peptide (Met 1-Ala19), as predicted by SignalP 4.1 (http://www.cbs.dtu.dk/services/Sig-nalP/), a N-terminal spacer peptide (Ser 20-Arg56) containing several acidic amino acids, a region containing twelve copies ofSMP and seven copies of SMP-like peptides with each peptidecopy bounded by dibasic cleavage sites (Phe 57-Arg402)a n daC - terminal region (Thr403-Arg426).",Non-OADS,/arxiv_data1/oa_pdf/7f/36/JNC-137-33.PMC5069636.pdf
"Dr.M.A.Suhm Institut f(o[z[rPhysikalisch eChemie Georg-Augu st-Unive rsit(o[[wt Gçttingen Tammannstr .6,37077 Gçttingen (Germa ny) E-mail :msuhm@gwd g.de Supportin ginformation, includin gexperim ental andcomputati onal details ofthereaction paths anddimer structures, andtheORCID identification numbe r(s)fortheauthor(s) ofthisarticle areavailab le under http://dx.doi.org/ 10.1002/ani e.201600603 .",Non-OADS,/arxiv_data1/oa_pdf/5e/f7/ANIE-55-4591.PMC5069640.pdf
"PubMed was also searched for in-process citations, and the major clinical trial registries (ClinicalTrials.gov: http://clinicaltrials.gov/; InternationalClinical Trials Registry Platform Search Portal (ICTRP): http://apps.who.int/trialsearch/) were searched for on- going trials.",OADS,/arxiv_data1/oa_pdf/5b/4a/BJS-103-656.PMC5069642.pdf
http://distillercer.com/resources/ [accessed 6 September 2015].,Non-OADS,/arxiv_data1/oa_pdf/5b/4a/BJS-103-656.PMC5069642.pdf
"Based on the Neuromorphometricslabels (http://neuromorphometrics.com), gray matter (GM), deepgray matter (DGM), and white matter (WM) regions of interest(ROIs) were created in MNI space, and the parameter estimateswere averaged over the subjects and analyzed in these ROIs.",OADS,/arxiv_data1/oa_pdf/f4/62/NBM-29-640.PMC5069652.pdf
DOI:http://dx.doi.org/10.1002/mrm.25410.,Non-OADS,/arxiv_data1/oa_pdf/f4/62/NBM-29-640.PMC5069652.pdf
DOI:http://dx.doi.org/10.1002/mrm.25506.,Non-OADS,/arxiv_data1/oa_pdf/f4/62/NBM-29-640.PMC5069652.pdf
Available at: http://www.nkcx.,Non-OADS,/arxiv_data1/oa_pdf/f2/79/IJC-138-2867.PMC5069657.pdf
Available at: http://www.folk- halsomyndigheten.se/documents/smittskydd-sjuk-domar/vaccinationer/HPV_vaccination_tom_14-12-31.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f2/79/IJC-138-2867.PMC5069657.pdf
Available at: http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret.,OADS,/arxiv_data1/oa_pdf/f2/79/IJC-138-2867.PMC5069657.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non- commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume 32, Number 8, 2016Mary Ann Liebert, Inc.DOI: 10.1089/jop.2015.0148 555",Non-OADS,/arxiv_data1/oa_pdf/ad/cf/jop.2015.0148.PMC5069706.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume 32, Number 8, 2016Mary Ann Liebert, Inc.DOI: 10.1089/jop.2015.0147 548",Non-OADS,/arxiv_data1/oa_pdf/fa/98/jop.2015.0147.PMC5069726.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommer-cial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.BRAIN CONNECTIVITY Volume 6, Number 8, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/brain.2015.0404 642",Non-OADS,/arxiv_data1/oa_pdf/20/34/brain.2015.0404.PMC5069733.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT02214407 NLM Identifier: NCT02214407.,Non-OADS,/arxiv_data1/oa_pdf/b2/a0/CBM-2016-0043.PMC5069836.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT02631070 NLM Identifier: NCT02631070.105.,Non-OADS,/arxiv_data1/oa_pdf/b2/a0/CBM-2016-0043.PMC5069836.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT02565498.34.,Non-OADS,/arxiv_data1/oa_pdf/41/e3/CBM-2016-0028.PMC5069839.pdf
Available from: http://www.birmingham.ac.uk/Documents/college- mds/trials/crctu/vortex/pdfsindexvortex/VORTEXProtocolversion6 02082010.pdf.44.,Non-OADS,/arxiv_data1/oa_pdf/41/e3/CBM-2016-0028.PMC5069839.pdf
Available from: https://www.eortc.be/clinicaltrials/Details.asp?protocol=62092&T63.,Non-OADS,/arxiv_data1/oa_pdf/41/e3/CBM-2016-0028.PMC5069839.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.,Non-OADS,/arxiv_data1/oa_pdf/bc/c4/JCIS-6-41.PMC5070031.pdf
"International Journal of Preventive Medicine 2016, 7:115 http://www.ijpvmjournal.net/content/7/1/115known to affect body weight before the study and/ or the participants who did not intend to continue  the study were excluded from the study.",Non-OADS,/arxiv_data1/oa_pdf/cf/26/IJPVM-7-115.PMC5070032.pdf
"International Journal of Preventive Medicine 2016, 7:115 http://www.ijpvmjournal.net/content/7/1/115studies, which in most studies of obesity and PA, have  been used.",Non-OADS,/arxiv_data1/oa_pdf/cf/26/IJPVM-7-115.PMC5070032.pdf
"International Journal of Preventive Medicine 2016, 7:115 http://www.ijpvmjournal.net/content/7/1/115Table 2: The components of health belief model in the groups (experimental and control) in the baseline, 3, and 6 months  after the intervention Variables Answer Baseline 3 months after intervention 6 months after intervention Experimentalf,  n (%)Controlg, n (%) Significant* Experimental,  n (%)Control,  n (%)Significant Experimental Control Significant PSUa 1 Agree 10 (25) 5 (12.5) 0.232 5 (12.5) 5 (12.5) 0.251 5 (12.5) 6 (15) 0.217 No idea 7 (17.5) 5 (12.5) 9 (23.1) 16 (40) 6 (15) 12 (30) Disagree 23 (57.5) 30 (75) 25 (64.1) 19 (47.5) 29 (72.5) 22 (55) 2 Agree 9 (22.5) 7 (17.5) 0.348 6 (15) 12 (30) 0.007 6 (15) 10 (25) 0.040 No idea 9 (22.5) 5 (12.5) 8 (20) 16 (40) 5 (12.5) 12 (30) Disagree 22 (55) 28 (70) 26 (65) 12 (30) 29 (72.5) 18 (45) 3 Agree 9 (22.5) 14 (35) 0.466 6 (15) 17 (42.5) 0.0001 5 (12.5) 11 (27.5) 0.001 No idea 6 (15) 5 (12.5) 7 (17.5) 16 (40) 7 (17.5) 19 (47.5) Disagree 25 (62.5) 21 (52.5) 27 (67.5) 7 (17.5) 28 (70) 10 (25) 4 Agree 13 (32.5) 14 (35) 0.945 10 (25) 13 (32.5) 0.003 6 (15) 12 (30) 0.004 No idea 7 (17.5) 6 (15) 7 (17.5) 18 (45) 7 (17.5) 16 (40) Disagree 20 (50) 20 (50) 23 (57.5) 9 (23.1) 27 (67.5) 12 (30) PSEb 1 Agree 16 (40) 13 (32.5) 0.753 5 (12.5) 16 (40) 0.0001 6 (15) 12 (30) 0.046 No idea 8 (20) 8 (20) 11 (27.5) 17 (42.5) 8 (20) 13 (32.5) Disagree 16 (40) 19 (47.5) 24 (60) 7 (17.5) 26 (65) 15 (37.5) 2 Agree 10 (25) 7 (17.5) 0.686 8 (20) 14 (35) 0.014 6 (15) 18 (45) 0.006 No idea 9 (22.5) 11 (27.5) 8 (20) 15 (37.5) 7 (17.5) 8 (20) Disagree 21 (52.5) 22 (55) 24 (60) 11 (27.5) 27 (67.5) 14 (35) 3 Agree 13 (32.5) 14 (35) 0.866 11 (27.5) 8 (20) 0.201 7 (17.5) 6 (15) 0.953 No idea 10 (25) 8 (20) 7 (17.5) 14 (35) 8 (20) 8 (20) Disagree 17 (42.5) 18 (45) 22 (55) 18 (45) 25 (62.5) 26 (65) PBEc 1 Agree 8 (20) 9 (22.5) 0.632 6 (15) 8 (20) 0.827 5 (12.5) 7 (17.5) 0.363 No idea 15 (37.5) 11 (27.5) 12 (30) 12 (30) 6 (15) 10 (25) Disagree 17 (42.5) 20 (50) 22 (55) 20 (50) 29 (72.5) 23 (57.5) 2 Agree 7 (17.5) 8 (20) 0.657 6 (15) 8 (20) 0.028 5 (12.5) 7 (17.5) 0.164 No idea 10 (25) 13 (32.5) 5 (12.5) 14 (35) 6 (15) 12 (60) Disagree 23 (57.5) 19 (47.5) 29 (72.5) 18 (45) 29 (72.5) 21 (52.5) 3 Agree 9 (22.5) 9 (22.5) 0.876 8 (20) 9 (22.5) 0.367 5 (12.5) 8 (20) 0.043 No idea 12 (30) 14 (35) 10 (25) 15 (37.5) 7 (17.5) 15 (37.5) Disagree 19 (47.5) 17 (42.5) 22 (55) 16 (40) 28 (70) 17 (42.5) PBAd 1 Agree 16 (40) 11 (27.5) 0.386 26 (65) 7 (17.5) 0.0001 27 (67.5) 18 (45) 0.040 No idea 7 (17.5) 6 (15) 7 (17.5) 10 (25) 7 (17.5) 6 (15) Disagree 17 (42.5) 23 (57.5) 7 (17.5) 23 (57.5) 6 (15) 16 (40) 2 Agree 26 (65) 22 (55) 0.446 28 (70) 7 (17.5) 0.0001 25 (62.5) 7 (17.5) 0.001 No idea 6 (15) 5 (12.5) 6 (15) 10 (25) 8 (20) 17 (42.5) Disagree 8 (20) 13 (32.5) 6 (15) 23 (57.5) 7 (17.5) 16 (40) 3 Agree 27 (67.5) 21 (52.5) 0.182 28 (70) 8 (20) 0.0001 28 (70) 8 (20) 0.001 No idea 7 (17.5) 6 (15) 7 (17.5) 20 (50) 7 (17.5) 16 (40) Disagree 6 (15) 13 (32.5) 5 (12.5) 12 (30) 5 (12.5) 16 (40) 4 Agree 13 (32.5) 15 (37.5) 0.879 24 (60) 8 (20) 0.001 26 (65) 12 (30) 0.003 No idea 6 (15) 5 (12.5) 10 (25) 16 (40) 7 (17.5) 8 (20) Disagree 21 (25.5) 20 (50) 6 (15) 16 (40) 7 (17.5) 20 (50) Contd...",Non-OADS,/arxiv_data1/oa_pdf/cf/26/IJPVM-7-115.PMC5070032.pdf
"International Journal of Preventive Medicine 2016, 7:115 http://www.ijpvmjournal.net/content/7/1/1151; P < 0.0001, PBE 2;  P = 0.028, PBA;  P < 0.0001,  and SE 1, 2;  P < 0.0001).",Non-OADS,/arxiv_data1/oa_pdf/cf/26/IJPVM-7-115.PMC5070032.pdf
"International Journal of Preventive Medicine 2016, 7:115 http://www.ijpvmjournal.net/content/7/1/115after the intervention, after baseline’s BMI was  adjusted P = 0.",Non-OADS,/arxiv_data1/oa_pdf/cf/26/IJPVM-7-115.PMC5070032.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112Maharashtra, India).",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112of India, Southern Regional Centre, Coimbatore  (No.",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112RESULTS The preliminary phytochemical analysis of the aqueous  extracts of E. littorale  revealed the presence of alkaloids,  flavonoids, saponins, carbohydrates, proteins, phenols,  glycosides, and tannins.",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112depression induced by both MIBK  (0.12  ±  0.03  IU)  and inhibitor (0.25  ±  0.04  IU).",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112Another noted outcome in this present study is the  reduced level of LPO during depression.",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:112 http://www.ijpvmjournal.net/content/7/1/112phospholipid arachidonate during microsomal lipid peroxidation.",Non-OADS,/arxiv_data1/oa_pdf/50/2a/IJPVM-7-112.PMC5070033.pdf
"International Journal of Preventive Medicine 2016, 7:113 http://www.ijpvmjournal.net/content/7/1/11318 years) with T ype 2 diabetes.",Non-OADS,/arxiv_data1/oa_pdf/4e/19/IJPVM-7-113.PMC5070034.pdf
"International Journal of Preventive Medicine 2016, 7:113 http://www.ijpvmjournal.net/content/7/1/113University of Medical Sciences, and in accordance with  the Helsinki Declaration of 1975, as revised in 2008.",Non-OADS,/arxiv_data1/oa_pdf/4e/19/IJPVM-7-113.PMC5070034.pdf
"International Journal of Preventive Medicine 2016, 7:113 http://www.ijpvmjournal.net/content/7/1/113History of coronary artery disease was not available in  13.2% of patients.",Non-OADS,/arxiv_data1/oa_pdf/4e/19/IJPVM-7-113.PMC5070034.pdf
"International Journal of Preventive Medicine 2016, 7:113 http://www.ijpvmjournal.net/content/7/1/113effects of glycaemia and blood pressure exposure on risk of complications in  type 2 diabetes: A prospective observational study  (UKPDS 75).",Non-OADS,/arxiv_data1/oa_pdf/4e/19/IJPVM-7-113.PMC5070034.pdf
Available from: https://www.diabetes.org.uk/ Documents/Professionals/primary_recs.pdf.,Non-OADS,/arxiv_data1/oa_pdf/4e/19/IJPVM-7-113.PMC5070034.pdf
J Clin Imaging Sci 2016;6:40.Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2016/6/1/40/191127,Non-OADS,/arxiv_data1/oa_pdf/8d/c6/JCIS-6-40.PMC5070038.pdf
"International Journal of Preventive Medicine 2016, 7:114 http://www.ijpvmjournal.net/content/7/1/114 Plantago psyllium  and Ocimum basilicum   components We measured macronutrients and fiber components of PP  and OB.",OADS,/arxiv_data1/oa_pdf/dc/59/IJPVM-7-114.PMC5070040.pdf
"International Journal of Preventive Medicine 2016, 7:114 http://www.ijpvmjournal.net/content/7/1/114 RESULTS Eight participants could not tolerate PP and OB because  of constipation, nausea or stomach-ache and were  excluded from our study.",Non-OADS,/arxiv_data1/oa_pdf/dc/59/IJPVM-7-114.PMC5070040.pdf
"International Journal of Preventive Medicine 2016, 7:114 http://www.ijpvmjournal.net/content/7/1/114Table 2: Result of within group and between groups comparison Variables OB group P aPP group P aPP and OB group P aControl group P aP b Before After Before After Before After Before After Weight Mean±SE 79.5±3.6 78.1±3.5 0.025 80.4±2.4 78.5±2.3 0 84.7±4.9 82.7±4.6 0.01 75.3±2.7 73.7±2.8 00.89 Median (IQR) 79.8 (70.5-83.6) 78.2 (69.7-83.1) 78.7 (73.3-88.9) 77.6 (70.5-82.6) 78.4 (75-94.7) 76.5 (74-87.4) 73.8 (68.5-83.6) 69.6 (66-82.7) BMI Mean±SE 30.1±1.1 29.5±1.1 0.01 29.9±0.8 29.2±0.8 0.01 34.6±1.8 33.6±1.7 0 31.2±1.1 30.6±1.1 0.02 0.92 Median (IQR) 30.1 (27.1-32.1) 29.1 (25.7-30.7) 29.7 (27.4-32.6) 29.2 (27-32.1) 31.4 (28.3-39) 31 (27.7-37.9) 29.9 (28.1-33) 30.2 (27.7-33.1) PBF Mean±SE 34.8±1.5 33.6±1.9 0.18 33.4±2.1 33.4±2.0 0.96 38.7±1.6 39.1±1.5 0.47 38.2±1.4 37.5±1.4 0.47 0.43 Median (IQR) 34.7 (28.6-39.7) 34.1 (27.8-39.3) 36.4 (27.4-39.0) 36.9 (26.3-40) 39.1 (30.1-44.1) 40.4 (33.1-44.1) 39.3 (35-41.1) 38.8 (35.1-41.3) MBF Mean±SE 27.8±2.0 26.5±2.3 0.68 26.6±1.7 25.9±1.7 0.12 33.8±3.2 33.2±2.9 0.24 29.2±2.0 28.0±2.0 0.11 0.73 Median (IQR) 27.4 (22.7-29.9) 27.3 (20.4-31.0) 26.8 (21.1-31.5) 27.3 (23.0-30.9) 29.5 (23.3-40.4) 30.1 (22.9-38.1) 27.8 (22.3-33.9) 26.9 (21.1-34.4) MBF trunk Mean±SE 14.3±1.0 13.6±1.2 0.04 13.6±0.9 13.3±0.8 0.08 17.4±1.6 17.1±1.5 0.31 14.9±1.0 14.3±1.0 0.13 0.68 Median (IQR) 14.0 (11.6-15.5) 14.4 (10.4-15.9) 13.7 (10.8-16.2) 14.0 (11.8-15.8) 15.1 (11.9-20.8) 15.4 (11.8-19.5) 14.2 (11.4-17.4) 13.7 (10.8-17.6 SLM Mean±SE 47.2±2.3 47.1±2.2 0.68 48.5±2.4 47.2±2.2 0.01 46.7±2.0 45.4±2.0 0.01 41.8±0.9 41.5±1.1 0.61 0.45 Median (IQR) 44.8 (39.2-55.1) 44.1 (40.1-53.4) 47 (42.7-52.9) 45.2 (41.2-51.4) 47.8 (41.5-51) 42.6 (40.3-48.1) 41.8 (40-45) 41 (37.1-45.9) SLM trunk Mean±SE 23.6±1.0 23.6±1.0 0.99 23.9±1.2 23.5±1.0 0.07 22.8±0.8 22.4±0.8 0.05 20.9±0.4 20.8±0.5 0.72 0.65 Median (IQR) 22.6 (19.7-27.0) 22.1 (19.9-27.2) 22.9 (21.1-26.6) 22.3 (20.5-26.1) 23.5 (20.2-25.4) 21 (20-23.9) 20.6 (19.9-22.7) 20.7 (18.6-23) LBM Mean±SE 51.7±2.4 51.5±2.4 0.80 53.0±2.5 51.6±2.3 0.01 51.49±2.3 50.1±2.3 0 46.0±1.0 45.6±1.2 0.53 0.44 Median (IQR) 49.2 (43.1-60.1) 48.6 (44.1-58.9) 51.6 (47.1-57.1) 49.4 (45.4-55.8) 52.1 (45.6-56) 47.1 (44.4-52.4) 45.8 (43.6-49.8) 44.8 (40.9-50.5) aResulted from paired sample t‑test, bResulted from ANCOVA; adjustment was made for baseline values, energy intake and age.",Non-OADS,/arxiv_data1/oa_pdf/dc/59/IJPVM-7-114.PMC5070040.pdf
"International Journal of Preventive Medicine 2016, 7:114 http://www.ijpvmjournal.net/content/7/1/114 reduction in weight and BMI  P = 0.00 and 0.02,  respectively, we examined among group changes as more  important aim in order to reach reliable consequences  of our intervention that we did not see any significant  effects among groups [ Table  2].",Non-OADS,/arxiv_data1/oa_pdf/dc/59/IJPVM-7-114.PMC5070040.pdf
"International Journal of Preventive Medicine 2016, 7:114 http://www.ijpvmjournal.net/content/7/1/114 Received:  10 Aug 16 Accepted:  23 Aug 16   Published:  10 Oct 6 REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/dc/59/IJPVM-7-114.PMC5070040.pdf
To view visit the journal (http://dx.doi.org/10.1136/esmoopen-2015- 000009).,Non-OADS,/arxiv_data1/oa_pdf/58/fc/esmoopen-2015-000009.PMC5070203.pdf
To view these files please visitthe journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000003).,Non-OADS,/arxiv_data1/oa_pdf/f8/59/esmoopen-2015-000003.PMC5070204.pdf
2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site 6.,Non-OADS,/arxiv_data1/oa_pdf/f8/59/esmoopen-2015-000003.PMC5070204.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000043).,Non-OADS,/arxiv_data1/oa_pdf/07/14/esmoopen-2016-000043.PMC5070205.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ Jassem J. ESMO Open 2016; 1:e000043.,Non-OADS,/arxiv_data1/oa_pdf/07/14/esmoopen-2016-000043.PMC5070205.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000032).,Non-OADS,/arxiv_data1/oa_pdf/af/65/esmoopen-2015-000032.PMC5070207.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000004).,Non-OADS,/arxiv_data1/oa_pdf/0e/ac/esmoopen-2015-000004.PMC5070208.pdf
ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology 2010. http://www.esmo.org/content/download/8171/168764/file/ESMO-ASCO-Revised-Recommenations-for-a-Global-Curriculum-in-Medical-Oncology.pdf (accessed 15 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/0e/ac/esmoopen-2015-000004.PMC5070208.pdf
2006. http://www.esmo.org/Policy/ Recognition-and-Status-of-Medical-Oncology/Status-of-Medical- Oncology-in-Europe (accessed 15 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/0e/ac/esmoopen-2015-000004.PMC5070208.pdf
2008. http://www.esmo.org/Policy/ Recognition-and-Status-of-Medical-Oncology/Status-of-Medical-Oncology-in-Europe (accessed 15 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/0e/ac/esmoopen-2015-000004.PMC5070208.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000017).,Non-OADS,/arxiv_data1/oa_pdf/a4/83/esmoopen-2015-000017.PMC5070210.pdf
2010. http://www.imagewisely.org/imaging-modalities/computed- tomography/medical-physicists/articles/the-pregnant-patient 9.,Non-OADS,/arxiv_data1/oa_pdf/a4/83/esmoopen-2015-000017.PMC5070210.pdf
2014. http://www.acr.org/~/media/9e2ed55531fc4b4fa53ef3b6d3b25df8.pdf 10.,Non-OADS,/arxiv_data1/oa_pdf/a4/83/esmoopen-2015-000017.PMC5070210.pdf
2014. http://www.acr.org/~/media/f7bc35bd59264e7cbe648f6d1bb8b8e2.pdf 33.,Non-OADS,/arxiv_data1/oa_pdf/a4/83/esmoopen-2015-000017.PMC5070210.pdf
"http://emedicine.medscape.com/ article/279116-overview#a6 Woitek R, et al.ESMO Open 2016; 1:e000017.",Non-OADS,/arxiv_data1/oa_pdf/a4/83/esmoopen-2015-000017.PMC5070210.pdf
To view these files please visitthe journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000031).,Non-OADS,/arxiv_data1/oa_pdf/07/ad/esmoopen-2015-000031.PMC5070211.pdf
ICH Harmonised Tripartite Guideline Statistical Principles for Clinical Trials E9 Current Step 4 version dated 5 February 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E9/Step4/E9_Guideline.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/07/ad/esmoopen-2015-000031.PMC5070211.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2015-000008).,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
2. http://www.uctv.tv/shows/The-Molecular-Diversity-of-Human- Cancers-16932 3.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
4. https://www.youtube.com/watch?v=_dJxd7n6tCU5.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
http://phrma.org/sites/default/files/pdf/oncology-report-2015.pdf6.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
http://www.sanger.ac.uk/science/groups/cancer-genome-project7.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
https://www.washingtonpost.com/national/health-science/ paradigm-change-in-the-development-of-cancer-drugs/2015/06/01/ 09fcb4c4 –086e-11e5-95fd-d580f1c5d44e_story.html 8. http://www.cancer.gov/research/nci-role/cancer-centers9.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
http://www.i-pri.org/oncology2013 10.,Non-OADS,/arxiv_data1/oa_pdf/bb/19/esmoopen-2015-000008.PMC5070212.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2015-000007).,Non-OADS,/arxiv_data1/oa_pdf/5c/71/esmoopen-2015-000007.PMC5070213.pdf
doi:10.1136/ esmoopen-2016-000072 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000072).,Non-OADS,/arxiv_data1/oa_pdf/5e/b3/esmoopen-2016-000072.PMC5070234.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/esmoopen-2016- 000063).,Non-OADS,/arxiv_data1/oa_pdf/f6/0c/esmoopen-2016-000063.PMC5070235.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000066).,Non-OADS,/arxiv_data1/oa_pdf/38/40/esmoopen-2016-000066.PMC5070236.pdf
7. http://app.drugabacus.org/abacus-mskcc8.,Non-OADS,/arxiv_data1/oa_pdf/38/40/esmoopen-2016-000066.PMC5070236.pdf
9. http://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale/ Scale-Evaluation-Forms 10.,Non-OADS,/arxiv_data1/oa_pdf/38/40/esmoopen-2016-000066.PMC5070236.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000021).,Non-OADS,/arxiv_data1/oa_pdf/b5/37/esmoopen-2015-000021.PMC5070237.pdf
See: http:// creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. http://seer.cancer.gov/statfacts/html/colorect.html 2.,Non-OADS,/arxiv_data1/oa_pdf/b5/37/esmoopen-2015-000021.PMC5070237.pdf
7. http://www.who.int/healthinfo/survey/ageingdefnolder/en/8.,Non-OADS,/arxiv_data1/oa_pdf/b5/37/esmoopen-2015-000021.PMC5070237.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000057).,Non-OADS,/arxiv_data1/oa_pdf/2f/6b/esmoopen-2016-000057.PMC5070238.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000053).,Non-OADS,/arxiv_data1/oa_pdf/20/44/esmoopen-2016-000053.PMC5070239.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/20/44/esmoopen-2016-000053.PMC5070239.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000071).,Non-OADS,/arxiv_data1/oa_pdf/bb/5c/esmoopen-2016-000071.PMC5070240.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000090).,Non-OADS,/arxiv_data1/oa_pdf/86/3c/esmoopen-2016-000090.PMC5070241.pdf
"Accepted 24 June 2016 ▸http://dx.doi.org/10.1136/ esmoopen-2016-000066 1Second University of Naples, Naples, Italy 2European Regulatory Affairs Unit, Italian Medicines Agency, Rome, Italy Correspondence to Dr Fortunato Ciardiello;Fortunato.CIARDIELLO@ unina2.itOur level of understanding of the biology of cancer at this point in time is amazing andcontinues to increase.",Non-OADS,/arxiv_data1/oa_pdf/86/3c/esmoopen-2016-000090.PMC5070241.pdf
"http://www.esmo.org/content/download/68849/ 1233986/file/ESMO-2020-vision-brochure.pdf 2 Ciardiello F, et al.ESMO Open 2016; 1:e000090.",Non-OADS,/arxiv_data1/oa_pdf/86/3c/esmoopen-2016-000090.PMC5070241.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000022).,Non-OADS,/arxiv_data1/oa_pdf/66/49/esmoopen-2015-000022.PMC5070242.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/esmoopen-2016- 000079).,Non-OADS,/arxiv_data1/oa_pdf/17/f7/esmoopen-2016-000079.PMC5070243.pdf
To view these files please visitthe journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000041).,Non-OADS,/arxiv_data1/oa_pdf/f4/ec/esmoopen-2016-000041.PMC5070244.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f4/ec/esmoopen-2016-000041.PMC5070244.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000099).,Non-OADS,/arxiv_data1/oa_pdf/95/10/esmoopen-2016-000099.PMC5070245.pdf
See: http://creativecommons.org/licenses/ by-nc/4.0/Click here to listen to the Podcast Merlano M. ESMO Open 2016; 1:e000099.,Non-OADS,/arxiv_data1/oa_pdf/95/10/esmoopen-2016-000099.PMC5070245.pdf
doi:10.1136/esmoopen-2016- 000073 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000073).,Non-OADS,/arxiv_data1/oa_pdf/c5/23/esmoopen-2016-000073.PMC5070246.pdf
Toview these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000047).,Non-OADS,/arxiv_data1/oa_pdf/d8/6c/esmoopen-2016-000047.PMC5070247.pdf
"Received 22 February 2016 Accepted 23 February 2016 ▸http://dx.doi.org/10.1136/ esmoopen-2016-000040 Find the ESMO Clinical Practice Guidelines on Prostate Cancer here:http://www.esmo.org/ Guidelines/Genitourinary- Cancers/Cancer-of-the- Prostate Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy Correspondence to Dr Cora N Sternberg, MD, FACP; cnsternberg@ corasternberg.comThe widespread use of prostatic speci ﬁc antigen (PSA) testing has greatly impacted on the epidemiology of prostate cancer.",Non-OADS,/arxiv_data1/oa_pdf/d8/6c/esmoopen-2016-000047.PMC5070247.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000065).,Non-OADS,/arxiv_data1/oa_pdf/96/e9/esmoopen-2016-000065.PMC5070248.pdf
To view these files please visitthe journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000061 ).,Non-OADS,/arxiv_data1/oa_pdf/bc/4e/esmoopen-2016-000061.PMC5070249.pdf
doi:10.1136/esmoopen-2016- 000058 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000058).,Non-OADS,/arxiv_data1/oa_pdf/4c/eb/esmoopen-2016-000058.PMC5070250.pdf
doi:10.1136/esmoopen-2015- 000018 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000018).,Non-OADS,/arxiv_data1/oa_pdf/ab/a9/esmoopen-2015-000018.PMC5070251.pdf
31 January 2016. https://www.rcr.ac.uk/publication/cancer-patients-crisis-responding-urgent-needs 29.,Non-OADS,/arxiv_data1/oa_pdf/ab/a9/esmoopen-2015-000018.PMC5070251.pdf
https://www.capc.org/ipal/ipal-icu/ (accessed 31 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/ab/a9/esmoopen-2015-000018.PMC5070251.pdf
Toview these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2015-000024).,Non-OADS,/arxiv_data1/oa_pdf/a2/2a/esmoopen-2015-000024.PMC5070252.pdf
Received 17 December 2015 Revised 4 February 2016 Accepted 12 February 2016 Find the definition of the Karnofsky and ECOG performance scale here: http://oncologypro.esmo.,Non-OADS,/arxiv_data1/oa_pdf/a2/2a/esmoopen-2015-000024.PMC5070252.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/a2/2a/esmoopen-2015-000024.PMC5070252.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000088).,Non-OADS,/arxiv_data1/oa_pdf/5b/5d/esmoopen-2016-000088.PMC5070253.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000038).,Non-OADS,/arxiv_data1/oa_pdf/66/40/esmoopen-2016-000038.PMC5070254.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/66/40/esmoopen-2016-000038.PMC5070254.pdf
http://globocan.iarc.fr/old/bar_sex_site_prev.asp?selection=3152&title=Breast&statistic=3&populations=6&window=1&grid=1&color1=5&color1e=&color2=4&color2e=&submit=%C2%A0Execute%C2%A0 (accessed 12 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/66/40/esmoopen-2016-000038.PMC5070254.pdf
Toview these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000081).,Non-OADS,/arxiv_data1/oa_pdf/bb/42/esmoopen-2016-000081.PMC5070255.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/bb/42/esmoopen-2016-000081.PMC5070255.pdf
"2. http://www.seer.cancer.gov, (n.d.).3.",Non-OADS,/arxiv_data1/oa_pdf/bb/42/esmoopen-2016-000081.PMC5070255.pdf
To view please visit the journal (http://dx.doi.org/10.1136/esmoopen-2016- 000045).,Non-OADS,/arxiv_data1/oa_pdf/e1/da/esmoopen-2016-000045.PMC5070256.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e1/da/esmoopen-2016-000045.PMC5070256.pdf
Toview these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000055).,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"This effort has resulted in articles published in prestigious journals,high representation at the most important oncology con- ferences, and recognition within the oncology commu- nity as one of the foremost collaborative groups incancer research worldwide (http://www.cecog.org).",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"This group has developed its own cancer research projects whichare sponsored by pharmaceutical companies, the public and government grants (http://www.lacog.org.br/).",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"Although this organisation does not participate directly in clinicaltrials development, it does provide a network for medical oncologists (http://www.slacom.org).",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
It also main- tains a website listing clinical trials (http://www.gaico.,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
The group is cur- rently conducting research on cholangiocarcinoma and gallbladder cancer (http://www.ilogi.com.ar/).,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
GBECAM (Brazilian Group for Breast Cancer Trials) This is a Brazilian group focused on the development of multicentre clinical trials on breast cancer in Brazil(http://www.gbecam.org.br/).,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"It is considered import-ant by Chilean cancer researchers, supports various clin- ical trials and it is a platform for new projects on cancer research (http://www.gocchi.org).",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
GOCUR (Uruguayan Oncological Collaborative Group) This is a group from Uruguay focused on the creation ofand participation in clinical cancer trials (http://www.sompu.org.uy/content/grupo-oncol%C3%B3gico- cooperativo-uruguayo).,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"Resolutions and Decisions Annex, 2005. http://apps.who.int/gb/ebwha/pdf_files/WHA58-REC1/english/A58_2005_REC1-en.pdf 4.",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
http://www.thelancet.com.,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"El País, Blog: Planeta Futuro, 13 Nov 2013. http://blogs.elpais.com/eco-americano/2013/11/cuánto-invierte-américa-latina-en-investigación-y-desarrollo.html 18.",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
http://www.australvaldivia.cl/impresa/2015/05/10/full/cuerpo-principal/2/texto/ 19.,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"Feb 2015. http://web.worldbank.org/WBSITE/EXTERNAL/NEWS/0,contentMDK:20352921~pagePK:64257043~piPK:437376~theSitePK:4607,00.html 22.",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
Oct/March 2015 Ano 2 n° 3. http://revistaonco.com.br/wp-content/uploads/2014/10/ ONCOURO_ED_03.pdf 26.,Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"The ASCO Post,25 May 2015, Volume 6, Issue 9. https://connection.asco.org/magazine/features/asco ’s-train-trainer-program-extends-reach- multidisciplinary-cancer-management 28.",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
"http://www.esmo.org/ Conferences/Workshops-Courses/SLACOM-ESMO-Clinical- Trials-Workshop Rolfo C, et al.ESMO Open 2016; 1:e000055.",Non-OADS,/arxiv_data1/oa_pdf/fd/c9/esmoopen-2016-000055.PMC5070258.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000037).,Non-OADS,/arxiv_data1/oa_pdf/bd/43/esmoopen-2016-000037.PMC5070259.pdf
http://www.silcom.com/~dwsmith/lbpqtxt.html 8.,Non-OADS,/arxiv_data1/oa_pdf/bd/43/esmoopen-2016-000037.PMC5070259.pdf
2. http://www.nccn.org/%20professionals/ physician_gls/recently_updated.asp 12.,Non-OADS,/arxiv_data1/oa_pdf/bd/43/esmoopen-2016-000037.PMC5070259.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2015-000013).,Non-OADS,/arxiv_data1/oa_pdf/d5/84/esmoopen-2015-000013.PMC5070260.pdf
http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed 5 Dec 2015).,Non-OADS,/arxiv_data1/oa_pdf/d5/84/esmoopen-2015-000013.PMC5070260.pdf
doi:10.1136/esmoopen-2016- 000089 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000089).,Non-OADS,/arxiv_data1/oa_pdf/db/3d/esmoopen-2016-000089.PMC5070261.pdf
"European Association of Urology, 2011. http://uroweb.org/wp-content/uploads/11-Testicular-Cancer_LR1.pdf 4.",Non-OADS,/arxiv_data1/oa_pdf/db/3d/esmoopen-2016-000089.PMC5070261.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000095).,Non-OADS,/arxiv_data1/oa_pdf/f9/04/esmoopen-2016-000095.PMC5070262.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f9/04/esmoopen-2016-000095.PMC5070262.pdf
http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-07- 20-cancer-research-uk-boosts-efforts-to-overcome-deadliest-cancer- as-rates-climb (last accessed 21 Jul 2016).,Non-OADS,/arxiv_data1/oa_pdf/f9/04/esmoopen-2016-000095.PMC5070262.pdf
doi:10.1136/esmoopen-2016- 000036 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000036).,Non-OADS,/arxiv_data1/oa_pdf/4c/08/esmoopen-2016-000036.PMC5070263.pdf
"Received 15 January 2016 Revised 26 March 2016 Accepted 1 April 2016 Find the ESO-ESMO guidelines for advancedbreast cancer here: http://www.esmo.org/ Guidelines/Breast-Cancer/ESO-ESMO-Advanced- Breast-Cancer Department for Internal Medicine I —Oncology, Comprehensive Cancer Center and Medical University Vienna, Vienna, Austria Correspondence to Dr Rupert Bartsch; rupert.",Non-OADS,/arxiv_data1/oa_pdf/4c/08/esmoopen-2016-000036.PMC5070263.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2015-000016).,Non-OADS,/arxiv_data1/oa_pdf/c7/06/esmoopen-2015-000016.PMC5070264.pdf
2016. https://www.nccn.org/professionals/physician_gls/f_ guidelines.asp 3.,Non-OADS,/arxiv_data1/oa_pdf/c7/06/esmoopen-2015-000016.PMC5070264.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000064).,Non-OADS,/arxiv_data1/oa_pdf/68/14/esmoopen-2016-000064.PMC5070266.pdf
"See: http://creativecommons.org/licenses/ by-nc/4.0/ Pondé N, et al.ESMO Open 2016; 1:e000064.",Non-OADS,/arxiv_data1/oa_pdf/68/14/esmoopen-2016-000064.PMC5070266.pdf
To view these files please visitthe journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000083).,Non-OADS,/arxiv_data1/oa_pdf/cd/26/esmoopen-2016-000083.PMC5070269.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000044).,Non-OADS,/arxiv_data1/oa_pdf/e7/df/esmoopen-2016-000044.PMC5070271.pdf
"A blog he ﬁrst wrote for his friends and which has been made public gives evidence of his fate in adirect and unpathetic, often disturbing, sometimes self- ironic way (http://www.wolfgang-herrndorf.de/).",Non-OADS,/arxiv_data1/oa_pdf/e7/df/esmoopen-2016-000044.PMC5070271.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000091).,Non-OADS,/arxiv_data1/oa_pdf/e6/2c/esmoopen-2016-000091.PMC5070272.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000039).,Non-OADS,/arxiv_data1/oa_pdf/e6/32/esmoopen-2016-000039.PMC5070273.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000040).,Non-OADS,/arxiv_data1/oa_pdf/77/b3/esmoopen-2016-000040.PMC5070274.pdf
Received 29 January 2016 Accepted 5 February 2016 ▸http://dx.doi.org/10.1136/ esmoopen-2016-000047 Find the ESMO Clinical Practice Guidelines on Prostate Cancer here: http://www.esmo.org/Guidelines/Genitourinary- Cancers/Cancer-of-the- Prostate For numbered affiliations see end of article.,Non-OADS,/arxiv_data1/oa_pdf/77/b3/esmoopen-2016-000040.PMC5070274.pdf
"In the USA, the American Urological Association (AUA) guidelines do not address intermit-tent use of ADT (http://www.auanet.org/education/ guidelines/).",Non-OADS,/arxiv_data1/oa_pdf/77/b3/esmoopen-2016-000040.PMC5070274.pdf
"The updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines(Prostate Cancer) (http://www.nccn.org/professionals/ physician_gls/pdf/prostate.pdf) recommend intermit- tent ADT for patients with biochemical failure andwithout metastases based on a clinical trial showing that overall survival was non-inferior versus continuous ADT (NCIC PR-7 trial), and intermittent use is not recom-mended for metastatic patients.",Non-OADS,/arxiv_data1/oa_pdf/77/b3/esmoopen-2016-000040.PMC5070274.pdf
Guidelines on Prostate Cancer 2015 http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf (accessed 10 Apr2015).,Non-OADS,/arxiv_data1/oa_pdf/77/b3/esmoopen-2016-000040.PMC5070274.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000060).,Non-OADS,/arxiv_data1/oa_pdf/6f/77/esmoopen-2016-000060.PMC5070275.pdf
http://seer.cancer.gov/statfacts/html/lungb.html 2.,Non-OADS,/arxiv_data1/oa_pdf/6f/77/esmoopen-2016-000060.PMC5070275.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000080).,Non-OADS,/arxiv_data1/oa_pdf/fd/9c/esmoopen-2016-000080.PMC5070276.pdf
"http://www.aiom.it/professionisti/ documenti-scientifici/linee-guida/1,413,1 4.",Non-OADS,/arxiv_data1/oa_pdf/fd/9c/esmoopen-2016-000080.PMC5070276.pdf
Toview these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2015-000023).,Non-OADS,/arxiv_data1/oa_pdf/2a/18/esmoopen-2015-000023.PMC5070277.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000076).,Non-OADS,/arxiv_data1/oa_pdf/91/c3/esmoopen-2016-000076.PMC5070278.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/esmoopen-2016- 000077).,Non-OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
2014. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth36a-eng.htm 2.,OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
CanadianCancer Statistics 2015. https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
http://canimpact.utoronto.ca/ 12.,Non-OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025006 14.,Non-OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
2014. http://www.riskofbias.info 17.,Non-OADS,/arxiv_data1/oa_pdf/88/31/esmoopen-2016-000077.PMC5070279.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000042).,Non-OADS,/arxiv_data1/oa_pdf/ad/56/esmoopen-2016-000042.PMC5070280.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000046).,Non-OADS,/arxiv_data1/oa_pdf/2a/53/esmoopen-2016-000046.PMC5070282.pdf
"2010 July;  available from: http://srdta.cochrane.org/ref) on SAS  version 9.4 (SAS Institute Inc., 2012, Cary, NC, USA).RESULTS The initial search proposed 747 articles, with 58  excluded as duplicates, 638 irrelevant records, and  51 assessed for full- text eligibility.",OADS,/arxiv_data1/oa_pdf/88/00/EUS-5-307.PMC5070288.pdf
Available from:  http://methods.cochrane.org/sdt/sites/methods.cochrane.org.sdt/files/uploads/ Chapter%2010%20‑%20Version%201.0.pdf.,OADS,/arxiv_data1/oa_pdf/88/00/EUS-5-307.PMC5070288.pdf
Available	 from:	http://www.giejournal.org/article/S0016‑5107(15) 	 02176‑8/fulltext.,Non-OADS,/arxiv_data1/oa_pdf/88/00/EUS-5-307.PMC5070288.pdf
Available	 from:	http://www.giejournal.,Non-OADS,/arxiv_data1/oa_pdf/88/00/EUS-5-307.PMC5070288.pdf
Available from: http://www.seer.cancer.gov/statfacts/html/thyro.html.,Non-OADS,/arxiv_data1/oa_pdf/8a/bd/EUS-5-328.PMC5070291.pdf
Available from: https://www.aamc.org/download/383628/data/ technologynowmassiveopenonlinecoursesmoocs.pdf.,OADS,/arxiv_data1/oa_pdf/00/56/EUS-5-348.PMC5070296.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ esmoopen-2015-000030).,Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
"For more information about UICC public policy initia- tives, please visit: http://www.UICC.org/essentialmeds.",Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
"http://www.who.int/ medicines/publications/essentialmedicines/en/ Figure 1 2015 WHO Model List of Essential Medicines (EML): An overview of the process coordinated by the Unionfor International Cancer Control (UICC) Eniu A, et al.ESMO Open 2016; 1:e000030.",Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
To be published in Annals of Oncology in 2016. http://www.esmo.org/Policy/Anti-Cancer-Medicines-Availability/European-Study 5.,Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
"To be published by ESMO in 2016. http://www.esmo.org/Policy/Anti-Cancer-Medicines-Availability/International-Study 6. http://www.who.int/selection_medicines/committees/expert/20/ applications/UICC_EMLreview-cost_pricing-2014.pdf?ua=1 7. http://www.esmo.org/Policy 4 Eniu A, et al.ESMO Open 2016; 1:e000030.",Non-OADS,/arxiv_data1/oa_pdf/43/df/esmoopen-2015-000030.PMC5070297.pdf
"ESMO/ASCO Global Core Curriculum for training in medical oncology, Log Book, 2008. https://www.esmo.org/content/download/8176/168808/file/The-ESMO-ASCO-Global-Core-Curriculum-for-Training-in-Medical-Oncology-Log-Book.pdf 4.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"ESMO/ASCO Global Core Curriculum for training in medical oncology, Log Book, 2008. http://www.asco.org/sites/new-www.asco.org/files/content-files/international-programs/documents/2008-ESMO-ASCO-Log-Book-pdf.pdf 5.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.org/Career-Development/Global-Curriculum-in-Medical-Oncology 6.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.asco.org/international-programs/global-curriculum 7.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://www.esmo.org/content/download/8171/168764/file/ESMO-ASCO-Revised-Recommendations-for-a-Global-Curriculum-in-Medical-Oncology.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.asco.org/sites/default/files/esmo-asco_revised_recommendations.pdf 9.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"ESMO/ASCO Global Curriculum for training in medical oncology, Log Book, second edition, 2016. http://www.esmo.org/content/download/81967/1487517/file/The-ESMO-ASCO-Global-Curriculum-for-Training-in-Medical-Oncology-Log-Book-2016.pdf 10.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"ESMO/ASCO Global Curriculum for training in medical oncology, Log Book, second edition, 2016. https://www.asco.org/sites/new- www.asco.org/files/content-files/international-programs/documents/2016-ESMO-ASCO-Log-Book-interactive.pdf 11.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://www.esmo.org/content/download/8171/168764/file/ESMO-ASCO-Revised-Recommendations-for-a-Global-Curriculum-in-Medical-Oncology.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.asco.org/sites/default/files/esmo-asco_revised_recommendations.pdf 3 SPECIAL REQUIREMENTS Nagi El-Saghir Jean-Pierre Lotzon behalf of the ESMO/ASCO GC Working Group 3.1 Programme Leader/Director of Medical Oncology Training Programme The Medical Oncology Programme Leader (or Directorof Medical Oncology Training Programme) must be qualiﬁed to supervise and educate trainees in medical oncology.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://www.esmo.org/content/download/8171/168764/file/ESMO-ASCO-Revised-Recommendations-for-a-Global-Curriculum-in-Medical-Oncology.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.asco.org/sites/default/files/esmo-asco_revised_recommendations.pdf 4 COMPETENCIES REQUIRED IN THE CURRICULUM Julia Lee Close Michael KostyJill Gilbert The following curriculum should be considered as the educational framework for the training of physicians inmedical oncology.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Cancer browser that includes mainly TCGA datasets and information, such as copy number variations, mutations and DNA methylation.https://genome-cancer.ucsc.edu/ or http://www.cbioportal.org/data_sets.jsp 7.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://genome-euro.ucsc.edu/index.html 4.1.2 Tumour immunology Priya K Gopalan Dennie V Jones Jr Ulrich KeilholzContinued Understanding of the exact tissue of origin of a cancer cell, the heterogeneity of epithelial and other cell lineages within all tissues, as well as relations of cancer cells to the linear transition from a stem cell toprogenitors and, eventually, to differentiated cells Familiarity with the complex and variable tumour-to-stroma interactions and the cellular heterogeneity of the host tissue, including the extracellular matrix and neighbouring non-cancerous cells (eg, fat cells, fibroblasts and various lymphoid and myeloid cells) Understanding of the coexistence within cancer cells of mutually interacting networks that process information (signalling), substances (metabolic) and ATP (energy), to maintain homeostasis Familiarity with the control of gene expression by epigenetic, transcriptional and post-transcriptional processes, including covalent modifications of DNA and chromatin, as well as regulation by non-coding RNAs Familiarity with phases and checkpoints of the cell cycle, their regulation by growth factors and control by protein complexes involved in carcinogenesis, as well as inhibition by apoptosis-inducing radio- andchemotherapeutic modalities Understanding of basic biochemical and molecular biological techniques, including polymerase chain reaction (PCR) to be inserted, western blots, immunofluorescence (IF), transgenic animal procedures and mass-spectrometry of proteins and metabolites Understanding of the mechanisms of drug resistance due to compensatory responses and emergence of new mutations Understanding of the terminology of biological systems, network biology and features conferring functional robustness to biological systems while exposing vulnerabilities of cancer Skills Ability to use information technology and data sets to understand the big landscape of disease and patient care Ability to discuss critically pharmacological interception strategies (eg, kinase inhibitors and monoclonal antibodies) and potential adverse effects based on cellular maps of signalling and metabolism, as well asphenotypes of genetically engineered animals Ability to discuss critically tumour heterogeneity and Darwinian evolution of rare, pre-existing clones in the face of environmental stress (eg, metastasis to a new tissue environment and switching to a new therapeutic modality) Objectives To have a basic knowledge of the components of the immune system To understand the interrelationship between the host ’s immune system and the tumour To understand mechanisms operational in immunotherapy strategies Awareness Awareness of the difference between tumour-associated antigens and neo-antigens Awareness of the role of cellular immunity in tumour killing Awareness of the existence of different effector immune cells Awareness of the concept of immune tolerance and immune regulation Appreciation of the principles of tumour vaccines Knowledge Understanding of the difference between cellular and humoral immunity, including the different components Understanding of the difference between innate and adaptive immunity, including the different components Continued 10 Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://emice.nci.nih.gov/ 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://en.wikipedia.org/wiki/Category: Molecular_biology_techniques 5.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.jove.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
Data analysis and public databases 1. http://cancer.sanger.ac.uk/cosmic 2. http://cancergenome.nih.gov/3.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://fiji.sc/Fiji4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.genecards.org/6.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.uniprot.org/7.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://en.wikipedia.org/wiki/List_of_biological_databases#Protein_ structure_databases 8. https://www.oncomine.org/ 9. https://www.r-project.org/ 10. http://onlinestatbook.com/11.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://statpages.org/12.,OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"4.3.1 Surgical oncology Piotr Rutkowski Chandrajit RautContinued Recognition that RECIST was developed to be broadly applicable, ie, across different solid tumours, but can be of limited use in certain settings due to specificities of some tumour types; for these, alternative response criteria mayexist Appreciation that RECIST was developed primarily for assessing activity (in terms of tumour shrinkage) of cytotoxic agents, as an end point in phase II trials, but is increasingly used as an end point for treatment efficacy in phase III trials (progression-free survival based on RECIST assessments) of non-cytotoxic agents Awareness that RECIST was developed for clinical trials; for the individual patient, treatment benefit should be based on medical judgement that results from a synthesis of clinical, imaging and laboratory data Awareness of the existence of a dedicated website which addresses frequently asked questions (http://www.eortc.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://www.astro.org/clinical-practice/guidelines/ index.aspx2.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://jco.ascopubs.org/site/misc/specialarticles.xhtml 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.org/Guidelines/Supportive-Care 5.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp 4.4 Supportive and palliative care 4.4.1 Supportive measuresTimothy Moynihan Jørn HerrstedtContinued Understanding that prescription, over-the-counter and complementary medicines have the potential to interact with anticancer therapy and thus contribute to adverse events Understanding of the diagnostic approach to complications of therapy, in particular the relevant history, examination and investigational findings Familiarity with the spectrum of therapeutic options available for complications of treatment, including pharmacological and non-pharmacological strategies Knowledge of evolving treatment paradigms for targeted therapy and immunotherapy Understanding that many other healthcare professionals will have a role in the diagnosis and management of the complications/toxicities of treatment, including medical, nursing, pharmacy and allied health personnel Understanding that effective prevention and/or prophylactic strategies can be employed to reduce the frequency and/or severity of some complications/toxicities Familiarity with potential mechanisms of complications/toxicities Familiarity with potential drug interactions contributing to complications/toxicities and the mechanisms of these interactions Familiarity with the psychological impact of treatment-related adverse events and the supportive measures available to the patient Understanding how the complications/toxicities of treatment will impact future delivery of anticancer therapy and when a dose delay, dose modification or treatment cessation may be applied Skills Ability to contribute actively to a wide variety of presentations of complications/toxicities of different classes of anticancer therapy Ability to perform a thorough history and clinical examination Ability to contribute actively to present patient cases Ability to discuss potential diagnostic investigations including the merits and limitations of the tests Ability to contribute to discussions on management strategies with reference to pharmacological and non- pharmacological methods Ability to discuss the role of other healthcare professionals for each scenario Ability to discuss prophylactic/preventative measures that can be instituted to protect patient safety Objectives To be able to understand, evaluate and provide supportive care to patients with cancer, including management of symptoms from the cancer and side effects of therapy from the time of diagnosis until deathor until rehabilitation and survivorship issues have been successfully managed To know the indications for the different supportive treatments and their limitations and side effects To be aware of the importance of a multidisciplinary approach Awareness Appreciation of common symptoms of malignant disease Appreciation of the pathophysiology of symptoms of malignant disease Awareness of common side effects of antineoplastic therapies Appreciation of the prevention and management of side effects of antineoplastic therapies Recognition of the need for multidisciplinary approach to supportive care Awareness of evidence-based supportive care guidelines —usage and limitations Awareness of agents used in the management of symptoms associated with the treatment of malignant disease Continued Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.cancer.gov/resources-for/hp/ education/epeco 4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nccn.org/ professionals/physician_gls/f_guidelines.asp#supportive 7.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.cancer.gov/resources-for/hp/ education/epeco4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nccn.org/ professionals/physician_gls/f_guidelines.asp#supportive 6.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/ professionals/physician_gls/f_guidelines.aspObjectives To be able to perform specialist assessment, treatment and counselling of patients with head and neck cancer (H&NC), including prevention and human papilloma virus (HPV)-related issues Awareness Awareness of the existence of different individual H&NC primary tumour sites with biological and pathological subtypes for the selection of the appropriate treatment strategies Awareness of the availability of different diagnostic procedures Awareness of the existence of H&NC-related prognostic factors such as age and HPV Appreciation of the importance of the multimodality approach to treat patients with H&NC Awareness of risk factor counselling and smoking cessation Appreciation of the importance of viral aetiology in specific anatomical subsites Knowledge Familiarity with stage-based treatment approaches Familiarity with recognising patients with or at risk of airway obstruction Familiarity with the implications of the different subsites, histotypes and biological subtypes of H&NC for the selection of the appropriate treatment strategies Familiarity with the risk assessment work-up, especially the staging system for H&NC Familiarity with the indications and value of surgery, radiation therapy, chemotherapy and monoclonal antibodies in H&NC, but also with their limitations (eg, treatment-related sequelae) Familiarity with preventive measures in preparation for multimodality treatment Understanding of the role of chemotherapy and monoclonal antibodies in the management of patients with advanced disease Understanding of the strengths of treatment personalisation opportunities and the importance of offering individualised treatment plans based on a global patient assessment (performance status, age, caregiver,nutritional status, patient preferences) Understanding of the complications derived from treatment and disease progression in the context of being familiar with supportive and palliative care strategies Understanding of the value of follow-up for rehabilitation Skills Ability to contribute actively to a variety of H&NC clinical scenarios and patient presentations Ability to discuss critically the treatment options/recommendations Ability to perform a history and physical examination in H&NC patients, including different subtypes Ability to contribute to discussions on general management strategies in order to understand all the considerations on which treatment to use and which sequence to select for the multidisciplinary strategy Ability to prescribe various therapeutic agents considering their potential interactions with radiation therapy Ability to correctly advise organ-preservation strategies Ability to evaluate conditions (such as performance status and patient ’s clinical condition, concomitant disease(s), previous treatments etc) that are important for considering whether and when to start and to stoptreatment or to switch to another option Ability to manage side effects of various chemotherapeutic agents and monoclonal antibodies as well as radiation therapy Ability to discuss prevention strategies with patients Ability to counsel about HPV related infections patients, partners and family Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdfObjectives To be able to perform specialist assessment, treatment and counselling of patients with small-cell lung cancer (SCLC), including secondary prevention Awareness Recognition that staging and determining the extent of SCLC are critical for guiding initial therapy Awareness of the availability of different diagnostic procedures and that not all are appropriate to be ordered Awareness of the existence of different prognostic factors Appreciation of the importance of the multimodality approach to treat patients with SCLC Awareness of the principles of personalising the multimodality approach in limited-stage and extensive-stage disease Recognition of the importance of avoiding delays in diagnostic work-up and management, compared to other solid malignancies Knowledge Familiarity with the different presentations of SCLC, especially the limited versus extensive and TNM staging of SCLC Familiarity with the indications for and limitations of the different diagnostic tools available for the identification of SCLC (including fine needle aspiration (FNA), bronchoscopy) Familiarity with the available treatments and the usual sequence in which they are given Familiarity with the indications and value of surgery, radiation therapy and chemotherapy in SCLC, but also with their limitations (eg, limited role of surgery in most patients) Understanding of the role of chemotherapy and therapeutic/prophylactic irradiation in the management of patients Understanding of the importance of initial response to therapy (and its duration) in determining patient survival Knowledge which complications arise from disease progression and which are treatment-associated Familiarity with supportive and palliative care strategies Skills Ability to perform a history and physical examination in SCLC patients and to interpret imaging studies to appropriately stage the patients Ability to effectively identify and present relevant information about the patient at multidisciplinary settings Ability to contribute to discussions on general management strategies, including limited and extensive stage in order to understand the rationale for selecting and sequencing treatments in a multidisciplinary setting Ability to identify situations where initiating systemic therapy quickly is more appropriate than waiting to start multimodality therapy Ability to prescribe various chemotherapeutic agents considering their potential interactions with radiation therapy Ability to effectively discuss data with patients regarding the impact of various treatments, and what would be recommended for them specifically Ability to minimise and manage side effects from various systemic therapies and irradiation to the brain/thorax Ability to guide a patient discussion about continuing systemic or radiation therapy versus pursuing supportive care only 38 Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfObjectives To be able to perform specialist assessment, treatment and counselling of non-small-cell lung cancer (NSCLC), including secondary prevention Awareness Awareness of the existence of different biological and pathological subtypes of NSCLC that are used to individually personalise treatment Awareness of the availability of different diagnostic procedures Awareness of the existence of different prognostic factors Recognition of the importance of the multimodality approach to treat patients with NSCLC Appreciation of the principles of the multimodality approach in limited-stage disease Awareness of the established and emerging biomarkers guiding therapy for NSCLC Knowledge Knowledge of the implications of the different biological and pathological subtypes of NSCLC for the selection of the appropriate treatment strategies Familiarity with the different presentations of NSCLC and the tests available for work-up and staging Familiarity with the indications for and limitations of the different diagnostic tools available for the identification of NSCLC (including fine needle aspiration (FNA), bronchoscopy) Knowledge of the available treatments and the usual sequence in which they are given Familiarity with the indications and value of surgery, radiation therapy, chemotherapy and immunotherapy in NSCLC, but also with their limitations (eg, criteria of operability) Understanding of the role of chemotherapy, immunotherapy, targeted therapy and radiation therapy in the management of patients with advanced disease Knowledge which complications arise from disease progression and which are treatment-associated Understanding of the strengths of treatment personalisation opportunities and the importance of offering individualised targeted therapies on the basis of molecular findings, such as epidermal growth factor receptor(EGFR) mutations, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase(ALK) and ROS translocation and programmed death-ligand 1 (PD-L1) expression Familiarity with supportive and palliative care strategies Skills Ability to identify patients at high risk for developing lung cancer who should undergo screening studies Ability to perform a history and physical examination in NSCLC patients, including different subtypes, and to interpret imaging studies to appropriately stage the patients Ability to contribute to discussions on general management strategies in order to understand the rationale for selecting and sequencing treatments in a multidisciplinary setting Ability to prescribe various therapeutic agents considering their potential interactions with radiation therapy Ability to effectively discuss data with patients regarding the impact of various treatments, and what would be recommended for them specifically Ability to identify clinical scenarios where neoadjuvant and adjuvant therapy is appropriate Ability to identify situations where surgery, radiation or multimodality therapy is preferred over systemic therapy alone Ability to select therapy for advanced disease according to pathological subtype, molecular marker status and performance status Ability to minimise and manage side effects from surgery, radiation or systemic therapies Ability to guide a patient discussion about continuing anticancer therapy versus pursuing supportive care only Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf 4.5.2.d Thymoma and thymic cancer Nicolas GirardObjectives To be able to perform specialist assessment, treatment and counselling of patients with mesothelioma Awareness Awareness of the existence of different pathological subtypes of mesothelioma and the availability of different diagnostic procedures Appreciation that mesothelioma causes morbidity and mortality by local invasion Awareness of the importance of the multimodality approach to treat patients with mesothelioma Awareness of the principles of the multimodality approach with early-stage disease Appreciation of established scoring systems for predicting prognosis Knowledge Knowledge of the implications of the extent of mesothelioma for the selection of appropriate treatments and the usual sequence in which they are given Familiarity with the different presentations of mesothelioma, as well as the tests available for work-up and staging Familiarity with the indications for and limitations of the different diagnostic tools available for the identification of mesothelioma (including fine needle aspiration (FNA), bronchoscopy) Familiarity with the indications and value of surgery, radiation therapy and chemotherapy in mesothelioma, but also with their limitations (eg, criteria of operability) Understanding of the role of chemotherapy, and radiation therapy in the management of patients with advanced disease Knowledge which complications arise from disease progression and which are treatment-associated Familiarity with various surgical techniques and when they are indicated Familiarity with supportive and palliative care strategies Skills Ability to perform a history and physical examination and to interpret imaging studies to appropriately stage mesothelioma patients Ability to effectively identify and present relevant information about the patient at multidisciplinary settings Ability to contribute to discussions on general management strategies in order to understand the rationale for selecting and sequencing treatments in a multidisciplinary setting Ability to effectively discuss data with patients regarding the impact of various treatments, and what would be recommended for them specifically Ability to identify situations where surgery, radiation or multimodality therapy is preferred over systemic therapy alone Ability to select therapy according to pathological subtype, extent of disease and performance status Ability to minimise and manage side effects from surgery, radiation or systemic therapies Ability to guide a patient discussion about continuing anticancer therapy versus pursuing supportive care only Objectives To be able to perform specialist assessment, treatment and counselling of patients with thymoma and thymic cancer Awareness Recognition of the rarity of thymoma and thymic cancer Appreciation of differences between thymoma and thymic cancer regarding pathology, biology and outcome, for the selection of appropriate treatment strategies Awareness of the association of thymoma with multiple endocrine neoplasia (MEN) type 1 Continued 40 Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.ncbi.nlm.nih.gov/books/NBK53508/ 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site 6.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nature.com/articles/nrdp201517 20.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf 4.5.12.b.2 Non-Hodgkin ’s lymphoma Merry Jennifer Markham Bertrand Coif ﬁerContinued Skills Ability to contribute actively to a variety of HL clinical scenarios and patient presentations Ability to discuss critically the treatment options/recommendations Ability to perform a history and physical examination in HL patients Ability to use effectively the prognostic factors in order to guide treatment selection in HL Ability to contribute to discussions on general management strategies in order to understand all the considerations on which treatment to use and when to incorporate radiation therapy Ability to prescribe various chemotherapeutic regimens Ability to manage side effects of various chemotherapeutic agents Ability to discuss survivorship care and the risk for late treatment effects with patients Objectives To be able to perform specialist assessment, treatment, and counselling of patients with the various subtypes of non-Hodgkin ’s lymphoma (NHL) Awareness Awareness of the existence of the enormous heterogeneity of NHL subtypes, including the clinical classification into indolent, aggressive or highly aggressive lymphomas Awareness of the existence of the enormous heterogeneity of clinical presentation, with at least 40% of cases without peripheral lymph nodes and 20% of cases with only extranodal location Awareness of the existence of the WHO pathological classification of the various NHL subtypes and the European Organisation for Research and Treatment of Cancer (EORTC)/WHO classification of cutaneousT-cell lymphoma (CTCL) and its subtypes Awareness of the existence of different prognostic factors Familiarity with prognostic scoring systems in the various subtypes of NHL Recognition of when treatment is indicated and when observation is appropriate Recognition that the goal of treatment may range from cure for more aggressive histologies to palliation or control of disease for more indolent histologies Awareness of the association of NHL with human immunodeficiency virus (HIV), immunosuppression and hepatitis C virus (HCV) Knowledge Familiarity with the characteristics of the different pathological subtypes of NHL as classified by the WHO classification Knowledge of the diagnostic criteria of the EORTC/WHO classification in diagnosing CTCL and its subtypes Familiarity with the indications for, expectations from and limitations of the different diagnostic approaches available for the identification and staging of NHL Understanding that fine needle aspiration (FNA) is not sufficient for making a diagnosis of NHL; biopsy is mandatory Familiarity with immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH) analysis and genetic abnormalities Familiarity with the Ann Arbor Staging system for NHL, the International Prognostic Index (IPI) or other indexes, and with the staging system for mycosis fungoides (MF), Sézary syndrome (SS) and non-MF/non-SS CTCL Understanding of the role of the prognostic scoring systems in NHL Familiarity with important prognostic parameters such as MYC or BCL-2 rearrangements Understanding of the role and the limitations of positron emission tomography (PET) imaging in the staging and restaging of various types of NHL Familiarity with the indications for and the value of chemotherapy, chemo-immunotherapy, monoclonal antibodies, targeted therapy, radiation therapy, supportive and palliative care, and survivorship care in NHL Understanding that cure may be reached only with the first-line therapy Continued 72 Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nccn.org/ professionals/physician_gls/pdf/nhl.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Published Online First: 3 February 2016. http://www.thelancet.com/series/rare-cancers 4.7 AIDS-associated malignancies Scot C Remick Patrick J Loehrer Objectives To define the natural history and spectrum of acquired immunodeficiency syndrome (AIDS)-defining neoplasms in the setting of underlying human immunodeficiency virus (HIV) infection and associated risk behaviours To define the natural history and spectrum of non-AIDS-defining neoplasms and associated risk behaviours in patients with HIV/AIDS To understand the various underlying tumourigenic viral pathogens, disease associations and pathogenesis To extrapolate treatment approaches with appropriate knowledge of tumour stage and clinical and immune status of the patient To become conversant in anticancer systemic and palliative therapeutics and underlying combination antiretroviral therapy (cART) and prophylaxis of opportunistic infections (OIs) Awareness Familiarity with the different tumour types (AIDS- and non-AIDS-defining) commonly seen in the backdrop of HIV infection Awareness of the importance of reliance on clinical skills of thorough history taking, physical examination and identification of signs and symptoms unique to patients with underlying immune deficiency Awareness of strengths and weaknesses of available diagnostic and staging capabilities Awareness of strengths and weaknesses of available pathological capacity —fine needle aspiration (FNA) versus core needle biopsy, histology, immunohistochemistry (IHC), molecular diagnostic profiling and tumourtissue interrogation Awareness of strengths and weaknesses of available laboratory capabilities to fully define stage of HIV infection, viral replication, resistance patterns and immune status Awareness of strengths and weaknesses of available therapeutic modalities (ie, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and cART and OI prophylaxis) Awareness of strengths and weaknesses of available palliative care interventions, pain management, symptom management, and supportive and hospice referral capabilities Awareness and resourcefulness of many complementary medical assessments such as tumour mapping, physical examination diagrams and measurements, simple photography of skin lesions and characterisation ofother physical findings Knowledge Knowledge sets composed of basic understanding of epidemiology, pertinent disease pathogenesis, natural history, clinical manifestations and general orientation to therapeutic and/or preventive approach of thedifferent AIDS-defining tumour types —Kaposi ’s sarcoma (KS); non-Hodgkin ’s lymphoma (NHL), including primary central nervous system lymphoma (PCNSL) and Burkitt lymphoma (BL); cervical cancer; squamous cell carcinoma of oral cavity (OSCC) Knowledge sets of the different non-AIDS-defining tumour types, especially Hodgkin ’s lymphoma (HL), anal cancer, lung cancer in certain settings and hepatocellular cancer Understanding and knowledge of disease pathogenesis by virtue of coinfection with other tumourigenic viruses (eg, Kaposi ’s sarcoma-associated herpes virus (KSHV), Epstein-Barr virus (EBV), human papilloma virus (HPV) and hepatitis-B virus (HBV)) in the backdrop of HIV infection Familiarity with differences in clinicopathological and molecular characterisation, disease patterns and natural history of KS (eg, classical vs endemic vs epidemic vs transplant less important) and NHL (eg, HIV-associated and non-HIV associated) Knowledge of the thoughtful clinical assessment of tumour stage and immune status in selecting and optimising therapeutic approaches to the HIV-infected patient with cancer Knowledge base in cART, monitoring of viral replication and immune status Familiarity with suitable therapeutic approaches employing all modalities of cancer therapy for all tumour types Knowledge of supportive and palliative care interventions, including pain management and hospice referral and usage Familiarity with suitable prevention strategies, including modifying risk behaviours Familiarity with systems-based knowledge and with multidisciplinary team approaches in the management of patients with AIDS-associated malignancies Understanding of cART treatment, drugs, monitoring and OI prophylaxis strategies Knowledge of systemic chemotherapy agents Continued 76 Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.ipos- society.org/multilingual-core-curriculum-in-psycho-oncology/ 5.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Camperdown, NSW, Australia: National Breast Cancer Centre, 2003. http://canceraustralia.gov.au/sites/default/files/ publications/pca-1-clinical-practice-guidelines-for-psychosocial-care-of-adults-with-cancer_504af02682bdf.pdf6.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Distress management.Version 1.2015, 2015. http://www.nccn.org/professionals/physician_gls/default.asp 8.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.cancercontrol.eu/ uploads/images/European_Guide_for_Quality_National_Cancer_Control_Programmes_web.pdfContinued Awareness of the availability of community resources and professional services to assist patients and families in overcoming emotional and social consequences of living with a life-threatening illness Recognition of the importance of emotional self-awareness and self-regulation for oncology clinicians Knowledge Familiarity with a conceptual biopsychosocial comprehensive patient-centred framework for assessing a patient ’s psychosocial needs (including psychological suffering and morbidity), and with a timely and efficient referral to psycho-oncology specialists, mental health professionals, social workers or chaplains depending onindividual needs and available resources Knowledge of simple instruments to screen for distress such as the National Comprehensive Cancer Network (NCCN) Distress Thermometer, quality of life assessment tools, and survivorship assessment tools Understanding of the importance of communication skills and strategies to elicit patients ’concerns, goals and values and to establish preferences for involvement in decision-making along the disease trajectory Knowledge of the different roles and areas of expertise of members of the multidisciplinary (medical professionals with different specialties) and interdisciplinary (non-medical healthcare professionals , includingnurses, psychologists, therapists, social workers and chaplains) teams Skills Ability to demonstrate proficiency in cross-cultural care based on a patient-centred approach to communication that avoids stereotyping and bias Ability to demonstrate competence in interviewing skills to identify psychological suffering and morbidity Ability to use and interpret simple instruments to screen for distress such as the NCCN Distress Thermometer, quality of life and survivorship assessment tools Ability to perform adequate referrals to psycho-oncology or mental health professionals Ability to conduct a family meeting Ability to exhibit excellence in communication skills for delivering patient-centred care, communicating serious news, using empathic responses that address the patient ’s emotions, perspectives and goals, eliciting a patient ’s concerns about his or her quality of life (including sexual function, mood and sleep), exploring the patient ’s beliefs and concerns, involving patients and caregivers in decision-making according to their expressed preference, as well as discussing goals of care and wishes for end-of-life care Ability to prescribe and monitor use of psychotropic drugs to reduce anxiety, depression, insomnia, delirium, and other common and distressing symptoms Ability to perform an adequate non-stigmatising referral to psycho-oncology or mental health professionals Ability to work effectively with nurses, psychologists, and psychiatrists, palliative care clinicians, therapists, social workers and chaplains, who are members of the oncology team, and to communicate effectively withreferring physicians to ensure a seamless plan of care for the patient Ability to show maturity in handling the emotional impact of caring for patients who are seriously ill and dying Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.cancer.net/ 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.org/Patients/ Patient-Guides 3.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.org/Patients/Getting-the-Most- out-of-Your-Oncologist4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.esmo.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.cancer.gov/ 6.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"http://www.uptodate.com/ contents/table-of-contents/patient-information/beyond-the-basics 9 SURVIVORSHIP Elizabeth Charlotte Moser Charles L Shapiro Lifang Liu In cancer, survivorship —as de ﬁned by the National Cancer Institute (NCI) of the USA —begins at the time of initial diagnosis and continues until the end of life.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Cancer rehabilitation, 2011. http://www.oncoline.nl/cancer- rehabilitation3.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Cancer survivorship care, 2011. http://www.oncoline.nl/ cancer-survivorship-care 4. van Halteren H, ed.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"Viganello –Lugano: ESMO Press, 2014. http://oncologypro.esmo.org/Publications/Handbooks/Rehabilitation-Issues-During-Cancer-Treatment-and-Follow-UpContinued Awareness Awareness of the existence of different roles of follow-up: ◦Screening for cancer recurrence and second primary cancers ◦Management of long-term and late side effects: mental/physical/socioeconomic ◦Family and lifestyle risk evaluation, including adverse health behaviours and interventions dedicated to promote healthier lifestyles ◦Empowerment among patients and patients ’advocates Awareness of the existence and risks of treatment-related problems including: ◦Chronic fatigue ◦Pain, disabling neuropathy ◦Skin, mucosal and dental problems ◦Second primary cancers (treatment-related, genetics-related or developing as the population ages) ◦Cardiovascular risk and early symptoms such as hypertension and shortness of breath ◦Cognitive dysfunction ◦Urological problems ◦Gastrointestinal problems ◦Changes due to cancer treatment, including premature menopause, bone loss with the possibility of subsequent osteoporosis, infertility, impotence and sexual dysfunction ◦Anxiety, depression and loss of self-esteem and confidence ◦Relational, social and financial impact (eg, retention to, resume work, inaccessibility to insurance and mortgages) Awareness of the signs or symptoms of cancer recurrence or treatment-related side effects and the use of diagnostic imaging modalities as indicated by best practice or guideline recommendations including: ◦Thorough investigation of new or persistent symptoms as clinically indicated ◦Indications for screening including imaging modalities and blood tests based on the primary cancer ◦The screening, detection and treatment of anxiety, depression, suicidal tendency and socioeconomic problems ◦The recognition that some new cancers and medical problems will occur in the course of normal ageing and that cancer survivors should receive routine standard preventative health maintenance (eg,immunisations, preventive screening for diabetes, hypertension etc); for this reason, a shared-care modelbetween the oncologist and the general practitioner delivers the most comprehensive care to promotewellness among cancer survivors Knowledge Familiarity with the risks of long-term and late effects of different cancer treatments and the interaction with comorbidities, medications, lifestyle, age and family risk Familiarity with the indications for and the limitations of the different diagnostic imaging modalities for screening for cancer recurrence and second cancers, as well as their psychological and financial impact Understanding of the importance of offering individualised treatment based on age, comorbidities, lifestyle, family history and cancer recurrence risk Understanding of the importance of educating patients, family, caregivers and primary care providers about the risks of cancer recurrence, familial/genetic risks, long-term and late side effects and maintaining healthylifestyles Skills Ability to contribute actively to multidisciplinary discussions and patient presentations taking into account age, sex, cancer recurrence risk, lifestyle, comorbidities and consequences of cancer treatments Ability to discuss critically the treatment options/recommendations of screening for cancer recurrences and second cancers, long-term and late effects, promoting empowerment and wellness among survivors and theirfamilies/caregivers by teaching or referring them to programmes/primary care providers that emphasise theimportance of adopting healthier lifestyles and the importance of obtaining routine preventative healthcare Ability to perform a thorough history, physical examination, laboratory studies and diagnostic imaging as indicated for new or persistent symptoms in cancer survivors Ability to discuss secondary prevention strategies with patients, family and related specialists Ability to discuss potential social challenges patients may face, such as job interruption during treatment Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://jgo.ascopubs.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://apps.who.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
Lancet Oncol 2015. http://www.thelancet.com/ commissions/global-cancer-surgery 7.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
Lancet Oncol 2015. http://www.thelancet.com/ commissions/radiotherapy 8. WHO Model Lists of Essential Medicines.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.who.int/ medicines/publications/essentialmedicines/en/ 9.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
https://www.esmo.org/content/download/8171/168764/file/ESMO-ASCO-Revised-Recommendations-for-a- Global-Curriculum-in-Medical-Oncology.pdf4.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
http://www.asco.org/sites/default/files/esmo-asco_revised_recommendations.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
"ACGME Program Requirements for Graduate Medical Education in Medical Oncology (Internal Medicine), 2015. https://www.acgme.org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/147_medical_oncology_int_med_07012015.pdfContinued To be able to assess treatment response to therapy using standard Response Evaluation Criteria in Solid Tumours (RECIST) or criteria appropriate to the specific tumour type (eg, Prostate Cancer Working Group criteria) Awareness Awareness of the interpretation of bone marrow aspirates and biopsies, including the role of cytogenetic, immunohistochemical and flow cytometric analysis Appreciation of the effectiveness and potential toxicities of treatments administered intrathecally, including the appropriate doses, which agents can be safely administered intrathecally, and potential toxicities of drugsadministered intrathecally Recognition of the specific indications for intraperitoneal therapy, including the limitations, contraindications and effectiveness of treatment administered by this route Appreciation of the definitions of complete and partial response, stable disease and progressive disease and of the significance of clinical benefit, and how often assessments of response to therapy should be undertaken Knowledge Anticancer agent administration Familiarity with the indications for each antineoplastic agent prescribed, including the role of monotherapy and combination therapy; this familiarity should include appropriate dose adjustments for toxicity, haematological,hepatic and renal dysfunction Knowledge of how to prescribe and safely administer anticancer agents by oral and parenteral routes Bone marrow aspiration, biopsy and interpretationFamiliarity with the interpretation of marrow aspirations and biopsies based on fundamental knowledge about marrow interpretation Ommaya reservoir and lumbar punctureFamiliarity with the indications Paracentesis, thoracentesisFamiliarity with the indications for, complications of, diagnostic and therapeutic thoracentesis and paracentesis, including appropriate laboratory evaluation of the specimen obtained Knowledge of the techniques of paracentesis and thoracentesis Familiarity with the indications for and administration of intraperitoneal chemotherapy, and the use of sclerosing agents for management of malignant pleural effusions Familiarity with the complications of these techniques and their management Tumour assessmentKnowledge how to assess tumour size and response to therapy by physical examination and radiological techniques Familiarity with RECIST and definitions of complete and partial responses, stable disease and progressive disease Understanding of the appropriate use of radiological studies in the initial staging of patients and in the monitoring of response to treatment Skills Ability to write appropriate orders for administration of antineoplastic agents, including relevant supportive care drugs and dose modifications based on current laboratory parameters and prior toxicities Ability to care and access indwelling venous catheters Ability to handle chemotherapeutic and non-chemotherapeutic anticancer agents Ability to perform supervised bone marrow aspiration and biopsies that includes obtaining appropriate consent, performing the procedure with minimal patient discomfort and basic interpretation of the results Ability to perform supervised intrathecal administrations of chemotherapy by lumbar puncture and/or Ommaya reservoir, a subcutaneous device Ability to administer chemotherapy through an Ommaya reservoir including obtaining appropriate consent, performing the procedure with minimal patient discomfort and treating potential complications of the procedure Ability to discuss the indications, contraindications and efficacy of intraperitoneal chemotherapy Ability to assess the response to therapy using standard RECIST or other appropriate criteria, including which imaging modalities are most appropriate for initial assessment of disease status, as well as subsequent assessments Dittrich C, et al.ESMO Open 2016; 1:e000097.",Non-OADS,/arxiv_data1/oa_pdf/ff/a8/esmoopen-2016-000097.PMC5070299.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000074).,Non-OADS,/arxiv_data1/oa_pdf/eb/f5/esmoopen-2016-000074.PMC5070300.pdf
See: http://creativecommons.org/licenses/ by-nc/4.0/Click here to listen to the Podcast Voest E. ESMO Open 2016; 1:e000074.,Non-OADS,/arxiv_data1/oa_pdf/eb/f5/esmoopen-2016-000074.PMC5070300.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000049).,Non-OADS,/arxiv_data1/oa_pdf/13/34/esmoopen-2016-000049.PMC5070301.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2016-000062).,Non-OADS,/arxiv_data1/oa_pdf/71/fb/esmoopen-2016-000062.PMC5070302.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000052).,Non-OADS,/arxiv_data1/oa_pdf/78/ca/esmoopen-2016-000052.PMC5070303.pdf
Available from: https://www.hcup‑us.ahrq.gov/reports/ statbriefs/sb160.jsp.,OADS,/arxiv_data1/oa_pdf/ec/ba/ACA-19-626.PMC5070322.pdf
Available from: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp.,Non-OADS,/arxiv_data1/oa_pdf/ec/ba/ACA-19-626.PMC5070322.pdf
Available from: https://www.clinicaltrials.gov/ct2/show/ NCT01784159.,Non-OADS,/arxiv_data1/oa_pdf/ec/ba/ACA-19-626.PMC5070322.pdf
2016; 2014 Available from: https://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/ec/ba/ACA-19-626.PMC5070322.pdf
Available from:  https://www.clinicaltrials.gov/ct2/show/NCT02326350.,Non-OADS,/arxiv_data1/oa_pdf/ec/ba/ACA-19-626.PMC5070322.pdf
"The questionnaire was fielded using SurveyMonkey™  software, and the link https://www.surveymonkey.com/r/IACTAICARETEEsurvey was sent by the  author (who did not participate in data analysis) via  E-mail to all members of IACTA from its database  of members.",OADS,/arxiv_data1/oa_pdf/42/a8/ACA-19-646.PMC5070324.pdf
"Based on these, the authors would like to make the  following recommendations to the ICCA/IACTA: • A standardized consent form for TEE is made  available by the ICCA/IACTA to all its members • Promote the use of standardized report for TEE  findings available at http://iacta.co.in/WP_iacta/ Downloads/TEE_Log%20Book%20Revised%20 22-05-2013.pdf • Educating the surgeons and administrators of tier  2 and 3 hospitals to procure TEE equipment • A structured remuneration to be made after  discussing with cardiac surgeons and the hospital  administrators • IACTA should ensure education of its members about  the need for documentation of TEE examinations.",Non-OADS,/arxiv_data1/oa_pdf/42/a8/ACA-19-646.PMC5070324.pdf
doi:10.1136/esmoopen- 2016-000056 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2016-000056).,Non-OADS,/arxiv_data1/oa_pdf/3c/94/esmoopen-2016-000056.PMC5070358.pdf
"Central European CooperativeOncology Group (CECOG), Vienna, Austria Correspondence to Professor Matthias Preusser; matthias.preusser@ meduniwien.ac.athttp://players.brightcove.net/2696240571001/default_default/index.html?",Non-OADS,/arxiv_data1/oa_pdf/3c/94/esmoopen-2016-000056.PMC5070358.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ esmoopen-2016-000082).,Non-OADS,/arxiv_data1/oa_pdf/4a/7b/esmoopen-2016-000082.PMC5070390.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ esmoopen-2015-000020).,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
2014. http://www.oegho.at/die-oegho/fokus-themen/future- demands.html 9.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
http://www.dosing.de/Niere/nierelst.htm 48.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
http://www.aarp.org/content/dam/aarp/livable-communities/learn/health/Healthy-Aging-Helping-People-to-Live-Long-and-Productive-Lives-and-Enjoy-a-Good-Quality-of-Life-2011-AARP.pdf 54.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
2015. http://ecancer.org/conference/699-siog-2015/video/4246/how-to-bring-geriatrics-and-oncology-together.php 55.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
2015.http://biblioteca.universia.net/html_bura/ficha/params/title/nationwide-implementation-of-multidisciplinary-geriatric-assessment-and-intervention-program-in/id/64867482.html 63.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
67. http://www.eortc.org/research-groups/cancer-in-elderly-task-force/ recent-achievements/ 2015.,Non-OADS,/arxiv_data1/oa_pdf/72/9f/esmoopen-2015-000020.PMC5070391.pdf
Available from: http://icmr.nic.in/art/art_clinics.htm.,Non-OADS,/arxiv_data1/oa_pdf/2a/8f/JHRS-9-173.PMC5070399.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/05/79/ircmj-18-08-38045.PMC5070407.pdf
[http://dx.doi.org/10.1177/0020764014535754 ] [PMID: 24869846 ] [2] Sea of Death: Many Migrants Drown Trying to Reach Italy [2015 April 19].,Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
Available from: http://www.nbcnews.com/news/world/sea- death-many-migrants-drown-trying-reach-italy-n344381  [Retrieved 9 October 2015].,Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
"[http://dx.doi.org/10.1093/eurpub/ckw010 ] [PMID: 27053728 ] [4] Carta MG, Oumar FW, Moro MF, et al.",Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
"[http://dx.doi.org/10.2174/1745017901309010189 ] [PMID: 24285982 ] [5] Guy W. ECDEU Assessment Manual for Psychopharmacology, revised.",Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2014.01.003 ] [PMID: 24503244 ] [7] Johnson H, Thompson A.",OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
[http://dx.doi.org/10.1016/j.cpr.2007.01.017 ] [PMID: 17383783 ] [8] Euorpeon  Commision.,OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
Available  from: http://ec.europa.eu/dgs/home-affairs/what-we-do/policies/asylum/examination-of-applicants/index_en.htm [9] United  Nations  -  Convention  on  the  Rights  of  Persons  with  Disabilities.,Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
"; Licensee Bentham Open This is an open access articles licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/e2/CPEMH-12-64.PMC5070422.pdf
Available from: http://www.safaids.net/files/ZNASP%202006-2010.pdf .,Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.2174/1874192401105010049 ] [PMID: 21643501 ] [3] Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1086/378131 ] [PMID: 12942391 ] [5] Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidemia.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
[http://dx.doi.org/10.4103/2230-8210.122600 ] [PMID: 24381869 ] [6] Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention.,Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/http://dx.doi.org/10.1093/qjmed/hcp ] [7] Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1016/0021-9150(89)90156-1 ] [PMID: 2502993 ] [11] Oguejiofor OC, Onwukwe CH, Odenigbo CU.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.4103/1596-3519.102846 ] [PMID: 23103917 ] [12] Strehlau R, Coovadia A, Abrams EJ, et al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1097/QAI.0b013e318243760b ] [PMID: 22134152 ] [13] Satyajit D. Mechanism of lipid disorder in HIV infection: apolipoprotein-B kinetics, fat distribution, insulin resistance and adipocytokines in patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
Available from: http://etheses.bham.ac.uk/1475 .,Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1186/1742-6405-11-32 ] [PMID: 25320632 ] [16] Tadewos A, Addis Z, Ambachew H, Banerjee S. .",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1186/1476-511X-12-50 ] [PMID: 23575345 ] [18] Tungsiripat M, Aberg JA.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.3949/ccjm.72.12.1113 ] [PMID: 16392725 ] [19] Buchacz K, Weidle PJ, Moore D, et al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1097/QAI.0b013e31815e7453 ] [PMID: 18398971 ] [20] Dimodi HT, Etame LS, Nguimkeng BS, et al.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.4236/wja.2014.41011 ] [21] Lazzaretti  RK,  Gasparotto  AS,  Sassi  MG,  et  al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
[http://dx.doi.org/10.1373/clinchem.2008.118356 ] [PMID: 19168552 ] [26] Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.,Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1007/s11745-010-3408-1 ] [PMID: 20524075 ] [27] Liu X, Wang Y, Qu H, et al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1093/jjco/hyt018 ] [PMID: 23444115 ] [28] Bogari NM, Abdel-Latif AM, Hassan MA, Fawzy A, Apolipoprotein B. XbaI) allele frequencies in an Egyptian Population: impact on blood lipids.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.3346/jkms.2001.16.6.719 ] [PMID: 11748351 ] [30] Srivastava N, Prakash J, Srivastava A, Agarwal CG, Pant DC, Mittal B.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
[http://dx.doi.org/10.4103/0971-6866.112880 ] [PMID: 23901190 ],Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.2478/v10034-011-0045-9 ] [PMID: 24052710 ] [33] Chauffert M, Larghero J, Ngohou-Botum K, Cisse A, Chevenne D, Trivin F. DNA polymorphisms of apolipoprotein B in the population of Senegal.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1046/j.1469-1809.1997.6160525.x ] [PMID: 9543553 ] [34] Zhao WY, Huang JF, Wang LY, et al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1097/FPC.0b013e32814db8b7 ] [36] Zhou DT, Kodogo V, Chokuona KFV, Gomo E, Oektedalen O, Stray-Pedersen B. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.2147/HIV.S78523 ] [PMCID: PMC4435239 ] [37] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1093/aje/kwn359 ] [PMID: 19126586 ] [41] Li XL, Wu ZL, Liu ZZ, Gong YF, Zhou RY, Zheng GR.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1093/jhered/esj026 ] [PMID: 16624893 ] [42] De Benedictis G, Rose G, Mazzei R, et al.",OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
[http://dx.doi.org/10.1186/1479-7364-1-2-111 ] [PMID: 15601539 ] © Kodogo et al.,OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"; Licensee Bentham Open This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/1d/TOAIDJ-10-190.PMC5070423.pdf
"[http://dx.doi.org/10.1097/DER.0b013e31826e4567] [PMID: 23010830] [3] Darlenski R, Kazandjieva J, Pramatarov K. The many faces of nickel allergy.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
[http://dx.doi.org/10.1111/j.1365-4632.2011.05233.x] [PMID: 22515577] Index of Th1/Th2 balance 2050 040 30 10 Index of Th1/Th2 balance 2050 040 30 10 NiCl 2-+-+ LPS-+ NiCl 2-+-+ LPS-+NiSO4++++****a b,Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
[http://dx.doi.org/10.1146/annurev.iy.07.040189.001045 ] [PMID: 2523712 ] [5] Sosroseno W. The immunology of nickel-induced allergic contact dermatitis.,Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/j.imbio.2010.12.004 ] [PMID: 21281979 ] [7] Gu X, Li P, Liu H, Li N, Li S, Sakuma T. The effect of influenza virus A on th1/th2 balance and alveolar fluid clearance in pregnant rats.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.3109/01902148.2011.587136 ] [PMID: 21777148 ] [8] Schroder WA, Gardner J, Le TT, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1111/j.1365-3024.2010.01241.x ] [PMID: 21086717 ] [9] Yang P, Qiu G, Wang S, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1111/j.1744-313X.2010.00899.x ] [PMID: 20193034 ] [10] Zhao Y, Yang J, Gao YD.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.3109/02770903.2011.570403 ] [PMID: 21492057 ] [11] Kobayashi H, Kumagai K, Eguchi T, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1371/journal.pone.0076385 ] [PMID: 24098486 ] [12] Büyüköztürk S, Gelincik A, Ünal D, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/j.intimp.2015.03.012 ] [PMID: 25797346 ] [13] Roediger B, Weninger W. How nickel turns on innate immune cells.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1038/icb.2010.114 ] [PMID: 20938456 ] [14] Schmidt M, Goebeler M. Nickel allergies: paying the Toll for innate immunity.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1007/s00109-011-0780-0 ] [PMID: 21698426 ] [15] Kaplan DH, Igyártó BZ, Gaspari AA.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1111/j.1365-2222.2007.02705.x ] [PMID: 17456222 ] [17] Kinbara  M,  Sato  N,  Kuroishi  T,  Takano-Yamamoto  T,  Sugawara  S,  Endo  Y.  Allergy-inducing  nickel  concentration  is  lowered  by lipopolysaccharide at both the sensitization and elicitation steps in a murine model.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1111/j.1365-2133.2010.10016.x ] [PMID: 20825406 ] [18] Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/S0264-410X(98)80122-9 ] [PMID: 9682382 ] [19] Krieg AM, Yi AK, Matson S, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1038/374546a0 ] [PMID: 7700380 ] [20] Takayama E, Seki S, Ohkawa T, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.4049/jimmunol.164.11.5652 ] [PMID: 10820240 ] [21] Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.3390/ijerph110808175 ] [PMID: 25116637 ] [23] Salsano F, Francia C, Roumpedaki I, et al.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"Promotion of Ni Allergy by Anamnestic Sensitization with LPS The Open Dentistry Journal, 2016, Volume 10    537 [http://dx.doi.org/10.1002/tox.22001 ] [PMID: 24801245 ] [25] Kaisho T, Akira S. Toll-like receptors as adjuvant receptors.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/S0167-4889(01)00182-3 ] [PMID: 11909637 ] [26] Takahashi H, Kinbara M, Sato N, Sasaki K, Sugawara S, Endo Y. Nickel allergy-promoting effects of microbial or inflammatory substances at the sensitization step in mice.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/j.intimp.2011.05.010 ] [PMID: 21621645 ] [27] Banchereau J, Steinman RM.",OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
[http://dx.doi.org/10.1038/32588 ] [PMID: 9521319 ] © Adachi et al.,Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"; Licensee Bentham Open This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cb/7a/TODENTJ-10-531.PMC5070425.pdf
"[http://dx.doi.org/10.1016/j.prosdent.2006.09.018 ] [PMID: 17174661 ] [2] Sadowsky SJ, Bedrossian E. Evidenced-based criteria for differential treatment planning of implant restorations for the partially edentulous patient.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/jopr.12014 ] [PMID: 23387389 ] [3] Bosse LP, Taylor TD.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/j.1600-0501.2009.01781.x ] [5] Corbella S, Taschieri S, Del Fabbro M. Long-term outcomes for the treatment of atrophic posterior maxilla: a systematic review of literature.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/cid.12077 ] [PMID: 23656352 ] [6] Del  Fabbro  M,  Corbella  S,  Weinstein  T,  Ceresoli  V,  Taschieri  S.  Implant  survival  rates  after  osteotome-mediated  maxillary  sinus augmentation: a systematic review.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/j.1708-8208.2011.00399.x ] [PMID: 22082056 ] [7] Esposito M, Grusovin MG, Rees J, et al.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/j.1600-051X.2008.01271.x ] [PMID: 18724851 ] [10] Li J, Wang HL.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1097/ID.0b013e31818c4992 ] [PMID: 19077576 ] [11] Srinivasan M, Vazquez L, Rieder P, Moraguez O, Bernard JP, Belser UC.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1177/0022034511425675 ] [PMID: 22034499 ] [13] Pommer B, Frantal S, Willer J, Posch M, Watzek G, Tepper G. Impact of dental implant length on early failure rates: a meta-analysis of observational studies.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
[http://dx.doi.org/10.1111/j.1600-051X.2011.01750.x ] [PMID: 21722154 ] [14] Lemons JE.,Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
[http://dx.doi.org/10.1563/0712.1 ] [PMID: 15587023 ] [15] Kopp CD.,OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1054/jcms.2002.0310 ] [PMID: 12220996 ] [17] Bourauel C, Aitlahrach M, Heinemann F, Hasan I. Biomechanical finite element analysis of small diameter and short dental implants: extensive study of commercial implants.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1515/bmt-2011-0047 ] [PMID: 23092989 ] [18] Chang SH, Lin CL, Hsue SS, Lin YS, Huang SR. Biomechanical analysis of the effects of implant diameter and bone quality in short implants placed in the atrophic posterior maxilla.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1016/j.medengphy.2011.07.005 ] [PMID: 21807548 ] [19] Turcio KH, Goiato MC, Gennari Filho H, dos Santos DM.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1097/SCS.0b013e31819b9926 ] [PMID: 19305247 ] [20] Assunção WG, Barão VA, Tabata LF, Gomes EA, Delben JA, dos Santos PH.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1097/SCS.0b013e3181acdb81 ] [PMID: 19568186 ] [21] Zanatta LC, Dib LL, Gehrke SA.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1097/SCS.0000000000000829 ] [PMID: 24777027 ] [22] Naert I, Duyck J, Vandamme K. Occlusal overload and bone/implant loss.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/j.1600-0501.2012.02550.x ] [PMID: 23062133 ] [23] Oh TJ, Yoon J, Misch CE, Wang HL.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
[http://dx.doi.org/10.1902/jop.2002.73.3.322 ] [PMID: 11922263 ] [24] Martin RB.,Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1007/s00223-002-1059-9 ] [PMID: 14565590 ] [25] van Oers RF, van Rietbergen B, Ito K, Huiskes R, Hilbers PA. Simulations of trabecular remodeling and fatigue: is remodeling helpful or harmful?",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1016/j.bone.2011.01.011 ] [PMID: 21256994 ] [26] Huang  YM,  Chou  IC,  Jiang  CP,  Wu  YS,  Lee  SY.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1016/j.prosdent.2004.12.019 ] [PMID: 15775923 ] [29] Hudieb MI, Wakabayashi N, Kasugai S. Magnitude and direction of mechanical stress at the osseointegrated interface of the microthread implant.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1902/jop.2010.100237 ] [PMID: 21189091 ] [30] Okumura N, Stegaroiu R, Kitamura E, Kurokawa K, Nomura S. Influence of maxillary cortical bone thickness, implant design and implant diameter on stress around implants: a three-dimensional finite element analysis.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1016/j.jpor.2009.12.004 ] [PMID: 20153281 ] [31] Guan H, van Staden R, Loo YC, Johnson N, Ivanovski S, Meredith N. Influence of bone and dental implant parameters on stress distribution in the mandible: a finite element study.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/jopr.12150 ] [PMID: 24750397 ] [34] Hong J, Lim YJ, Park SO.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1111/j.1600-0501.2011.02285.x ] [PMID: 22092387 ] [35] de Paula GA, da Mota AS, Moreira AN, de Magahlães CS, Cornacchia TP, Cimini CA Jr.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1097/SCS.0b013e31824dbab7 ] [PMID: 22565882 ] [37] Vargas LC, de Almeida EO, Rocha EP, et al.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"[http://dx.doi.org/10.1563/AAID-JOI-D-10-00157 ] [PMID: 21231868 ] [38] de Castro Ferreira E, Corbella S, Zanatta LC, Taschieri S, del Fabbro M, Gehrke SA.",OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
[http://dx.doi.org/10.1007/s00784-011-0517-z ] [PMID: 21301903 ] © Gehrke et al.,Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
"; Licensee Bentham Open This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/75/fb/TODENTJ-10-522.PMC5070426.pdf
Available from: http:// www.CUM19760315‑V45‑06.pdf; http://www.documents.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from: http://www.aarc.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Availabl from: http://www.zs5emtqK_ Attachmen_‑_List_of_Off‑campus_Distance_Education_ Programs_July_2008_.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available  from: http://www.cobgrte.org/images/Coalition_Chronicle_ April_2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from:  http://www.scfhs.org.sa/en/about/Pages/default.aspx.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from: http://www.scfhs.org.sa/en/registration/ Pages/default.aspx.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from: http://www.he.moe.gov.sa/en/aboutus/ Institutions/Pages/academic‑accreditation.aspx.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from: http://www.irccouncil.org/ newsite/links/.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available  from: http://www.ssrc.org.sa/ssrc‑profile/.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available  from: http://www.moh.gov.sa/en/Ministry/Statistics/book/ Documents/Statistical‑Book‑for‑the‑Year‑1435.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from: http://www.cbahi.gov.sa/apps/ en/home.aspx.,Non-OADS,/arxiv_data1/oa_pdf/86/9a/ATM-11-237.PMC5070431.pdf
Available from:  http://www.wcpt.org/policy/ps‑descriptionPT.,Non-OADS,/arxiv_data1/oa_pdf/1a/11/ATM-11-243.PMC5070432.pdf
Available from: https://www.pcrs‑uk.org/news/update‑ gold‑guidelines.,Non-OADS,/arxiv_data1/oa_pdf/1b/e5/ATM-11-261.PMC5070435.pdf
Available from: http://www.connectingforhealth.nhs.uk/ systemsandservices/data/uktc/readcodes.,OADS,/arxiv_data1/oa_pdf/1b/e5/ATM-11-261.PMC5070435.pdf
Available at:   http://ctri.nic.in/Clinicaltrials/showallp.,Non-OADS,/arxiv_data1/oa_pdf/00/51/ATM-11-283.PMC5070438.pdf
Available  from: http://www.ginasthma.org/gina‑report‑global‑strategy‑ for‑asthma‑management‑and‑prevention/.,Non-OADS,/arxiv_data1/oa_pdf/00/51/ATM-11-283.PMC5070438.pdf
Available from: http://www.nhlbi.,Non-OADS,/arxiv_data1/oa_pdf/00/51/ATM-11-283.PMC5070438.pdf
Available from: http://www.doi.,Non-OADS,/arxiv_data1/oa_pdf/00/51/ATM-11-283.PMC5070438.pdf
Available from: http://www.who.int/mediacentre/factsheets/ fs311/en/.,Non-OADS,/arxiv_data1/oa_pdf/ed/6d/ATM-11-294.PMC5070440.pdf
Clinical Trial Registrationhttp://www.clinicaltrials.gov .,Non-OADS,/arxiv_data1/oa_pdf/68/b7/ehw233.PMC5070447.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/b7/ehw233.PMC5070447.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/12/18/ehw285.PMC5070448.pdf
"The History of GalaFLEX P4HB Scaffold Simon F. Williams, PhD; David P. Martin, PhD; and Arikha C. Moses, PhDAesthetic Surgery Journal 2016, Vol 36(S2) S33 –S42 © 2016 The American Society forAesthetic Plastic Surgery, Inc.This is an Open Access articledistributed under the terms of theCreative Commons AttributionNon-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution,and reproduction in any medium,provided the original work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/f5/dd/sjw141.PMC5070449.pdf
Adapted from: https://www.davol.com/product-listing/sp/phasix-mesh .S36 Aesthetic Surgery Journal 36(S2),Non-OADS,/arxiv_data1/oa_pdf/f5/dd/sjw141.PMC5070449.pdf
28. http://www.davol.com/product-listing/sp/phasix-mesh/ .,Non-OADS,/arxiv_data1/oa_pdf/f5/dd/sjw141.PMC5070449.pdf
"nCounter Gene Expression Assay For multiplexed analysis, RNA samples (200 ng/striatum) were analyzed using the Nanostring nCounter System at thePrincess Margaret Genomics Centre (Toronto, ON, Canada;http://www.pmgenomics.ca/pmg enomics), last accessed 23 August 2016.",OADS,/arxiv_data1/oa_pdf/2e/fc/nlw081.PMC5070459.pdf
"“Primer3O utput” (http://bioinfo.ut.ee/pri mer3-0.4.0, last accessed 23 August 2016) was used to design theprimers as follows.",OADS,/arxiv_data1/oa_pdf/2e/fc/nlw081.PMC5070459.pdf
"That is, area fractions were quantified in ImageJ (http://rsbweb.nih.gov/ij, last accessed 23 August 2016) after subtract-ing the background fluorescence and converting the images togray scale.",OADS,/arxiv_data1/oa_pdf/2e/fc/nlw081.PMC5070459.pdf
"Body Hair Transplant by Follicular Unit Extraction: My Experience With 122 Patients Sanusi Umar, MDAesthetic Surgery Journal 2016, Vol 36(10) 1101 –1110 © 2016 The American Society forAesthetic Plastic Surgery, Inc.This is an Open Access articledistributed under the terms of theCreative Commons Attribution-NonCommercial-NoDerivs licence(http://creativecommons.org/licenses/by-nc-nd/4.0/), whichpermits non-commercialreproduction and distribution ofthe work, in any medium, providedthe original work is not altered ortransformed in any way, and thatthe work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ce/34/sjw089.PMC5070467.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/9b/ircmj-18-08-38374.PMC5070484.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/51/num-08-04-37666.PMC5070485.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7d/aa/ircmj-18-08-37918.PMC5070486.pdf
"For reprints and permission queries, plea se visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/ae/38/10.1177_2325967116668138.PMC5070495.pdf
2015. http://www.uspta.com/default.aspx/MenuItemID/2229/MenuGroup/ HOME.htm.,Non-OADS,/arxiv_data1/oa_pdf/ae/38/10.1177_2325967116668138.PMC5070495.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ © The Author(s) (2016) Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/57/ed/mtm201666.PMC5070512.pdf
"This is an Open Access article distr ibuted under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-co mmercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2014. https://www.healthit.gov/providers-professionals/achieve-meaningful-use/ core-measures-2/clinical-decision-support-rule .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
http://www.msnbc.msn.com/id/43529641/ns/health- health_care/t/nurses-suicide-highlights-twin-tragedies-medical-errors/ .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2009. http://www.msnbc.msn.com/id/28655104/#.Tph-b3I2Y9Z .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
"2011. http://www.latimes.com/health/ct-met-technology- errors-20110627,0,2158183.story .",Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2010. http://huffpostfund.org/stories/2010/04/doctors-shift- electronic-health-systems-signs-harm-emerge .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2011. http://www.post-gazette.com/pg/11147/1149429- 114-0.stm#ixzz1amZZEw6Y .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2015. https://s3.amazonaws.com/pub- lic-inspection.federalregister.gov/2015-06612.pdf .,OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
2014. https://www.healthit.gov/sites/default/files/safety_plan_master.pdf .,Non-OADS,/arxiv_data1/oa_pdf/1f/f7/ocw005.PMC5070518.pdf
"This is an Open Access article distr ibuted under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-co mmercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
2010. http://www.rand.org/pubs/technical_reports/TR664.html .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
European Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data.http://europa.eu/legislation_summaries/information_society/data_protec- tion/l14012_en.htm .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
13.Reform of Data Proection Legislation .http://ec.europa.eu/justice/data-pro- tection/ .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
Location: Health and Social Care Information Centre; 2014. https://www.go- v.uk/government/publications/review-of-data-releases-made-by-the-nhs-information-centre .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
2010. http://www.projectpact.eu/privacy-security-research-paper-series/ privacy-security-research-paper-series/PACT_ResearchPapers_10_FINAL.pdf .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
2007. http://weis2007.econinfosec.org/papers/66.pdf .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
PACT D2.2 Methodological report on survey design and survey question- naire: http://www.projectpact.eu/deliverables/wp3-fieldwork .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
http://www.projectpact.eu/ deliverables/wp3-fieldwork .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
2005. http://www.cs.cmu.edu/ /C24ponguru/CMU-ISRI-05-138.pdf .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
PACT D 4.2 Public Perception of Security and Privacy: Results of the com- prehensive analysis of PACT’s pan-European Survey: http://www.project- pact.eu/deliverables/wp3-fieldwork .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
2009;161. http://www.prospectmagazine.co.uk/features/longlivethedatabasestate .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
http://www.theguar- dian.com/commentisfree/2014/feb/28/care-data-is-in-chaos .,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
"The collection, linking and use of data in bio- medical research and health care: ethical issues, 2015. http://nuffield- bioethics.org/project/biological-health-data/#sthash.pdXEZZ7t.dpuf http://nuffieldbioethics.org/project/biological-health-data/ .",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ocw012.PMC5070520.pdf
"This is an Open Access article distr ibuted under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-co mmercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
http://bd2k.nih.gov/about_bd2k.html#bigdata .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
https://cbiit.nci.nih.gov/ncip/nci-cancer- genomics-cloud-pilots .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
http://opensciencegrid.org .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
"Risk Management Guide for Information Technology Systems — NIST Special Publication 800-30. http://www.hhs.gov/ocr/privacy/hipaa/administrative/securityrule/nist 800-30.pdf , July 2002.",Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
http://fasterdata.es.net/science-dmz/ .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
"Guidelines on Firewalls and Firewall Policy — NIST Special Publication 800-41, revision 1.http://csrc.nist.gov/publications/nistpubs/800-41-Rev1/sp800-41-rev1.pdf , September 2009.",Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
https://www.bro.org .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
http://globalnoc.iu.edu/sdn/scipass.html .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
"Security and Privacy Controls for Federal Information Systems and Organizations — NIST SpecialPublication 800-53, revision 4. http://nvlpubs.nist.gov/nistpubs/Special Publications/NIST.SP.800-53r4.pdf , April 2013.",Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
"An Introductory Resource Guide forImplementing the Health Insurance Portability and Accountability Act (HIPAA) Security Rule, October 2008. http://csrc.nist.gov/publications/nistpubs/800- 66-Rev1/SP-800-66-Revision1.pdf .",Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
https://globalnoc.iu.edu .,Non-OADS,/arxiv_data1/oa_pdf/3d/3c/ocw032.PMC5070525.pdf
"In this analysis, for both instruments, we use release three of the spin-averaged, ≈11 s data available at http://www.rbsp-ect.lanl.gov.",OADS,/arxiv_data1/oa_pdf/26/2f/JGRA-121-397.PMC5070526.pdf
"Figures 2f –2h show solar wind speed, the interplanetary magnetic ﬁeld (IMF) Bz, and the Dstindex from OMNIWeb (http://omniweb.gsfc.nasa.gov).",OADS,/arxiv_data1/oa_pdf/26/2f/JGRA-121-397.PMC5070526.pdf
"Data Cent., Boulder, Colo. [Available at http://www.ngdc.noaa.gov/mgg/bathymetry/arctic/ibcaorelatedsites.html.]",OADS,/arxiv_data1/oa_pdf/ca/6c/JGRC-120-7827.PMC5070527.pdf
NCEP/NCAR Reanalysis data are provided by the NOAA Physical Sciences Division (http://www.esrl.noaa.gov/psd/data/reanalysis/reanalysis.shtml).,OADS,/arxiv_data1/oa_pdf/ca/6c/JGRC-120-7827.PMC5070527.pdf
CFS data were obtained from (http://cfs.ncep.noaa.,OADS,/arxiv_data1/oa_pdf/ca/6c/JGRC-120-7827.PMC5070527.pdf
Data and Method In this study we used monthly surface air data at observational station obtained from the Goddard Institutefor Space Studies Surface Temperature Analysis (GISTEMP) (http://data.giss.nasa.gov/gistemp/station_data/).,OADS,/arxiv_data1/oa_pdf/60/de/JGRD-120-12474.PMC5070534.pdf
"INTENSIFICATION OF THE FERREL CELL 12,484Acknowledgments The authors thank the Physical Science Division (PSD) for providing the NCEPReanalysis I data from their websitehttp://www.esrl.noaa.gov/psd/, Sergei N. Rodionov for providing RSI tool from the website http://www.climatelogic.com/home, and the Climate ResearchUnit (CRU) for providing global land surface monthly temperature data from the website www.cru.uea.ac.uk/data.This research is supported by a project“NIMR-2012-B-2 (Development and application of methodology for climate change prediction) ”.",Non-OADS,/arxiv_data1/oa_pdf/60/de/JGRD-120-12474.PMC5070534.pdf
The processing of the C3M data used in thisanalysis was funded under the NASAEnergy and Water Cycle Studies program and is available from the Langley Atmospheric Science DataCenter (http://eosweb.larc.nasa.gov).,OADS,/arxiv_data1/oa_pdf/a3/fb/JGRD-120-12656.PMC5070557.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/1a/hepatmon-16-08-35312.PMC5070561.pdf
Available from: http://www.who.int/ mediacentre/factsheets/fs280/en /.,Non-OADS,/arxiv_data1/oa_pdf/2b/1a/hepatmon-16-08-35312.PMC5070561.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/66/53/hepatmon-16-08-37786.PMC5070562.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/d5/hepatmon-16-08-38584.PMC5070563.pdf
"Central corneal thickness:  Therefore, to determine the  time point of rejection, Flynn and coworkers suggested Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > Received 5 July 2016 | Accepted 14 October 2016 | Published 17 October 2016© 2016 Molecular Vision 1248Optimizing rejection readouts in a corneal allograft  transplantation model Thabo Lapp, Antonia Hildebrand, Daniel Böhringer, Paola Kammrath Betancor, Günther Schlunck, Thomas  Reinhard (The first two authors contributed equally to this work) Eye Center Medical Center, Faculty of Medicine, University of Freiburg, Germany Purpose:  To evaluate the feasibility of anterior segment spectral domain optic coherence tomography (ASOCT) as  rejection readout in a keratoplasty mouse model and to compare ASOCT against the current standard (i.e., a clinical  score system).",Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1249pachymetry [ 14].,Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1250Rat and murine graft models are well-established in  experimental transplant studies.,Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1251average central thickness in pixels.,Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
"Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1252GraphPad Prism (GraphPad Software Inc., LaJolla, CA;  version 6.0) or R. Before the analysis, the results were  subjected to descriptive analysis and determination of  normality using a Kolmogorov–Smirnov test.",OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
"Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1253The initial edema in the syngeneic group dissolved over time  (Appendix 1, left upper panel).",Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1254double-masked fashion.,Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
Molecular Vision  2016; 22:1248-1255 <http://www.molvis.org/molvis/v 22/1248 > © 2016 Molecular Vision  1255REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
"Vienna, Austria: R Foundation for Statistical  Computing; 2013. http://www.R-project.org .",Non-OADS,/arxiv_data1/oa_pdf/90/44/mv-v22-1248.PMC5070569.pdf
"In addition, a C>T Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > Received 30 August 2016 | Accepted 14 October 2016 | Published 17 October 2016© 2016 Molecular Vision 1239North Carolina macular dystrophy (MCDR1) caused by a novel  tandem duplication of the PRDM13  gene Sara J. Bowne,1 Lori S. Sullivan,1 Dianna K. Wheaton,2 Kirsten G. Locke,2 Kaylie D. Jones,2 Daniel C.  Koboldt,3 Robert S. Fulton,3 Richard K. Wilson,3 Susan H. Blanton,4 David G. Birch,2,5 Stephen P. Daiger1,6 (The first two authors contributed equally to this work.)",Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
"Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1240substitution at chr6:100,041,040 was found in an additional  family with NCMD.",Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1241data using Genotyping Console™ (Affymetrix).,OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
"Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1242Exome Library v2.0 (Roche, Madison, WI) according to the  manufacturer’s protocol.",Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1243marked using Picard v1.46 .,Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1244 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1245at approximately the same region as the RFS355 family [ 9].,Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
"Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  1246As there is only a partial copy of the CCNC  gene, it is  probable that any mRNA generated undergoes nonsense- mediated decay and no additional CCNC protein is produced,  regardless of the presence of the extra DNase I hypersensitive  site.",Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
Molecular Vision  2016; 22:1239-1247 <http://www.molvis.org/molvis/v 22/1239 > © 2016 Molecular Vision  124716.,Non-OADS,/arxiv_data1/oa_pdf/46/db/mv-v22-1239.PMC5070570.pdf
"Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > Received 26 August 2016 | Accepted 14 October 2016 | Published 17 October 2016© 2016 Molecular Vision 1221Human postmortem lacrimal and submandibular glands stored  in RNA later are suitable for molecular, biochemical, and cell  biological studies Dillon Hawley,1 Hema Aluri,1 Helene Armaos,1 Gina Kim,1 Claire Kublin, Driss Zoukhri1,2 (The first two authors contributed equally to this work.)",Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
"Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1222For a long time, the markers of tissue quality have been post - mortem interval, agonal conditions, and donor age and health  [14,15].",Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1223after another to the RNeasy MinElute spin column and centri - fuged at 5000 × g for 5 min.,Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1224 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1225 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
"Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  122640 s at 94 °C, annealing for 40 s at 53 °C, extension for 1  min at 72 °C, and a final extension at 72 °C for 10 min.",Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1227incubated overnight at 4  °C with the appropriate primary  antibodies prepared in diluted blocking buffer.,Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
Molecular Vision  2016; 22:1221-1228 <http://www.molvis.org/molvis/v 22/1221 > © 2016 Molecular Vision  1228Relevancy for understanding pathologic conditions.,Non-OADS,/arxiv_data1/oa_pdf/25/86/mv-v22-1221.PMC5070571.pdf
"Mutations in CYP1B1  have been shown to Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > Received 1 August 2016 | Accepted 14 October 2016 | Published 17 October 2016© 2016 Molecular Vision 1229Analysis of CYP1B1  in pediatric and adult glaucoma and other  ocular phenotypes Linda M. Reis,1 Rebecca C. Tyler,1 Eric Weh,1 Kathryn E. Hendee,1,2 Ariana Kariminejad,3 Omar Abdul- Rahman,4 Tawfeg Ben-Omran,5 Melanie A. Manning,6 Ahmet Yesilyurt,7 Catherine A. McCarty,8 Terrie E.  Kitchner,8 Deborah Costakos,9 Elena V .",Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1230cause various glaucoma phenotypes [ 7].,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1231junctions of CYP1B1  (reference sequence NM_000104.3 )  were screened with direct DNA sequencing of PCR products  in the cases and controls.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1232evidence that this is a benign polymorphism.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
"Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1233one, p.(Tyr81Asn), was computed to be damaging by four  of the five programs (Table 2).",OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1234The contribution of CYP1B1  to POAG is less clear.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
"Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1235reported in three other families with JOAG/POAG; family  history was noted for one family, in which a sibling with  pseudoexfoliative glaucoma carried the same truncating  mutation [ 24,52,53].",Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1236of patients with pediatric CYP1B1  phenotypes should be  monitored for adult-onset glaucoma.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  1237Matrix in Glaucoma Patients.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Molecular Vision  2016; 22:1229-1238 <http://www.molvis.org/molvis/v 22/1229 > © 2016 Molecular Vision  123842.,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Available at: http://exac.broadinstitute.org .,Non-OADS,/arxiv_data1/oa_pdf/67/ad/mv-v22-1229.PMC5070572.pdf
Available  online from http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeeting   Materials/Drugs/Endocrinologicand   MetabolicDrugsAdvisoryCommittee/ UCM379648.pdf.,OADS,/arxiv_data1/oa_pdf/ce/e8/181.PMC5070584.pdf
Available online from http://www.fda.gov/ downloads/AdvisoryCommittees/   CommitteesMeetingMaterials/Drugs/   EndocrinologicandMetabolicDrugs  AdvisoryCommittee/UCM379648.pdf.,OADS,/arxiv_data1/oa_pdf/ce/e8/181.PMC5070584.pdf
Available from http://clinicaltrials.gov/ct2/show/ NCT01529424.,Non-OADS,/arxiv_data1/oa_pdf/ce/e8/181.PMC5070584.pdf
Available from  http://www.ncsl.org/research/health/   diseases-and-conditions/diabetes.aspx.,Non-OADS,/arxiv_data1/oa_pdf/aa/3b/187.PMC5070585.pdf
Available from http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/aa/3b/187.PMC5070585.pdf
Available from http://www.ncqa.,Non-OADS,/arxiv_data1/oa_pdf/aa/3b/187.PMC5070585.pdf
Available  from http://www.prnewswire.com/news-   releases/continued-epidemic-rise-in- diabetes-and-prediabetes-shows-need-for- immediate-congressional-action-263708381.,Non-OADS,/arxiv_data1/oa_pdf/aa/3b/187.PMC5070585.pdf
[Database Online] Available from https://prospectorx.com/Home.aspx.,Non-OADS,/arxiv_data1/oa_pdf/09/72/201.PMC5070587.pdf
[Database Online]  Available from https://prospectorx.com/aspx .,OADS,/arxiv_data1/oa_pdf/09/72/201.PMC5070587.pdf
Available  from http://www.medscape.com/viewarti - cle/849608.,Non-OADS,/arxiv_data1/oa_pdf/09/72/201.PMC5070587.pdf
"Available from http://www.novonordisk   medicalinformation.com/file_upload/ Novolin%20R%20Prescribing%20 Information,%20March%202013.pdf.",Non-OADS,/arxiv_data1/oa_pdf/09/72/201.PMC5070587.pdf
Available from http://www.diabetesforecast.,Non-OADS,/arxiv_data1/oa_pdf/09/72/201.PMC5070587.pdf
Available from  http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm?source=govdelivery&utm_ medium=email&utm_source=govdelivery.,Non-OADS,/arxiv_data1/oa_pdf/b8/47/214.PMC5070590.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/ba/hepatmon-16-08-38973.PMC5070613.pdf
PLoS Genet 2016; 12(5): e1006037; http://dx.doi.org/10.1371/journal.pgen.1006037 © 2016 Marjo K. Hyt €onen and Hannes Lohi.,Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which per- mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"1, e1241362 (6 pages)http://dx.doi.org/10.1080/21675511.2016.1241362",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Canine heritable monogenicdiseases, with the current list of 201 known causativegenetic variants, are recorded in the public databaseOnline Mendelian Inheritance in Animals (OMIA)(http://omia.angis.org.au ).",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"ORCID Hannes Lohi http://orcid.org/0000-0003-1087-5532 References [1] Wang GD, Zhai W, Yang HC, Wang L, Zhong L, Liu YH, Fan RX, Yin TT, Zhu CL, Poyarkov AD, et al.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Cell Res 2016; 26:21-33;PMID:26667385; http://dx.doi.org/10.1038/cr.2015.147 [2] Frantz LA, Mullin VE, Pionnier-Capitan M, Lebrasseur O, Ollivier M, Perri A, Linderholm A, Mattiangeli V,Teasdale MD, Dimopoulos EA, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Science 2016; 352:1228-31; PMID:27257259; http://dx.doi.org/10.1126/science.aaf3161 [3] Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, 3rd, Zody MC, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Nature 2005; 438:803-19; PMID:16341006; http://dx.doi.org/10.1038/nature04338 [4] Karlsson EK, Baranowska I, Wade CM, Salmon Hillbertz NH, Zody MC, Anderson N, Biagi TM, Patterson N, Piel-berg GR, Kulbokas EJ, 3rd, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Genome Res 2004; 14:2388-96; PMID:15545498; http://dx.doi.org/ 10.1101/gr.3147604 [7] Dr €ogem €uller C, Karlsson EK, Hyt €onen MK, Perloski M, Dolf G, Sainio K, Lohi H, Lindblad-Toh K, Leeb T. A mutation inhairless dogs implicates FOXI3 in ectodermal development.Science 2008; 321:1462; PMID:18787161; http://dx.doi.org/10.1126/science.1162525 [8] Hyt €onen MK, Arumilli M, Lappalainen AK, Kallio H, Snellman M, Sainio K, Lohi H. A novel GUSB mutation in Brazilian terriers with severe skeletal abnormalitiesdeﬁnes the disease as mucopolysaccharidosis VII.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS One 2012; 7:e40281; PMID:22815736; http://dx.doi.org/10.1371/journal.pone.0040281 [9] Sepp €al€a EH, Reuser AJ, Lohi H. A nonsense mutation in the acid a-glucosidase gene causes Pompe disease in Finnish and Swedish Lapphunds.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS One 2013; 8: e56825; http://dx.doi.org/10.1371/journal.pone.0056825 [10] Ky €ostila K, Lappalainen AK, Lohi H. Canine chondro- dysplasia caused by a truncating mutation in collagen-binding integrin asubunit 10.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS One 2013; 8: e75621; PMID:24086591; http://dx.doi.org/10.1371/journal.pone.0075621 [11] Ky €ostila K, Cizinauskas S, Sepp €al€a EH, Suhonen E, Jeserevics J, Sukura A, Syrj €a P, Lohi H. A SEL1L mutation links a canine progressive early-onset cerebellar ataxia to the endo- plasmic reticulum-associated protein degradation (ERAD)machinery.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS Genet 2012; 8:e1002759; PMID:22719266;http://dx.doi.org/10.1371/journal.pgen.1002759 [12] Ky €ostila K, Syrj €a P, Jagannathan V, Chandrasekar G, Jokinen TS, Sepp €al€a EH, Becker D, Dr €ogem €uller M, Die- tschi E, Dr €ogem €uller C, et al.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS Genet 2015; 11: e1005169; PMID:25875846; http://dx.doi.org/10.1371/journal.pgen.1005169 [13] Sepp €al€a EH, Jokinen TS, Fukata M, Fukata Y, Webster MT, Karlsson EK, Kilpinen SK, Steffen F, Dietschi E,Leeb T, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS Genet 2011; 7:e1002194; http://dx.doi.org/10.1371/journal.pgen.1002194 [14] Casal ML, Lewis JR, Mauldin EA, Tardivel A, Ingold K, Favre M, Paradies F, Demotz S, Gaide O, Schneider P.Signiﬁcant correction of disease after postnatal adminis- tration of recombinant ectodysplasin A in canine X-linked ectodermal dysplasia.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Am J Hum Genet 2007;81:1050-6; PMID:17924345; http://dx.doi.org/10.1086/521988 [15] Callan MB, Haskins ME, Wang P, Zhou S, High KA, Arruda VR.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"PLoS One 2016; 11:e0151800; PMID:27011017; http://dx.doi.org/ 10.1371/journal.pone.0151800 [16] Beltran WA, Cideciyan AV, Iwabe S, Swider M, Kosyk MS, McDaid K, Martynyuk I, Ying GS, Shaffer J, DengWT, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Proc Natl Acad Sci U S A 2015; 112:E5844-53; PMID:26460017; http://dx.doi.org/ 10.1073/pnas.1509914112 [17] Hyt €onen MK, Arumilli M, Lappalainen AK, Owczarek- Lipska M, Jagannathan V, Hundi S, Salmela E, Venta P,Sarkiala E, Jokinen T, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
PLoS Genet2016; 12:e1006037; PMID:27187611; http://dx.doi.org/ 10.1371/journal.pgen.1006037 [18] Thornburg LP.,OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
Bone 2014; 60:246-51;PMID:24389367; http://dx.doi.org/10.1016/j.bone.2013.12.,OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"J Clin Invest 2005; 115:1250-7; PMID:15864348; http://dx.doi.org/10.1172/JCI22760 [21] Kitaoka T, Miyoshi Y, Namba N, Miura K, Kubota T, Ohata Y, Fujiwara M, Takagi M, Hasegawa T, Juppner H, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Eur J Pediatr2014; 173:799-804; PMID:24390061; http://dx.doi.org/10.1007/s00431-013-2252-8 [22] Chou JY, Mans ﬁeld BC.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Curr Top Membr 2014; 73:357-82; PMID:24745989; http://dx.doi.org/10.1016/ B978-0-12-800223-0.00010-4 [23] Kim JY, Tillison K, Zhou S, Wu Y, Smas CM.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Proteomics 2008; 8:2625-39; PMID:18600791; http://dx.doi.org/10.1002/pmic.200701192 [25] Saksa N, Neme A, Ryyn €anen J, Uusitupa M, de Mello VD, Voutilainen S, Nurmi T, Virtanen JK, TuomainenTP, Carlberg C. Dissecting high from low responders in a vitamin D3 intervention study.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"J Steroid Biochem Mol Biol 2015; 148:275-82; PMID:25448738; http://dx.doi.org/10.1016/j.jsbmb.2014.11.012 [26] Anastasio N, Ben-Omran T, Teebi A, Ha KC, Lalonde E, Ali R, Almureikhi M, Der Kaloustian VM, Liu J, Rose-nblatt DS, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
Am J Hum Genet 2010;87:553-9; PMID:20887961; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"J BiolChem 2002; 277:39696-702; PMID:12154095; http://dx.doi.org/10.1074/jbc.M206140200 [28] Hwang M, Morasso MI.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"J Biol Chem 2003; 278:47827-33;PMID:12970338; http://dx.doi.org/10.1074/jbc.M306561200 [29] Hwang M, Kalinin A, Morasso MI.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"The temporal and spatial expression of the novel Ca 2C-binding proteins, Scarf and Scarf2, during development and epidermal differentiation.Gene Expr Patterns 2005; 5:801-8; PMID:15922673; http://dx.doi.org/10.1016/j.modgep.2005.03.010[30] Takeyari S, Yamamoto T, Kinoshita Y, Fukumoto S, Glori- eux FH, Michigami T, Hasegawa K, Kitaoka T, Kubota T,Imanishi Y, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Bone 2014; 67:56-62; PMID:24982027; http://dx.doi.org/10.1016/j.bone.2014.06.026 [31] Rafaelsen SH, Raeder H, Fagerheim AK, Knappskog P, Carpenter TO, Johansson S, Bjerknes R. Exome sequenc-ing reveals FAM20c mutations associated with ﬁbroblast growth factor 23-related hypophosphatemia, dentalanomalies, and ectopic calci ﬁcation.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"J Bone Miner Res 2013; 28:1378-85; PMID:23325605; http://dx.doi.org/10.1002/jbmr.1850 [32] Simpson MA, Hsu R, Keir LS, Hao J, Sivapalan G, Ernst LM, Zackai EH, Al-Gazali LI, Hulskamp G, Kingston HM, et al.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"AmJ Hum Genet 2007; 81:906-12; PMID:17924334; http://dx.doi.org/10.1086/522240 [33] Simpson MA, Scheuerle A, Hurst J, Patton MA, Stewart H, Crosby AH.",OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
"Clin Genet 2009; 75:271-6; PMID:19250384; http://dx.doi.org/10.1111/j.1399-0004.2008.01118.x [34] Wang X, Wang S, Lu Y, Gibson MP, Liu Y, Yuan B, Feng JQ, Qin C. FAM20C plays an essential role inthe formation of murine teeth.",Non-OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
J Biol Chem 2012;287:35934-42; PMID:22936805; http://dx.doi.org/10.1074/jbc.M112.386862e1241362-6 M. K. HYT €ONEN AND H. LOHI,OADS,/arxiv_data1/oa_pdf/74/eb/krad-04-01-1241362.PMC5070630.pdf
PLoS Genet 2016; 12(3): e1005907; http://dx.doi.org/10.1371/journal.pgen.1005907 #These authors contributed equally to this work.,Non-OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"1, e1241361 (6 pages)http://dx.doi.org/10.1080/21675511.2016.1241361",Non-OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
Front Endocrinol 2014; 5:109; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Congenital Hypogonadotropic Hypogonadism and Kallmann Syndrome: Past, Present, and Future.Endocrinol Metab 2015; 30:456-66; http://dx.doi.org/10.3803/EnM.2015.30.4.456 [3] Rance NE, Young WS, 3rd, McMullen NT.",Non-OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J Comp Neurol 1994; 339:573-86;PMID:8144747; http://dx.doi.org/10.1002/cne.903390408 [4] Cariboni A, Maggi R, Parnavelas JG.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
Trends Neurosci 2007; 30:638-44;PMID:17981344; http://dx.doi.org/10.1016/j.tins.2007.,OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Front Neuroen-docrinol 2011; 32(1):43-52; PMID:20650288; http://dx.doi.org/10.1016/j.yfrne.2010.07.005 [6] Forni PE, Wray S. GnRH, anosmia and hypogonado- tropic hypogonadism –where are we?",Non-OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Front Neuroendoc- rinol 2015; 36:165-77; PMID:25306902; http://dx.doi.org/10.1016/j.yfrne.2014.09.004 [7] Miura K, Acierno JS, Jr, Seminara SB.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J HumGenet 2004; 49:265-8; PMID:15362570; http://dx.doi.org/ 10.1007/s10038-004-0137-4 [8] Trarbach EB, Baptista MT, Garmes HM, Hackel C. Molecular analysis of KAL-1, GnRH-R, NELF and EBF2genes in a series of Kallmann syndrome and normosmichypogonadotropic hypogonadism patients.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J Endocrinol2005; 187:361-8; PMID:16423815; http://dx.doi.org/10.1677/joe.1.06103 [9] Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, Plummer L, Hughes V, Seminara S, Cheng YZ, et al.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J ClinInvest 2007; 117:457-63; PMID:17235395; http://dx.doi.org/10.1172/JCI29884 [10] Pedersen-White JR, Chorich LP, Bick DP, Sherins RJ, Lay- man LC.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Mol Hum Reprod 2008; 14:367-70; PMID:18463157; http://dx.doi.org/10.1093/molehr/gan027 [11] Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, Dwyer AA, Quinton R, Hall JE, GusellaJF, et al.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"of digenic mutations in patients with normosmic hypo- gonadotropic hypogonadism and Kallmann syndrome.Fertil Steril 2011; 96:1424-30; PMID:22035731; http://dx.doi.org/10.1016/j.fertnstert.2011.09.046 [13] Xu N, Kim HG, Bhagavath B, Cho SG, Lee JH, Ha K, Meliciani I, Wenzel W, Podolsky RH, Chorich LP, et al.Nasal embryonic LHRH factor (NELF) mutations in patients with normosmic hypogonadotropic hypogonad- ism and Kallmann syndrome.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Fertil Steril 2011; 95:1613-20.e1-7; PMID:21300340; http://dx.doi.org/10.1016/j.fertnstert.2011.01.010 [14] Costa-Barbosa FA, Balasubramanian R, Keefe KW, Shaw ND, Al-Tassan N, Plummer L, Dwyer AA, Buck CL,Choi JH, Seminara SB, Quinton R, Monies D, et al.",Non-OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J Clin Endocrinol Metab 2013; 98:E943-953; PMID:23533228; http://dx.doi.org/10.1210/jc.2012-4116 [15] Dieterich DC, Karpova A, Mikhaylova M, Zdobnova I, K€onig I, Landwehr M, Kreutz M, Smalla KH, Richter K, Landgraf P, et al.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"PLoSBiol 2008; 6:e34; PMID:18303947; http://dx.doi.org/ 10.1371/journal.pbio.0060034 [16] Kindler S, Dieterich DC, Schutt J, Sahin J, Karpova A, Mikhaylova M, Schob C, Gundel ﬁnger ED, Kreienkamp HJ, Kreutz MR. Dendritic mRNA targeting of Jacob andN-methyl-d-aspartate-induced nuclear translocationafter calpain-mediated proteolysis.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"J Biol Chem 2009;284:2543140; PMID:19608740; http://dx.doi.org/10.1074/jbc.M109.022137 [17] Karpova A, Mikhaylova M, Bera S, B €ar J, Reddy PP, Beh- nisch T, Rankovic V, Spilker C, Bethge P, Sahin J, et al.Encoding and transducing the synaptic or extrasynapticorigin of NMDA receptor signals to the nucleus.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Cell2013; 152:1119-33; PMID:23452857; http://dx.doi.org/10.1016/j.cell.2013.02.002 [18] Kaushik R, Grochowska KM, Butnaru I, Kreutz MR. Pro- tein traf ﬁcking from synapse to nucleus in control of activity-dependent gene expression.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Neuroscience 2014; 280:340-50; PMID:25230285; http://dx.doi.org/10.1016/j.neuroscience.2014.09.011 [19] Panayotis N, Karpova A, Kreutz MR, Fainzilber M. Mac- romolecular transport in synapse to nucleus communica-tion.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Trends Neurosci 2015; 38:108-16; PMID:25534890;http://dx.doi.org/10.1016/j.tins.2014.12.001[20] R €onicke R, Mikhaylova M, R €onicke S, Meinhardt J, Schr €oder UH, F €a n d r i c hM ,R e i s e rG ,K r e u t zM R ,R e y m a n nK G .E a r l y neuronal dysfunction by amyloid boligomers depends on activation of NR2B-containing NMDA receptors.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"NeurobiolAging 2011; 32:2219-28; PMID:20133015; http://dx.doi.org/10.1016/j.neurobiolaging.2010.01.011 [21] Gomes GM, Dalmolin GD, B €ar J, Karpova A, Mello CF, Kreutz MR, Rubin MA.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"PLoS One 2014; 9:e99184; PMID:24921942;http://dx.doi.org/10.1371/journal.pone.0099184 [22] Behnisch T, Yuanxiang P, Bethge P, Parvez S, Chen Y, Yu J, Karpova A, Frey JU, Mikhaylova M, Kreutz MR. Nucleartranslocation of Jacob in hippocampal neurons after stim- uli inducing long-term potentiation but not long-term depression.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"PLoS One 2011; 6:e17276; PMID:21364755;http://dx.doi.org/10.137 1/journal.pone.0017276 [23] Kramer PR, Wray S. Novel gene expressed in nasal region inﬂuences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neu-rons.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Dev Dyn 2009; 238:66-75; PMID:19097186; http://dx.doi.org/10.1002/dvdy.21823 [25] Mikhaylova M, Karpova A, B €ar J, Bethge P, YuanXiang P, Chen Y, Zuschratter W, Behnisch T, Kreutz MR. Cellulardistribution of the NMDA-receptor activated synapto- nuclear messenger Jacob in the rat brain.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"Brain Struct Funct 2014; 219:843-60; PMID:23539133; http://dx.doi.org/10.1007/s00429-013-0539-1 [26] Spilker C, Nullmeier S, Grochowska KM, Schumacher A ,B u t n a r uI ,M a c h a r a d z eT ,G o m e sG M ,Y u a n x i a n gP, Bayraktar G, Rodenstein C, et al.",OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
Mol Cell Endocrinol 2015; 407:26-36; PMID:25731822; http://dx.doi.org/10.1016/j.mce.2015.02.015e1241361-6 C. SPILKER ET AL.,OADS,/arxiv_data1/oa_pdf/54/11/krad-04-01-1241361.PMC5070631.pdf
"This is an open access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
Available at http://www.who.int/tb/publica - tions/global_report/en/.,Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
Available at http://www.who.int/mediacen - tre/factsheets/fs104/en.,Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
"More than 130 national constitutions include the right to health care, see https://www.constituteproject.org.",Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
Available at http://www.msfaccess.org/content/dr-tb-drugs-under-microscope-4th-edition.,Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
Available at http://www.treatmentac - tiongroup.org/tbrd2015.,Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
Available at http://kenyalaw.org/caselaw/cases/view/120363/.,Non-OADS,/arxiv_data1/oa_pdf/10/3c/hhr-18-001.PMC5070676.pdf
"This is an open access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at: http://www.treatmentactiongroup.org/tbrd2015.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at: http://www.who.int/tb/publications/glob - al_report/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www2.ohchr.org/english/law/cescr.htm.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1354788.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Médecins Sans Frontières Access Campaign, “How  many pills does it take?” Available at http://www.msfac - cess.org/content/how-many-pills-does-it-take.",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available  at http://www.who.int/tb/publications/global_report/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.who.int/tb/challenges/mdr/ programmatic_guidelines_for_mdrtb/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available at:  http://www.croiconference.org/sessions/majority-xdr-tb- cases-are-due-transmission-high-hiv-prevalence-setting;  S. Auld, “HIV-associated XDR-TB is transmitted in  households and hospitals in South Africa” (presentation at  Conference on Retroviruses and Opportunistic Infections,  Boston, MA, February 22–25, 2016).",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available  at http://www.stoptb.org/global/plan/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.treatmentac - tiongroup.org/tbrd2015.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available at  http://www.amfar.org/articles/on-the-hill/2013/issue-brief--the-costs-of-flat-funding-for-biomedical-research/ ;  Department of Health & Human Services, Biomedical research and development price index (BRDPI): fiscal year  2013 update and projects for FY 2014-FY 2019 (January 2014).",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://officeofbudget.od.nih.gov/pdfs/FY15/BRDPI_Proj_Jan_2014_508.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available at https://www.pharma - medtechbi.com/publications/pharmasia-news/2013/5/13/pfizer-draws-curtain-on-antiinfective-research-re - focuses-on-nextgen-vaccines; E. Mullin, “Global tuberculosis R&D takes hit with AstraZeneca site closure,” FierceBiotech  (February 24, 2014).",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available  at http://www.reuters.com/article/2014/08/20/us-novar - tis-tuberculosis-idUSKBN0GK19J20140820.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.msfaccess.org/sites/default/files/TB_report__DR-TB_DRUGS_UT - M__4th_edition_2016.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at  http://www.pipelinereport.org.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available at: http://www.dndi.org/wp-con - tent/uploads/2009/03/DNDi_Modelpaper_2013.pdf; and  J. DiMasi, H. Grabowski, and R. Hansen, “Innovation in  the pharmaceutical industry: new estiamtes of R&D costs,”  Journal of Health Economics  47 (2016), pp.",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.otsuka.co.jp/en/company/re - lease/2014/0430_01.html.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available  at http://www.ema.europa.eu/docs/en_GB/document_li - brary/EPAR_-_Summary_for_the_public/human/002753/WC500160681.pdf ; Clayden (see note 36).,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at: http://www.pipelinereport.org.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at https://clinicaltrials.gov/ct2/results?term=sutezolid&Search= - Search.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.who.int/medicines/publica - tions/essentialmedicines/EML2015_8-May-2015.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.who.int/mediacentre/news/releases/2015/new-es - sential-medicines-list/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.pipelinereport.org.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.refworld.org/docid/3ae6b3a10.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.aaas.org/sites/default/files/con - tent_files/UNReportAAAS.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available at http://www.ohchr.org/ Documents/HRBodies/HRCouncil/RegularSession/Ses - sion20/A-HRC-20-26_en.pdf, p. 8.",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.treatmentactiongroup.org/,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.msfaccess.org/3Ps-project.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at  http://www.unfpa.org/resources/human-rights-principles.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.cptrinitiative.org/downloads/resources/GPP-TB%20Oct1%202012%20 FINAL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"Available  at http://www.brics.utoronto.ca/docs/130111-health.html;   The Beijing “Call for Action” on Tuberculosis Control and Patient Care  (Ministerial Meeting of High M/XDR-TB  Burden Countries, Beijing, China, 1–3 April, 2009).",Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Avail - able at http://www.who.int/tb_beijingmeeting/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
Available at http://www.who.int/tb/fea - tures_archive/researchforTBelimination_meeting/en/.,Non-OADS,/arxiv_data1/oa_pdf/94/c3/hhr-18-009.PMC5070677.pdf
"This is an open access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.unesco.org.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://tbinternet.ohchr.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at https://www.wto.org/english/tratop_e/ trips_e/t_agm3_e.htm#7.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at: http://www.iprcommission.org/graphic/documents/final_report.htm .,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://ir.unither.com/releasedetail.cfm?ReleaseID=928100 21.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://us3.campaign-archive1.com/?u=8 5207b84f0f2d8ddc9bd878de&id=a2d0bb121e.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.ohchr.org/EN/ProfessionalInterest/Pages/ OPCESCR.aspx.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at https://www.usaid.gov/what-we-do/global-health/tuberculosis/technical-areas/bedaquiline-donation-program.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.resisttb.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
"Available at http://europa.eu/pol/rd/index_ en.htm ; National Economic Council, Council of Economic  Advisers, and Office of Science and Technology Policy, A Strategy for American Innovation.",Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at https://www.whitehouse.gov/sites/ default/files/uploads/InnovationStrategy.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
"Available at http://www.au.int/en/sites/default/files/EX%20CL%20DEC%20236%20-%20 277%20%28VIII%29%20_E.pdf; African Union, Science,  Technology and Innovation Strategy for Africa 2024 (2014).",Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://hrst.au.int/en/sites/default/files/ STISA-Published%20Book.pdf.,OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.who.int/healthsystems/publications/abuja_report_ aug_2011.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.msfaccess.org/spotlight-on/trans-pacific-partnership- agreement.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
"M. Salomon, Global Responsibility for Human Rights  (Oxford: Oxford University Press, 2007), p. 193; See for example the Stop TB Partnership, http://www.stoptb.org.",Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at http://www.ohchr.org/Documents/Issues/Business/A-HRC-17-31_AEV.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available  at: http://www.phcfm.org/index.php/phcfm/article/ view/698 ; L. Shiffman.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
Available at: http://www.biomedcentral.com/content/pdf/1471-2458-7-14.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
"Available at http:// www.uct.ac.za/mondaypaper/archives/?id=9498; and see  Drugs for Neglected Diseases Initiative, http://www.dndi.org; see Critical Path to TB Drug Regimes, http://www.cptrinitiative.org/.",Non-OADS,/arxiv_data1/oa_pdf/2e/d0/hhr-18-025.PMC5070678.pdf
"This is an open access article distributed under the terms of the  Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/dc/f2/hhr-18-043.PMC5070679.pdf
"AIDS Law Project (see note 32); C. Wangechi, “TB patient  jailed for defaulting treatment, in Kellect,” Internews Kenya   (April 16, 2011) Available at http://www.internewskenya.org/ summaries.php?id=915; C. Ngeno “Narok TB patient gets  one year for failing to take medicine,” The Standard  (July  10, 2015).",Non-OADS,/arxiv_data1/oa_pdf/dc/f2/hhr-18-043.PMC5070679.pdf
Available at http://www.standardmedia.co.ke/article/2000168622/narok-tb-patient-gets-one-year-for-fail - ing-to-take-medicine.,Non-OADS,/arxiv_data1/oa_pdf/dc/f2/hhr-18-043.PMC5070679.pdf
Available at  http://www.who.int/tb/publications/2006/istc_charter.pdf  94.,Non-OADS,/arxiv_data1/oa_pdf/dc/f2/hhr-18-043.PMC5070679.pdf
"This is an open access article distributed under the terms of the  Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/1f/d2/hhr-18-055.PMC5070680.pdf
Esto es  lo que debes saber del conflicto que podría convertirse en  otro Baguazo.” Available at http://utero.pe/2015/02/11/que- esta-pasando-en-pichanaki-esto-es-lo-debes-saber-sobre- el-conflicto-que-podria-convertirse-en-otro-baguazo/  18.,Non-OADS,/arxiv_data1/oa_pdf/1f/d2/hhr-18-055.PMC5070680.pdf
"Available at http://www4.congreso.gob.pe/ac- cesible/constitucion/disposicionesfinales.htm (November  17, 2004.)",Non-OADS,/arxiv_data1/oa_pdf/1f/d2/hhr-18-055.PMC5070680.pdf
“Americas Quarterly Social  Inclusion Index 2015.” Available at http://www.ameri - casquarterly.org/charticles/social-inclusion-index-2015/social_inclusion_index_2015-english.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1f/d2/hhr-18-055.PMC5070680.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at http://www.tbcindia.nic.in.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at: http://health.bih.nic.in/Docs/ Guidelines/Guidelines-DOTS-Plus.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at  http://www.tbfacts.org/tb-statistics-india/.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Avail - able at http://www.tbcindia.nic.in/pdfs/TB%20INDIA%20 2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at http://www.hrln.org/hrln/ images/stories/pdf/RR-fact-findings-reports-11.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at http://www.catchnews.com/india-news/is- the-modi-govt-hounding-lawyers-collective-1457880024.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
"See, for example, UNICEF, Improving Child Nutri - tion, The achievable imperative for global progress (Geneva: UNICEF, 2013), p. 13; See , Right to Food Campaign, Na - tional Food Security Act Violated,  (June 18, 2015)., Available  at: http://www.sacw.net/article11302.html ; H. Mander,  Living Rough, Surviving City Streets: A Study of Homeless  Populations in Delhi, Chennai, Patna, and Madurai for the Planning Commission of India (New Delhi: Planning  Commission of India, February 12, 2014).",Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at  http://www.legallyindia.com/SCOI-Reports/7-cases-show - ing-why-sc-s-social-justice-bench-has-failed-to-close-a-sin - gle-case-of-social-justice.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available  at http://www.ndtv.com/india-news/government-cancels- licenses-of-4-470-erring-ngos-entities-barred-from-fund - ing-supreme-court-bar-asso-770210.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
Available at http://www.greenpeace.org/ india/en/Press/Victory-for-Greenpeace-activist-Priya-Pil - lai—Delhi-HC-overturns-offloading-terms-move-undem - ocratic/.,Non-OADS,/arxiv_data1/oa_pdf/0e/1b/hhr-18-069.PMC5070681.pdf
"This is an open access article distributed under the terms of the  Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/de/2a/hhr-18-085.PMC5070682.pdf
Available  at http://files.unaids.org/en/media/unaids/contentassets/doc - uments/factsheet/2014/20140716_FactSheet_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/de/2a/hhr-18-085.PMC5070682.pdf
"10 (A/66/10) Available at http://legal.un.org/ilc/texts/instruments/english/com - mentaries/9_11_2011.pdf ; ETO Consortium, Maastricht",Non-OADS,/arxiv_data1/oa_pdf/de/2a/hhr-18-085.PMC5070682.pdf
"World Health Organization Media Centre, “Health  and Human Rights,” Fact Sheet Number 323 (December  2015), p. e1, Available at http://www.who.int/mediacentre/ factsheets/fs323/en/  62.",Non-OADS,/arxiv_data1/oa_pdf/de/2a/hhr-18-085.PMC5070682.pdf
"ICESCR (see note 64), Article 22; ETO Consortium,  Maastricht Principles on Extraterritorial Obligations of  States in the Area of Economic, Social and Cultural Rights  (Fian International; Heidelberg, Germany, 2013), Principles  26, 29, 31, Available at http://www.etoconsortium.org/en/ library/maastricht-principles/  89.",Non-OADS,/arxiv_data1/oa_pdf/de/2a/hhr-18-085.PMC5070682.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/db/49/hhr-18-103.PMC5070683.pdf
"65 of 2010 Available  at http://kenyalaw.org/caselaw/cases/view/90359/ (accessed April 11, 2016).",Non-OADS,/arxiv_data1/oa_pdf/db/49/hhr-18-103.PMC5070683.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
"UN Human Rights Council, Report of the detailed  findings of the Commission of Inquiry on human rights  in the Democratic People’s Republic of Korea (Geneva, Switzerland: UNHRC, 2014) A/HRC/25/CRP.1 Available at http://www.ohchr.org/EN/HRBodies/HRC/CoIDPRK/Pages/CommissionInquiryonHRinDPRK.aspx.",Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://journals.plos.org/plos - medicine/article?id=10.1371/journal.pmed.1001486#s4.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://www.keia.org/sites/default/files/publications/perry.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://www.doctorswithoutborders.org/news-stories/voice-field/tb-crisis-former-soviet-states.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at  https://www.hrnk.org/publications/hrnk-publications.php?page=2 .,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://ap.ohchr.org/docu - ments/alldocs.aspx?doc_id=24540.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at  https://www.hrnk.org/publications/hrnk-publications.php.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at  http://www.refworld.org/docid/47a6eba20.html.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://www.kinu.or.kr/eng/pub/pub_04_01.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
"Available at http://www.upi.com/Top_News/World-News/2015/05/19/United-Nations-2500-North-Ko - reans-die-annually-from-tuberculosis/8021432087914/Amnesty International, “The crumbling state of health  care in North Korea” (New York: Amnesty Interna - tional 2010).",Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://www.cfr.org/ health-policy-and-initiatives/amnesty-internation - al-crumbling-state-health-care-north-korea/p22647.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Avail - able at http://newfocusintl.com/un-tuberculosis-aid/.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://www.pih.org/blog/mdr-tuberculosis-north-korea.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://newfocusintl.com/un-tuberculosis-aid/.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at http://newfocusintl.com/north-korea-every - one-doctor/.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
Available at  http://fletcher.tufts.edu/Resilience/Current_Issue.,Non-OADS,/arxiv_data1/oa_pdf/0c/66/hhr-18-109.PMC5070684.pdf
"This is an open access article distributed under the terms  of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available  at http://apps.who.int/ebola/current-situation/ebola-situa - tion-reports 2.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
"Available at http://globalhealth.thelancet.com/2014/09/04/ ebola-or-messy-cocktail-public-health-and-globalisa - tion-post-colonial-africa; S. Philpott and U. Schüklenk, “A  study that should not have been done,” (Garrison: Hastings Center, 2010).",Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://www.thehastingscenter.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://www.cdc.gov/vhf/ebola/resources/out - break-table.html;  Ebola Response Anthropology Platform .,OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://www.ebola-anthropology.net.5.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://web.undp.org/eval - uation/documents/thematic/conflict/sierraleone.pdf 14.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at https://plan-international.org/about-plan/resources/news/teen - age-pregnancy-rates-rise-in-ebola-stricken-west-africa/20.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://www.achpr.org/instruments/achpr/39.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
Available at http://blogs.plos.org/ speakingofmedicine/2014/11/11/factors-might-led-emer - gence-ebola-west-africa/48.,Non-OADS,/arxiv_data1/oa_pdf/f0/6e/hhr-18-115.PMC5070685.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.un.org/en/ga/search/view_doc.asp?symbol - =A/RES/70/1.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.globalhealthtreaty.org .,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www2.ohchr.org/english/law/cescr.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/2015/09/02/ sdg-series-sdgs-and-the-importance-of-formal-independent- review-an-opportunity-for-health-to-lead-the-way/.4.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/wp-con - tent/uploads/sites/13/2013/07/9-Maru.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/wp-content/uploads/sites/13/2014/12/Yamin-final.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/wp-con - tent/uploads/sites/13/2014/12/Flood-final.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://apps.who.int/iris/bitstre am/10665/132673/1/9789241507523_eng.pdf.,OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.transparency.org/whatwedo/publication/global_cor - ruption_report_2006_corruption_and_health.16.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available  at http://repository.essex.ac.uk/9717/1/accountabil - ity-right-highest-attainable-standard-health.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://ptfund.org/wp-content/ uploads/2015/05/Case-Study-Samuhik-Abhiyan-Nepal.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://r4d.org/blog/2012-06-04/video-where-have-they-gone-ict- address-health-worker-absenteeism-india.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://blog.transparency.org/2012/07/11/community-empowerment-in-uganda-us - ing-icts-for-better-health-service-delivery/.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.un.org/en/ga/search/view_doc.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214439/.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.un.org/en/ga/search/view_doc.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at   http://www.hhrjournal.org/2014/12/09/four-strategic- pathways-for-the-realization-of-the-right-to-health- through-civil-society-actions-challenges-and-practi - cal-lessons-learned-in-the-egyptian-context/.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available  at http://www.globalhealthrights.org.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www1.umn.edu/humanrts/in - stree/opt-prot08.html.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/wp-content/up - loads/sites/13/2013/06/Friedman-FINAL2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/2014/07/01/ human-rights-and-the-global-fund-to-fight-aids-tubercu - losis-and-malaria/.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www1.umn.edu/humanrts/gencomm/escgencom14.htm .,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.ohchr.org/Documents/Publications/Human_rights_indica - tors_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.hhrjournal.org/2012/12/13/ approaches-to-the-development-of-human-rights-indica - tors-for-womens-health/.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.fes.de/gpol/pdf/A-HRC-15-WG2-TF-2-Add2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1478&context=djcil.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.state.gov/ documents/organization/226844.pdf.,OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.cehurd.org/wp-content/uploads/ downloads/2015/01/CEHURD-FCGH-Paper.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available  at http://www.who.int/fctc/guidelines/adopted/en/.32.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www2.ohchr.org/ english/issues/women/docs/A.HRC.21.22_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at  http://tbinternet.ohchr.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www1.umn.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.dplf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at   http://www.ishr.ch/sites/default/files/article/files/ishr_   submission_to_21st_meeting_of_special_procedures.pdf.39.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.msmgf.org/index.cfm/id/65/alert_id/20.,OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://ozone.unep.org/en/handbook-montre -al-protocol-substances-deplete-ozone-layer/2117.42.,OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at https://www.wto.org/ english/docs_e/legal_e/28-dsu.pdf.43.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www1.umn.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www1.umn.edu/humanrts/instree/protocol-africancourt.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.ohchr.org/Documents/Publications/GuidingPrinciplesBusi - nessHR_EN.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.oecd.org/daf/inv/ mne/48004323.pdf.47.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.who.int/medicines/areas/human_rights/A63_263.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
Available at http://www.who.int/medicines/areas/ human_rights/A_HRC_11_12_Add_2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8c/38/hhr-18-129.PMC5070686.pdf
"This is an open access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://apps.who.int/gb/ ebwha/pdf_files/MTSP-08-13-PPB-10-11/mtsp-3en.pdf ;  G. Backman, P. Hunt, R. Khosla, et al., “Health systems and the right to health: An assessment of 194 countries,” The Lancet 9655 (2008), pp.",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://www.who.int/bulletin/volumes/88/11/10-078733/en/ ; S. Perehudoff, Health,  human rights & national constitutions  (Amsterdam:  Vrije Universiteit Amsterdam, 2008).",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.who.int/medicines/areas/human_rights/Pere - hudoff_report_constitutions_2008.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://www.gallala_en.pdf ; X. Con - tiades, “Introduction: The global financial crisis and the constitution,” in X. Contiades (ed),  Constitutions in the  global financial crisis  (Surrey: Ashgate; 2013), pp.",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://papers.ssrn.com/sol3/papers.cfm?ab - stract_id=2298601 .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://apps.who.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.who.int/trade/glos - sary/story002/en/ .14.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.ned.org/sites/default/files/Feb - ruary-2011-APSA-CD.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at  http://dx.doi.org/10.1080/17441692.2013.810765 .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constituteproject.org/ ontology/chronology?lang=en .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at  http://www.constituteproject.org ; ConstitutionNet.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constitutionnet.org ; Political  Database of the Americas (1995-2008).,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at  http://pdba.georgetown.edu/Constitutions/constudies.html ; International Constitutional Law (1994-2010).,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.servat.unibe.ch/icl/index.html ;  Constitution Finder.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://confinder.rich - mond.edu/contact.html ; African Human Rights Law  Document Database.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.chr.up.ac.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://papers.ssrn.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://www.who.int/about/regions/ en/; World Bank, Country and lending groups (2016) .",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://data.worldbank.org/about/country- and-lending-groups .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at  http://pdba.georgetown.edu/Constitutions/ElSal/consti - tucion.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constituteproject.org/ constitution/Portugal_2005.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constitute- project.org/constitution/Bolivia_2009.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Accessed https://http://www.constituteproject.org/ constitution/Ecuador_2011.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constituteproject.org/ constitution/Panama_2004.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://workspace.unpan.org/ sites/internet/Documents/UNPAN042808.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.constituteproject.org/constitu - tion/Nepal_2010.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at  http://www.haiweb.org/20102009/OxfamHAIReport - TradingAwayAccesstoMedicines.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://www.mcser.org/journal/index.php/ mjss/article/view/1811 ; J. Uddin, S. Momtaz, and M. S.  Islam, “State Obligation towards the fulfillment of the right to health: A study in Bangladesh perspective,”  Mediterranean Journal of Social Sciences 13 (2013), pp.",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.mcser.org/journal/index.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://www.haiweb.org/ MedPriceDatabase/ .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://apps.who.int/medicinedocs/docu - ments/s16374e/s16374e.pdf?ua=1 .,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at http://jhrp.ox - fordjournals.org/content/1/1/14.abstract ; Hogerzeil et al.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at http://www.rug.nl/research/groningen-cen - tre-for-law-and-governance/onderzoekscentra/ghlg/access-to-medicines?lang=en 62.  WHO (2008, see note 2), p. 96.",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"Available at: http://onlinelibrary.wiley.com/doi/10.1002/hpm.949/ full; S. Zaidi, M. Bigdeli, N. Aleem, and A. Rashidian.",Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at: http://dx.plos.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
Available at: http://journals.plos.org/plosmedicine/arti - cle?id=10.1371/journal.pmed.1000330.,Non-OADS,/arxiv_data1/oa_pdf/a6/e1/hhr-18-141.PMC5070687.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
"UNAIDS Eastern and Southern Africa, “Kenya:  Country profile.” Available at http://www.unaidsrstesa.",Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.unaids.org/sites/default/files/en/dataanalysis/knowyo - urresponse/countryprogressreports/2014countries/KEN_narrative_report_2014.pdf.,OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available  at http://www.stigmaindex.org/sites/default/files/reports/ Kenya%20People%20Living%20with%20HIV%20Stig - ma%20Index%20Report%202009.pdf.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at  http://www.kenyalaw.org:8181/exist/kenyalex/actview.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
"Available at http://www.hcourt.gov.au/assets/publications/speeches/former-justices/kirbyj/ kirbyj_27may06a.pdf; UNAIDS, Judging the epidemic: A  judicial handbook on HIV, human rights and the law (Ge - neva: UNAIDS, 2013), p. 3.",Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Avail - able at http://www.undp.org/content/dam/kenya/docs/Democratic%20Governance/HIV%20and%20AIDS%20 TRIBUNAL%20STRATEGIC%20PLAN.pdf.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://kelinkenya.org/wp-content/up - loads/2010/12/Advisory-Note-on-Section-24-of-HAPCA.pdf.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.standardmedia.co.ke/health/article/2000140872/i-ve-lived-a-full-life-despite- being-hiv-positive-says-phd-candidate-joe-muriuki.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.kenyalaw.org:8181/exist/kenyalex/actview.xql?actid=Const2010.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.capitalfm.co.ke/news/2013/04/tribunal-to-hear-hivaids- cases-sworn-in/.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://kenyalaw.org/caselaw/cases/view/105138/.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.globalpressjournal.com/africa/kenya/kenyans-await-de - layed-hivaids-tribunal#sthash.UnjUJQQB.dpuf.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
Available at http://www.businessdailyafrica.com/-/539444/1190786/-/121e3s1z/-/.,Non-OADS,/arxiv_data1/oa_pdf/40/c8/hhr-18-169.PMC5070689.pdf
"This is an open access article distributed under  the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://www.state.gov/documents/orga - nization/226844.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://www.state.gov/documents/organization/167334.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at  http://mspny.org/wp-content/uploads/2013/06/Traffick - ing-Assessment.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://www.luc.edu/media/lucedu/chrc/pdfs/BCWRHandbook2011.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
"Available at https://d28whvbyjonrpc.cloudfront.net/s3fs-public/attachments/ Covenant-House-trafficking-study.pdf; Mount Sinai Emer - gency Medical Department, Human Trafficking Information and Resources for Emergency Healthcare Providers (New York: Mount Sinai Hospital, 2005).",Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://mha.ohio.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
"Available at http://www.safvic.org/ content/uploads/safvic/documents/Resources%20-%20 HT/Medical%20Assessment%20Tool%20-%20HT.pdf; Vera Institute of Justice, Screening for Human Trafficking  (New  York: Vera Institute of Justice, 2014).",Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
"Available at http://www.vera.org/sites/default/files/resources/downloads/ human-trafficking-identification-tool-and-user-guidelines.pdf; Via Christi Health, Human Trafficking Assessment for  Clinicians.",Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Avail - able at https://www.viachristi.org/sites/default/files/pdf/about_us/2015-0625%20Human%20trafficking%20assess - ment_web.pdf; L.M.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
"Available at http://traffickingresourcecenter.org/sites/de - fault/files/Williams%20Pathways%20Final%20Report%20 2006-MU-FX-0060%2010-31-09L.pdf; Wisconsin Statewide Human Trafficking Committee, Wisconsin Human Traffick - ing Protocol and Resource Manual (Madison, WI: Wisconsin  Office of Justice Assistance, Violence Against Women Pro - gram, 2012).",Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://www.endabusewi.org/sites/ default/files/resources/Wisconsin%20Human%20Traffick - ing%20Protocol%20and%20Resource%20Manual.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://archive.acf.hhs.gov/trafficking/about/form.htm; Via Christi (see note 26).,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
Available at http://ipsr.ku.edu/ASHTI/teaching.html.,Non-OADS,/arxiv_data1/oa_pdf/a8/97/hhr-18-181.PMC5070690.pdf
"This is an open access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://data.un.org/Data.aspx?q=bhu - tan&d=MDG&f=seriesRowID%3A553%3BcountryID%3A64#MDG.,OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.wipo.int/wipolex/en/text.jsp?file_id=167939.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at  http://www.newdevelopmentparadigm.bt/about-us/history/.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.bhutanfound.org/?p=151.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.un.org/en/ga/search/view_doc.asp?symbol=%20A/RES/66/281.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.gnhc.gov.bt/wp-content/uploads/2012/04/nationalHpoli - cy.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.bhutan.gov.bt/government/minis - tries.php 29.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.grossnationalhappiness.com/9-domains/health/ 30.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Avail - able at http://www.unicef.org/rosa/community.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at  http://erc.undp.org/evaluationadmin/manageevaluation/ viewevaluationdetail.html?evalid=1446; S.D.,OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.searo.who.int/entity/human_resources/data/Bhutan_HRH_Coun - try_Profile.pdf 34.,OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://faolex.fao.org/docs/pdf/bhu106322.pdf; WHO (see note 35).,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.health.gov.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
"Available at http://www.umsb.edu.bt/index.php; Ministry of Foreign Affairs of Denmark (see note 38), p. 46; Human Resources Division, Ministry of Health (see note 45), p. 24.",Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://apps.who.int/medicinedocs/documents/s19041en/s19041en.pdf; WHO (see note 35).,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.hsph.harvard.edu/news/magazine/the- road-to-health-and-wellbeing/.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.bhtf.bt/about-us/ about-bhtf/; Tobgay et al.,OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at  http://www.health.gov.bt/wp-content/uploads/ppd-files/ health-bulletins/bulletins/ahb2014/ahbContent2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.searo.who.int/entity/medicines/ nmp_bhu_2007_who_ok.pdf.,OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available http://www.hrw.org/news/2011/03/30/bhutan-s-refugees-there-s-no-place-home.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
"UN Office of the High Commissioner of Human  Rights, Status of ratification interactive dashboard, Avail - able at: http://indicators.ohchr.org/.",Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://today.law.harvard.edu/ feature/elevation/.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.upr-info.org/ sites/default/files/document/bhutan/session_6_-_novem - ber_2009/recommendationstobhutan2009.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.biomedcentral.com/1471-2431/12/151/; WHO (see note 35).,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
Available at http://www.nsb.gov.bt/publication/files/pub10ks2884sy.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0b/c8/hhr-18-193.PMC5070691.pdf
"This is an open access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
Available at  http://www1.folha.uol.com.br/fsp/especial/158639-judicial - izacao-faz-desigualdade-na-saude-avancar.shtml.,Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
"Available at http://revistaepoca.globo.com/Revista/Epoca/0,,ERT59499-15257,00.html; A.L.",Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
"Available at http://ssrn.com/abstract=1133620 ; Economic Intelligence Unit, “Broad - ening Health Care Access in Brazil through Innovation”  (2010), Available at http://www.economistinsights.com/ healthcare/analysis/broadening-healthcare-access-bra - zil-through-innovation ; The Economist, “An Injection of  Reality” (Jul 30, 2011) The Economist .",Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
"F. Bassette, “RS reúne metade das ações judiciais de  saúde.” O Estado de São Paulo (Apr 29, 2011), Available at  http://www.estadao.com.br/noticias/geral,rs-reune-meta - de-das-acoes-judiciais-de-saude-imp-,712418.",Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
Available at:  http://www.who.int/classifications/icd/en/.,OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
Available at http://portalsaude.saude.gov.br/index.php/cidadao/principal/banco-de-precos-em-saude/mais- banco-de-precos-em-saude.,Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
"451-62; Government of Brazil, “Constituição da República Federativa do Brasil de 1988.” (1988), available at http://www.planalto.gov.br/ccivil_03/constituicao/constituicao.htm; J. Luo, M.A.",Non-OADS,/arxiv_data1/oa_pdf/75/94/hhr-18-209.PMC5070692.pdf
"This is an open access article  distributed under the terms of the Creative Commons Attribution NonCommercial IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits distribution and reproduction in any medium, for non-commercial uses provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www.un.org/esa/socdev/unpfii/documents/SOWIP/en/SOWIP_web.pdf.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://tbinternet.ohchr.org/_layouts/treatybodyexternal/Download.aspx - ?symbolno=E/C.12/BRA/CO/2&Lang=En.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://tbinternet.ohchr.org/_layouts/ treatybodyexternal/Download.aspx?symbolno=CRC%2f - C%2fGC%2f11&Lang=en.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www.ilo.org/indigenous/Resources/Publications/WCMS_100897/lang- -en/index.htm.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
"Available at: http://www.ohchr.org/Documents/ HRBodies/CRC/Discussions/Recommendations/Recom - mendations2003.pdf and UN Committee on the Rights of the Child, General Comment No.",Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available  at: http://www2.ohchr.org/english/bodies/crc/docs/CRC.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www.paho.org/hq/index.php?option=com_docman&Itemid=1358&lang=es.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available  at: http://www.paho.org/hq/index.php?option=com_doc- man&Itemid=1358&lang=es.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
"Pan American Health Organization/World Health  Organization (PAHO/WHO), CD50/12 and CD50.R8 of the 50 PAHO Directing Council (2010), Health and Human  Rights, available at http://www2.paho.org/hq/dmdocu - ments/2010/CD50-12-e.pdf.",Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available  at http://www.paho.org/hq/index.php?option=com_con - tent&view=article&id=9774&Itemid=41062&lang=en.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://tbinternet.ohchr.org/_layouts/treatybodyexternal/Download.aspx?symbolno=CRC%2f - C%2f15%2fAdd.241&Lang=en.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www.ohchr.org/EN/Issues/IPeoples/ SRIndigenousPeoples/Pages/SRIPeoplesIndex.aspx.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www1.paho.org/ english/gov/cd/CD47-13-e.pdf.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at http://www.planalto.gov.br/ccivil_03/leis/l8080.htm.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
Available at: http://www.ohchr.org/EN/HRBodies/UPR/Pages/BRSession13.aspx.,Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
"Available at: http://tbinternet.ohchr.org/_layouts/TreatyBodyExternal/Countries.aspx?Coun - tryCode=BRA&Lang=EN and National Household  Sample Survey (PNAD), 2012.",Non-OADS,/arxiv_data1/oa_pdf/63/66/hhr-18-221.PMC5070693.pdf
"This is an open access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
"World Health Organization, Investing in children: the  European child and adolescent health strategy 2015  –2020  (World Health Organization Regional Office for Europe,  2014), Available at: http://www.euro.who.int/__data/ assets/pdf_file/0010/253729/64wd12e_InvestCAHstrate - gy_140440.pdf?ua=1.",Non-OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
Available at: http://www.hphnet.org/index.php?option=com_content&view=arti - cle&id=1551:hp-for-children-a-adolescents-in-a-by-hospi- tals-&catid=20 .,Non-OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
Available at: http://www.euro.who.int/__data/assets/ pdf_file/0020/252542/Assessing-the-respect-of-childrens-rights-in-hospitals-in-Kyrgyzstan-and-Tajikistan-Eng.,Non-OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
WHO; available at: http://www.euro.who.int/__data/assets/pdf_file/0004/180706/e96733.pdf?ua=1  last accessed:  17 June 2015; Stasii E. (2012) Assessment of pediatric hospi - tal care in Tajikistan 2-18 July 2012: Mission report.,Non-OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
WHO;  available at: http://www.euro.who.int/__data/assets/pdf_file/0005/181796/e96753-Eng.pdf  last accessed 17 June 2015.,OADS,/arxiv_data1/oa_pdf/64/82/hhr-18-235.PMC5070694.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at http://www2ohchr.org/english/law/ cescr.htm.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at https://www2.ohchr.org/english/law/crc.htm.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at: http://www.euro.who.int/en/health-topics/ noncommunicable-diseases.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at http://www.telegraph.co.uk/foodanddrink/healthyeating/10667066/Obese-chil - dren-removed-from-families.html.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at  https://treaties.un.org/Pages/ViewDetails.aspx?mtdsg_ no=IV-11&chapter=4&lang=en.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at: http://www.unicef.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Avail - able at http://www.ohchr.org/EN/ProfessionalInterest/ Pages/InternationalLaw.aspx 59.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
Available at http://www.euro.who.int/en/ health-topics/noncommunicable-diseases/obesity/obesity.,Non-OADS,/arxiv_data1/oa_pdf/d6/f8/hhr-18-249.PMC5070695.pdf
"This is an open access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/31/95/hhr-18-263.PMC5070696.pdf
Available at http://www.who.int/men - tal_health/policy/legislation/en/; N. Drew et al.,Non-OADS,/arxiv_data1/oa_pdf/31/95/hhr-18-263.PMC5070696.pdf
"Available at  http://www.un.org/Overview/rights.html; International Covenant on Economic, Social and Cultural Rights (ICE - SCR), G.A.",Non-OADS,/arxiv_data1/oa_pdf/31/95/hhr-18-263.PMC5070696.pdf
Available at http://www2.ohchr.org/english/law/cescr.htm 9.,Non-OADS,/arxiv_data1/oa_pdf/31/95/hhr-18-263.PMC5070696.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution  Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
"June 27, 2014 (accessed 2 Jan  2016). http://allafrica.com/stories/201406271549.html.",Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
(accessed 3 Oct 2015) http://www.ohchr.org/en/profession - alinterest/pages/ccpr.aspx,Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
(accessed 3 Oct 2015) http://www.unicef.org/crc/ 8.,Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
"World Health Statistics,  2015, p. 126-135; The World Bank, GDP per capita (current US$) http://data.worldbank.org/indicator/NY.GDP.PCAP.CD 22.",Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
2015. https://sustainabledevelopment.un.org/sdgsproposal.,Non-OADS,/arxiv_data1/oa_pdf/8d/90/hhr-18-277.PMC5070697.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.Health and Human Rights JournalHHr HHR_final_logo_alone.indd   1 10/19/15   10:53 AM",Non-OADS,/arxiv_data1/oa_pdf/5b/9c/hhr-18-283.PMC5070698.pdf
"M. Kirby  / perspective, 283-292292JUNE 2016   VOLUME 18   NUMBER 1   Health and Human Rights JournalJuly 24, 2015 Available at: http://www.thetimes.co.uk/tto/ opinion/leaders/article4506681.ece 14.",Non-OADS,/arxiv_data1/oa_pdf/5b/9c/hhr-18-283.PMC5070698.pdf
"Sung Hee Baek, E-mail: sbaek@snu.ac.kr,  Keun Il Kim, E-mail: kikim@sookmyung.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.5.053Received 9 March 2016Keywords: HIF-1, LSD1, Lysine methylation, SET7/9, Ubiquitin Abbreviations:  CUL2, cullin 2; DMOG, dimethyloxalylglycine; HIF-  1, hypoxia-inducible factor-1 ; LSD1, lysine-specific demethylase 1; MEF , mouse embryonic fibroblast; PHD, proline hydroxylase do-main; VHL, von Hippel-Lindau Perspective to:  Yunho Kim et al., Methylation-dependent Regulation  of HIF-1 stability restricts retinal and tumor angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/BMB-49-245.PMC5070701.pdf
Regulation of HIF-1  stability by lysine methylation Sung Hee Baek and Keun Il Kim 246 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/10/f6/BMB-49-245.PMC5070701.pdf
"E-mail: jso678@yonsei.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.5.067Received 14 April 2016Keywords: CHIP , Lysosome, Necroptosis, RIPK3, Ubiquitylation Abbreviations:  RIPK3, Receptor-interacting protein kinase 3;  RIPK1, Receptor-interacting protein kinase 1; CHIP , C-terminus HSC70-interacting protein; TNF , Tumor necrosis factor; TLR, Toll like receptor; INFR, Interferone receptor; MLKL, Mixed lineage kin-ase domain-like; DAMP , Damage associated molecular patterns; HMGB1, High-mobility group box 1; PTEN, Phosphatase and ten-sin homolog; MEF , Mouse embryonic fibroblast; FADD, Fas-asso-ciated death domain Perspective to:  Jinho Seo et al (2016), CHIP controls necroptosis  through ubiquitylation- and lysosome-dependent degradation o f  RIPK3, Nat Cell Biol.",Non-OADS,/arxiv_data1/oa_pdf/34/b9/BMB-49-247.PMC5070702.pdf
248 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/34/b9/BMB-49-247.PMC5070702.pdf
"Tel: +82-51-200-7270; Fax: +82-51-200-  7269; E-mail: jwchung@dau.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.5.045Received 4 March 2016Keywords: Comparative genomics, Dedifferentiation, Lizard, Re- generation, Stem cells ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Spot the difference: Solving th e puzzle of hidden pictures in  the lizard genome for identification of regeneration factors Jin Woong Chung * Department of Biological Science, Dong-A University, Busan 49315, Korea All living things share some common life processes, such as  growth and reproduction, and have the ability to respond to their environment.",Non-OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
"Identification of regeneration factors in the lizard genome Jin Woong Chung 250 BMB Reports http://bmbreports.orgEVOLUTIONARY AND GENOMIC CHARACTERISTICS  OF LIZARDS Reptiles first evolved from amphibians in the late Carboniferous  period about 320 million years ago, when they evolutionarily parted ways with other amoniotes such as birds and mammals  (5).",OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
 Identification of regeneration factors in the lizard genome Jin Woong Chung 251 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
Identification of regeneration factors in the lizard genome Jin Woong Chung 252 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
 Identification of regeneration factors in the lizard genome Jin Woong Chung 253 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
Identification of regeneration factors in the lizard genome Jin Woong Chung 254 BMB Reports http://bmbreports.orgevolution.,Non-OADS,/arxiv_data1/oa_pdf/6c/ef/BMB-49-249.PMC5070703.pdf
"Tel: +82-32-899-6588; Fax: +82-32-899-  6039; E-mail: geretics@gachon.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.5.036Received 19 February 2016Keywords: Angiogenesis, Central nervous system, Cerebral cav- ernous malformation, Signaling, Vascular permeability ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Introduction to cerebral cavernous malformation: a brief review Jaehong Kim1,2,* 1Department of Biochemistry, School of Medicine, Gachon University, Incheon 21936, 2Department of Health Sciences and Technology,  Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon 21999, Korea The disease known as cerebral cavernous malformations most- ly occurs in the central nervous system, and their typical histo-logical presentations are multiple lumen formation and vas- cular leakage at the brain capillary level, resulting in disruption  of the blood-brain barrier.",Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
Pathogenesis of cerebral cavernous malformation Jaehong Kim 256 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
 Pathogenesis of cerebral cavernous malformation Jaehong Kim 257 http://bmbreports.org BMB Reportstivation is a major mechanism in CCM pathogenesis (48).,Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
Pathogenesis of cerebral cavernous malformation Jaehong Kim 258 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
" Pathogenesis of cerebral cavernous malformation Jaehong Kim 259 http://bmbreports.org BMB Reportsbringing the GCKIII kinases to the STRIPAK phosphatase for the  regulation of cell polarity, further linking CCM3 with vascular development (70, 90).",Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
"Pathogenesis of cerebral cavernous malformation Jaehong Kim 260 BMB Reports http://bmbreports.orgMol Biol 53, 834-843 8.",Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
 Pathogenesis of cerebral cavernous malformation Jaehong Kim 261 http://bmbreports.org BMB Reportsthe disruption of the cerebral cavernous malformations 2  (CCM2) interaction with Krev interaction trapped 1 (KRIT1) by disease-associated mutations.,Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
Pathogenesis of cerebral cavernous malformation Jaehong Kim 262 BMB Reports http://bmbreports.orgidentification of the cerebral cavernous malformation sig- naling complex.,Non-OADS,/arxiv_data1/oa_pdf/d3/0d/BMB-49-255.PMC5070704.pdf
"Tel: +81-3-5449-5270; Fax: +81-3-5449-  5411; E-mail: kiyono@ims.u-tokyo.ac.jp http://dx.doi.org/10.5483/BMBRep.2016.49.5.041Received 26 February 2016Keywords: Homeostasis, Inflammation, Intestine, MicroRNA, Patho- physiology ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.MicroRNA-orchestrated pathophysiologic control in gut  homeostasis and inflammation Juneyoung Lee1,2, Eun Jeong Park1,3 & Hiroshi Kiyono1,2,4,* 1Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of  Tokyo, Tokyo 108-8639, 2Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The  University of Tokyo, Chiba 277-8561, 3Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School  of Medicine, Mie University, Mie 514-8507, 4International Research and Development Cent er for Mucosal Vaccines, The Institute of  Medical Science, The University of Tokyo, Tokyo 108-8639, Japan The intestine represents the largest and most elaborate im- mune system organ, in which dynamic and reciprocal inter-play among numerous immune and epithelial cells, commen- sal microbiota, and external antigens contributes to establish- ing both homeostatic and pathologic conditions.",Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
"264 BMB Reports http://bmbreports.orgsponses (2, 3).",OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
"265 http://bmbreports.org BMB ReportsmiRNAs Expression Tissue or cell type Targets References miR-21 Increased Blood and colon in UCaRhoB, Cdc42 (51-4) miR-155 Increased Colon in UC Foxp3, SOCS1 (55-0) miR-223 Decreased Myeloid cells C/EBP  (61-4) miR-1224-5p Increased Inflamed large-IECsbAQP8 (65) miR-3473a Increased Inflamed large-IECs AQP8 (65) miR-5128 Increased Inflamed large-IECs ABCG2, AQP8 (65) aUC, ulcerative colitis.",Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
266 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
267 http://bmbreports.org BMB Reportsfunctionally characterized in vivo  and in vitro  to further clarify  their contributions to IBD pathology.,Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
268 BMB Reports http://bmbreports.org23.,Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
269 http://bmbreports.org BMB Reportsregulatory T cells.,Non-OADS,/arxiv_data1/oa_pdf/74/82/BMB-49-263.PMC5070705.pdf
"Tel: +82-2-958-5086; Fax: +82-2-958-5170;  E-mail: ejsong@kist.re.kr  http://dx.doi.org/10.5483/BMBRep.2016.49.5.187Received 10 September 2015, Revised 5 October 2015,  Accepted 16 November 2015 Keywords: Brotezomib, Cholesterol-induced cardiac hypertrophy, H9c2 cells, MG132, Proteasome inhibitors ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Proteasome inhibitors attenuated cholesterol-induced cardiac  hypertrophy in H9c2 cells Hyunjung Lee1, Jinyoung Park1, Eunice EunKyeong Kim2, Young Sook Yoo1 & Eun Joo Song1,* 1Molecular Recognition Research Center, Ko rea Institute of Science and Technology, 2Biomedical Research Institute, Korea Institute of  Science and Technology, Seoul 02792, Korea  The Ubiquitin proteasome system (UPS) plays roles in protein  degradation, cell cycle control, and growth and inflammatory cell signaling.",Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
271 http://bmbreports.org BMB Reports       Fig.,Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
272 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
273 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
"274 BMB Reports http://bmbreports.orgunderstood, inactivation of signaling molecules in the hyper- trophic pathway is suggested as the main reason.",Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
275 http://bmbreports.org BMB Reportsassociated with dysregulation of the ubiquitin-proteasome  system in dilated cardiomyopathy.,Non-OADS,/arxiv_data1/oa_pdf/67/78/BMB-49-270.PMC5070706.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.5.241Received 19 November 2015, Revised 24 November 2015,  Accepted 25 November 2015 Keywords: Acute inflammation, Corosolic acid, Inflammasome,  IRAK-1, Macrophages ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Corosolic acid ameliorates acute inflammation through  inhibition of IRAK-1 phosphorylation in macrophages Seung-Jae Kim1,#, Ji-Young Cha2,3,#, Hye Suk Kang1, Jae-Ho Lee1, Ji Yoon Lee4, Jae-Hyung Park1, Jae-Hoon Bae1,  Dae-Kyu Song1 & Seung-Soon Im1,* 1Department of Physiology, Keimyung University School of Medicine, Daegu 42601, 2Department of Biochemistry, Lee Gil Ya Cancer and  Diabetes Institute, Gachon University, Incheon 21999, 3Gachon Medical Research Institute, Gill Hospital, Incheon 21936, 4Severance  Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea Corosolic acid (CA), a triterpenoid compound isolated from  Lagerstroemia speciosa  L. (Banaba) leaves, exerts anti-inflam- matory effects by regulating phosphorylation of interleukin re- ceptor-associated kinase (IRAK)-2 via the NF- B cascade.",Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
277 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
278 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
279 http://bmbreports.org BMB ReportsCA treatment and by approximately 40% after treatment with  gentamicin and ibuprofen.,Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
280 BMB Reports http://bmbreports.orgInterleukin-1 Receptor-Associated-kinase 1/4 inhibitor (PubChem  CID : 11983295) were purchased from Sigma-Aldrich and dis-solved in the recommended solvents.,Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
281 http://bmbreports.org BMB ReportsREFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/52/c1/BMB-49-276.PMC5070707.pdf
"Tel: +82-62-230-6294; Fax: +82-62-226-  4165; E-mail: thkim65@chosun.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.5.245Received 25 November 2015, Revised 9 December 2015,  Accepted 11 December 2015 Keywords: Apoptosis, Cell death, Isoleucine zipper, Multimeriza- tion, TRAIL ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Potentiation of TRAIL killing activity by multimerization  through isoleucine zipper hexamerization motif Ji Hye Han1, Ae Ran Moon1, Jeong Hwan Chang2, Jeehyeon Bae4, Jin Myung Choi3, Sung Haeng Lee3 & Tae-Hyoung Kim1,* Departments of 1Biochemistry, 2Surgery, 3Cellular and Molecular Medicine, Chosun University School of Medicine, Gwangju 61452,  4School of Pharmacy, Chung-Ang University, Seoul 06974, Korea Tumor necrosis factor (TNF)-related apoptosis-inducing ligand  (TRAIL) is a homo-trimeric cytotoxic ligand.",Non-OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
283 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
284 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
"Sedimentation velocity AUC was performed, and AUC data were ana-lyzed by continuous size distribution  analysis using SEDFIT software (avail- able at http://www.analyticalultracentri-fugation.com).",OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
285 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
286 BMB Reports http://bmbreports.orgzation motif can enhance their biological activity.,OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
"287 http://bmbreports.org BMB Reportsand Ashkenazi A (1996) Induction of apoptosis by Apo-2  ligand, a new member of the tumor necrosis factor cyto-kine family.",Non-OADS,/arxiv_data1/oa_pdf/12/2f/BMB-49-282.PMC5070708.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.5.231Received 10 November 2015, Revised 11 December 2015,  Accepted 28 December 2015 Keywords: Apoptosis, Chemotherapy-induced side effect, Cisplatin,  Nephrotoxicity, Neuropeptide Y ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Neuropeptide Y protects kidney against cisplatin-induced  nephrotoxicity by regulating p53-dependent apoptosis pathway Namoh Kim1,2,3,#, Woo-Kie Min4,#, Min Hee Park1,2,3, Jong Kil Lee1,2,3, Hee Kyung Jin1,5,* & Jae-sung Bae1,2,3,* 1Stem Cell Neuroplasticity Research Group, Kyungpook National University, 2Department of Physiology, Cell and Matrix Research Institute,  School of Medicine, Kyungpook National University, 3Department of Biomedical Science, BK21 Plus KNU Biomedical Convergence Program,  Kyungpook National University, 4Department of Orthopaedic Surgery, Kyungpook National University Hospital, Daegu 41944, Korea,  5Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea Cisplatin is a platinum-based chemotherapeutic drug for trea- ting various types of cancers.",Non-OADS,/arxiv_data1/oa_pdf/c0/d0/BMB-49-288.PMC5070709.pdf
289 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/c0/d0/BMB-49-288.PMC5070709.pdf
290 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/c0/d0/BMB-49-288.PMC5070709.pdf
291 http://bmbreports.org BMB Reportsside effect on normal tissues.,Non-OADS,/arxiv_data1/oa_pdf/c0/d0/BMB-49-288.PMC5070709.pdf
292 BMB Reports http://bmbreports.orgClontech.,Non-OADS,/arxiv_data1/oa_pdf/c0/d0/BMB-49-288.PMC5070709.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.5.023Received 3 February 2016, Revised 19 February 2016,  Accepted 3 March 2016 Keywords: Contact hypersensitivity, ILC10, Innate lymphoid cells  (ILCs), Interleukin-10, regulatory ILCs ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.A novel IL-10-producing innate lymphoid cells (ILC10) in a  contact hypersensitivity mouse model Hyuk Soon Kim1,#, Jong-Hwa Jang2,#, Min Bum Lee1, In Duk Jung1, Yeong-Min Park1,*, Young Mi Kim3,* & Wahn Soo Choi1,* 1Department of Immunology, School of medicine, Konkuk University, Chungju 27478, 2Department of Dental Hygiene, Hanseo University,  Seosan 31962, 3College of Pharmacy, Duksung Women’s University, Seoul 01369, Korea The immunoregulatory cytokine Interleukin 10 (IL-10) protein  is produced by various cells during the course of inflammatory disorders.",Non-OADS,/arxiv_data1/oa_pdf/fe/04/BMB-49-293.PMC5070710.pdf
294 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/fe/04/BMB-49-293.PMC5070710.pdf
295 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/fe/04/BMB-49-293.PMC5070710.pdf
"296 BMB Reports http://bmbreports.orgD7), and anti-CD25 (PC61.5), which were purchased from  eBioscience, and anti-CD45 (30-F11), which was purchased from BD Biosciences.",OADS,/arxiv_data1/oa_pdf/fe/04/BMB-49-293.PMC5070710.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.5.058Received 16 March 2016, Revised 18 March 2016,  Accepted 18 March 2016 Keywords: Cytokines, Protein therapy, Tat-DJ-1, Toxicity, Wild type  and mutants ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Transduced Tat-DJ-1 protein inhibits cytokines-induced  pancreatic RINm5F cell death Hyo Sang Jo#, Hyeon Ji Yeo#, Hyun Ju Cha, Sang Jin Kim, Su Bin Cho, Jung Hwan Park, Chi Hern Lee, Eun Ji Yeo,  Yeon Joo Choi, Won Sik Eum * & Soo Young Choi * Department of Biomedical Science and Research Institute of Bi oscience and Biotechnology, Hallym University, Chunchon 24252, Kor ea Loss of pancreatic -cells by oxidative stress or cytokines is  associated with diabetes mellitus (DM).",Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
298 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
299 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
300 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
301 http://bmbreports.org BMB Reportswere purified using affinity column chromatograph.,Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
302 BMB Reports http://bmbreports.org7.,Non-OADS,/arxiv_data1/oa_pdf/72/a6/BMB-49-297.PMC5070711.pdf
"E-mail: iskim14@kist.re.kr http://dx.doi.org/10.5483/BMBRep.2016.49.6.078Received 7 May 2016Keywords: Muscle regeneration, Myoblast fusion, Phosphatidylse- rine, Stabilin-2 Abbreviations:  Stab2, stabilin-2; PS, phosphatidylserine Perspective to:  Seung-Yoon Park et al (2016), Stabilin-2 modulates  the efficiency of myoblast fusion during myogenic differentiation and muscle regeneration, Nature Communications, 7:10871, doi: 10.1038/ncomms10871 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Novel function of stabilin-2 in myoblast fusion:  the recognition of extracellu lar phosphatidylserine as a  “fuse-me” signal  Go-Woon Kim1, Seung-Yoon Park1,2 & In-San Kim1,3,* 1Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, 2Department of  Biochemistry, School of Medicine, Dongguk University, Gyeongju 38066, 3KU-KIST School, Korea University, Seoul 02841, Korea Myoblast fusion is important for skeletal muscle formation.",Non-OADS,/arxiv_data1/oa_pdf/38/9d/BMB-49-303.PMC5070716.pdf
"304 BMB Reports http://bmbreports.orgweight relative to body weight, which was due to the  reduction of myofiber size rather than changes in the number of myofibers.",Non-OADS,/arxiv_data1/oa_pdf/38/9d/BMB-49-303.PMC5070716.pdf
"Tel: +82-2-3277-3770; Fax: +82-2-3277-  3760; E-mail: leesy@ewha.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.6.059Received 18 March 2016Keywords: Glycogen synthase kinase 3  (GSK3, Inflammatory cy- tokines ,  Tol l -li ke r eceptor ( TLR),  Type I  i nterf erons (I FNs ) ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Glycogen synthase kinase 3  in Toll-like receptor signaling Ryeojin Ko & Soo Young Lee * Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul 03760, Korea Toll-like receptors (TLRs) play a critical role in the innate  immune response against pathogens.",Non-OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
The role of GSK3  in TLR-mediated responses Ryeojin Ko and Soo Young Lee 306 BMB Reports http://bmbreports.org Fig.,OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
 The role of GSK3  in TLR-mediated responses Ryeojin Ko and Soo Young Lee 307 http://bmbreports.org BMB Reportsregulates pro- and anti-inflammatory cytokine production in  TLR4 responses.,Non-OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
The role of GSK3  in TLR-mediated responses Ryeojin Ko and Soo Young Lee 308 BMB Reports http://bmbreports.org Fig.,OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
" The role of GSK3  in TLR-mediated responses Ryeojin Ko and Soo Young Lee 309 http://bmbreports.org BMB ReportsRecently, we demonstrated that GSK3  had a positive role in  regulating the pro-inflammatory cytokine production in TLR3 signaling (20).",OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
The role of GSK3  in TLR-mediated responses Ryeojin Ko and Soo Young Lee 310 BMB Reports http://bmbreports.org20.,OADS,/arxiv_data1/oa_pdf/8f/2c/BMB-49-305.PMC5070717.pdf
"Tel: +82-42-580-8243; Fax: +82-42-585-  3686; E-mail: hayoungj@cnu.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.6.056Received 16 March 2016Keywords: Inflammation, Innate immune, MicroRNA, miR-125,  miR-146 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.MiR-146 and miR-125 in the regulation of innate immunity  and inflammation Hye-Mi Lee1, Tae Sung Kim1,2 & Eun-Kyeong Jo1,2,* 1Department of Microbiology and 2Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015,  Korea Innate immune responses are primary, relatively limited, and  specific responses to numerous pathogens and toxic molecules.",Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
"312 BMB Reports http://bmbreports.orgintracellular signaling pathways triggered by these PRRs will  culminate in the activation of innate immune effectors and inflammatory mediators during infections (15, 17).",Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
313 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
314 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
315 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
316 BMB Reports http://bmbreports.orgchronic eosinophilic rhinosinusitis and nasal polyps because  the levels of miR-125b are elevated in patients and such elevation can regulate the extent of inflammation in sinonasal  mucosal samples of these patients (80).,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
317 http://bmbreports.org BMB Reportsreceptors.,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
318 BMB Reports http://bmbreports.org57.,Non-OADS,/arxiv_data1/oa_pdf/98/c2/BMB-49-311.PMC5070718.pdf
"Tel: +82-43-840-3903; Fax: +82-43-852-  3616; E-mail: bahk12@empal.com http://dx.doi.org/10.5483/BMBRep.2016.49.6.240Received 19 November 2015, Revised 30 November 2015,  Accepted 15 December 2015 Keywords: CTD phosphatase, CTDSPL2 inducible HEK293T cell  line, CTDSPL2, Immunoprecipitation, Nuclear interactome ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.A systematic study of nuclear interactome of C-terminal  domain small phosphatase-like 2 using inducible expression system and shotgun proteomics NaNa Kang1, JaeHyung Koo1, Sen Wang2, Sun Jin Hur3& Young Yil Bahk4,* 1Department of Brain & Cognitive Sciences, DGIST, Daegu 42988, Korea, 2Qiqihar Medical University, Qiqihar City, Heilongjiang, 161006,  China, 3Department of Animal Science and Technology, Chung-Ang University, Anseong 17546, 4Department of Biotechnology, Konkuk  University, Chungju 27478, Korea RNA polymerase II C-terminal domain phosphatases are newly  emerging family of phosphatases that contain FCPH domain with Mg ＋2-binding DXDX(T/V) signature motif.",Non-OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
320 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
321 http://bmbreports.org BMB Reports  Fig.,Non-OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
cBased on Panther Database (http://www.pantherdb.org).Table 1.,OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
322 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
"Based on the Panther Database (http://www.pantherdb.org), these identified proteins  were grouped systematically.",OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
323 http://bmbreports.org BMB Reportsber of key family of co-activators involved in the regulation of  steroid receptor-mediated transcription.,Non-OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
"324 BMB Reports http://bmbreports.orgtein database version 3.20 (European Bioinformatics Institute,  Hinxton, UK), NCBI- nonredundant protein databases, EST data-base, and other database using Mascot operating on a local server  (24).",OADS,/arxiv_data1/oa_pdf/b7/fa/BMB-49-319.PMC5070719.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.6.248Received 30 November 2015, Revised 23 December 2015,  Accepted 23 December 2015 Keywords: Hepatocellular carcinoma, MAX dimerization protein 1,  Protein degradation, Protein-protein interaction, T-complex protein 10A homolog 2 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.TCP10L synergizes with MAD1 in transcriptional suppression  and cell cycle arrest through mutual interaction Suqin Shen1, Jie Zuo1, Huan Feng1, Meirong Bai2, Chenji Wang1, Youheng Wei1, Yanhong Li1, Yichen Le1, Jiaxue Wu1,  Yanhua Wu1,* & Long Yu1,* 1State Key Laboratory of Genetic Engineering, Institute of Gene tics, School of Life Sciences, Fudan University, Shanghai 200433,  P. R.  China, 2Cardiovascular Research Institute and Department of Physiology, University of California, San Fr ancisco, San Francisco, CA 9415 8,  USA T-complex protein 10A homolog 2 (TCP10L) was previously  demonstrated to be a potential tumor suppressor in human hepatocellular carcinoma (HCC).",Non-OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
326 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
327 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
328 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
"329 http://bmbreports.org BMB Reportswe also observed that HCC cells over-expressing MAD1 ex- hibited suppressed gene transcription, G1 arrest and inhibited cell growth rate.",OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
330 BMB Reports http://bmbreports.orgUSA).,Non-OADS,/arxiv_data1/oa_pdf/a2/a2/BMB-49-325.PMC5070720.pdf
"Tel: +82-2-3290-3160; Fax: +82-2-927-  9028; E-mail: sehopark@korea.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.6.207Received 13 October 2015, Revised 3 November 2015,  Accepted 10 January 2016 Keywords: Collagen-induced arthritis, Immunotherapy, Rheumatoid arthriti, Recombinant MHC II, Type-II collagen ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Induction of tolerance against the arthritogenic antigen with  type-II collagen peptide-linked soluble MHC class II molecules Yoon-Kyung Park, Sundo Jung & Se-Ho Park * Department of Life Sciences, Korea University, Seoul 02841, Korea In murine collagen-induced arthritis (CIA), self-reactive T cells  can recognize peptide antigens derived from type-II collagen (CII).",Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
332 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
333 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
334 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
335 http://bmbreports.org BMB Reportswere inserted into pET21d ＋ expression vector and expressed in  Escherichia coli  using 1 mM IPTG at 37oC for 4 hr.,Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
336 BMB Reports http://bmbreports.orgadaptive immunity and cytokine networks in rheumatoid  arthritis.,Non-OADS,/arxiv_data1/oa_pdf/b3/b7/BMB-49-331.PMC5070721.pdf
"Tel: +82-2-3010-4241; Fax: +82-2-3010-  8038; E-mail: ysy@amc.seoul.kr http://dx.doi.org/10.5483/BMBRep.2016.49.6.212Received 16 October 2015, Revised 13 November 2015,  Accepted 18 January 2016 Keywords: Alzheimer disease (AD), -amyloid, Chaperone medi- ated autophagy, Hsc70, LAMP2 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Regulation of amyloid precursor protein processing by its  KFERQ motif Ji-Seon Park1,2,3,4, Dong-Hou Kim1,2,3,4 & Seung-Yong Yoon1,2,3,4,* 1Alzheimer’s Disease Experts Lab (ADEL), Asan Medical Center, 2Department of Brain Science, 3Bio-Medical Institute of Technology  (BMIT), 4Cell Dysfunction Research Center (CDRC), Universi ty of Ulsan College of Medicine, Seoul 05505, Korea Understanding of trafficking, processing, and degradation  mechanisms of amyloid precursor protein (APP) is important because APP can be processed to produce -amyloid (A ), a  key pathogenic molecule in Alzheimer’s disease (AD).",Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
338 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
339 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
"340 BMB Reports http://bmbreports.orgwe wondered whether it could have potential effects on AD  pathologies, we checked phosphorylation level of tau.",Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
"341 http://bmbreports.org BMB ReportsCo-immunoprecipitation and western blotting For co-immunoprecipitation, SH-SY5Y cells transiently ex- pressing various APP constructs (wild type, WT-APPKFERQ,  CTF, CTFKFERQ, CTF, CTFKFERQ AICD, and AICDKFERQ)  were lysed with lysis buffer (1% Triton X-100, 20 mM  HEPESpH7.5, 150 mM NaCl, 10% glycerol, 1 mM EDTA, pro-tease inhibitor cocktail (Calbiochem, USA) and phosphatase  inhibitor cocktail (Sigma, USA) for 20 min at 4 oC as previously  described with some modifications (27-29).",Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
342 BMB Reports http://bmbreports.org13.,Non-OADS,/arxiv_data1/oa_pdf/e2/41/BMB-49-337.PMC5070722.pdf
"Nacksung Kim, Tel: +82-62-220-4418;  Fax: +82-62-223-4018; E-mail: nacksung@jnu.ac.kr, Insun Song,  Tel: +82-62-220-4418; Fax: +82-62-223-4018; E-mail: song1009@  gmail.com http://dx.doi.org/10.5483/BMBRep.2016.49.6.032Received 15 February 2016, Revised 11 March 2016,  Accepted 11 March 2016 Keywords: Bone sialoprotein, GATA4, Gene regulation, Runx2,  Sox9 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.GATA4 negatively regulates bone sialoprotein expression in  osteoblasts Insun Song1,*, Byung-chul Jeong2,3, Yong Jun Choi4, Yoon-Sok Chung4 & Nacksung Kim2,3,* 1Shool of Biological Sciences, Seoul National University, Seoul 08826, Departments of 2Pharmacology and 3Biomedical Sciences, Chonnam  National University Medical School, Gwangju 61469, 4Department of Endocrinology, Ajou University, Suwon 16499, Korea GATA4 has been reported to act as a negative regulator in  osteoblast differentiation by inhibiting the Dlx5 transactivation of Runx2 via the attenuation of the binding ability of Dlx5 to  the Runx2 promoter region.",Non-OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
344 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
345 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
346 BMB Reports http://bmbreports.organd Sox9.,Non-OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
347 http://bmbreports.org BMB Reportssystem (Promega) according to the manufacturer’s instructions.,Non-OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
348 BMB Reports http://bmbreports.orgbone sialoprotein.,OADS,/arxiv_data1/oa_pdf/53/57/BMB-49-343.PMC5070723.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.6.077Received 7 May 2016, Revised 17 May 2016, Accepted 17 May 2016Keywords: Carboxylesterase, Molecular modeling, Site-directed mu- tagenesis, Sulfolobus solfataricus  P1, Thermostability ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Identification of amino acids related to catalytic function of  Sulfolobus solfataricus P1 carboxylesterase by site-directed  mutagenesis and molecular modeling Yun-Ho Choi1,#, Ye-Na Lee1,#, Young-Jun Park2, Sung-Jin Yoon2 & Hee-Bong Lee1,* 1Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, 2Metabolic Regulation  Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea The archaeon Sulfolobus solfataricus  P1 carboxylesterase is a  thermostable enzyme with a molecular mass of 33.5 kDa belonging to the mammalian hormone-sensitive lipase (HSL)  family.",Non-OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
350 BMB Reports http://bmbreports.orgCarboxylesterase Sp.,Non-OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
351 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
"352 BMB Reports http://bmbreports.orgesterases from the same Sulfolobus genus: The esterase from S.  acidocaldarius (SacEst) with 99% identity was the most similar,  and the next were those from S. solfataricus P2 (SsoP2Est, 77%),  S. shibatae (SshEst, 77%), S. islandicus (SisEst, 77%), S.  solfataricus P1 (DSM 5354; 75%), and S. tokodaii (StoEst, 70%),  but it showed low identities with those of other archaeal  esterases from P. calidifontis (PcaEst, 46%), the metagenomic  library (MetEst, 43%), and A. fulgidus (AfuEst, 34%).",OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
"353 http://bmbreports.org BMB Reportsresidue, Cys184, in the SsoP1Est is not conserved at the same  position in these two esterases (Fig.",Non-OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
354 BMB Reports http://bmbreports.orgDetermination of molecular mass of native recombinant  SsoP1Est and mutant enzymes  The molecular weight of the purified native recombinant or  mutant carboxylesterase was determined on 12.5% (w/v)  SDS-polyacrylamide gel using low-molecular-weight standards.,OADS,/arxiv_data1/oa_pdf/a7/50/BMB-49-349.PMC5070724.pdf
"E-mail: jhhan551@skku.edu http://dx.doi.org/10.5483/BMBRep.2016.49.8.116Received 30 June 2016Keywords: Adipogenesis, Epigenetics, EZH2, Histone modification, S6K1 Abbreviations:  EZH2, enhancer of zeste homolog 2; H2BS36p, his- tone H2B serine 36 phosphorylation; H3K27me3, histone H3 lysine 27 trimethylation; mTOR, mammalian target of rapamycin; S6K1, ribosomal protein S6 kinase 1 Perspective to:  Sang Ah Yi et al (2016), S6K1 Phosphorylation o f  H2B Mediates EZH2 Trimethylation of H3: A Determinant of Early  Adipogenesis, Molecular Cell, May 5;62(3):443-52, doi: 10.1016 /  j.molcel.2016.03.011.",Non-OADS,/arxiv_data1/oa_pdf/48/52/BMB-49-401.PMC5070725.pdf
402 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/48/52/BMB-49-401.PMC5070725.pdf
"E-mail: Sathish-Srinivasan@omrf.org http://dx.doi.org/10.5483/BMBRep.2016.49.8.112Received 14 July 2016Keywords: FOXC2, Lymphatic valves, Lymphovenous valves, Wnt /  -catenin signaling  Abbreviations:  ECs, endothelial cells; LVs, lymphatic valves; LVVs,  lymphovenus valves; OSS, oscillatory shear stress Perspective to:  Cha et al (2016) Mechanotransduction activates  canonical Wnt/ -catenin signaling to promote lymphatic vascular  patterning and the development of lymphatic and lymphovenous valves, Genes Dev.",Non-OADS,/arxiv_data1/oa_pdf/9e/5a/BMB-49-403.PMC5070726.pdf
Mechanosensitive -catenin signaling regulates lymphatic vascular development Boksik Cha and R. Sathish Srinivasan 404 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/9e/5a/BMB-49-403.PMC5070726.pdf
"Tel: +82-32-621-5221; Fax: +82-32-621-  5014; E-mail: sapark@schmc.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.8.084Received 16 May 2016Keywords: Isoform, Mechanism, Splicing, Tau, Tauopathy ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Tau mis-splicing in the pathogenesis of neurodegenerative  disorders Sun Ah Park1,*, Sang Il Ahn1 & Jean-Marc Gallo2 1Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea, 2Department of Basic and Clinical  Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Inst itute of Psychiatry, Psychology and Neuroscience, King’s Colleg e London,  London SE5 9NU, UK Tau proteins, which stabilize the structure and regulate the  dynamics of microtubules, also play important roles in axonal transport and signal transduction.",Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
406 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
"407 http://bmbreports.org BMB Reportscis-elements SequenceEffect on  E10  SC35-like enhancer E10, TGCAGATA Inclusion Polypurine enhancer  (PPE)E10, AAGAAGCTG Inclusion A/C-rich enhancer  (ACE)E10, AGCAACGTCCAGTCC Inclusion Exonic splicing  silencer (ESS)E10,  TCAAAGGATAATATCAAAExclusion Exonic splicing  enhancer (ESE)E10,  CACGTCCCGGGAGGCGGCInclusion Intronic splicing  silencer (ISS)I10, tcacacgt Exclusion Intronic splicing  modulator (ISM)I10, cccatgcg SR proteins 　Effect on  E10  SRSF1: ASF, SF2,  SRp30a Inclusion SRSF2: SC35,  PR264, SRp30b Inclusion SRSF3: SRp20 Exclusion SRSF4: SRp75 Exclusion SRSF6: SRp55, B52 ExclusionSRSF7: SRSF3 9G8 Exclusion SRSF9: SRp30c Inclusion SRSF11: P54, SRp54 Exclusion Other RNA binding  proteins　Effect on  E10  RBM4 Inclusion Tra2 Inclusion DDX5 (RNA helicase p68) InclusionhnRNPE2 and hnRNPE3 Inclusion hnRNPG Exclusion SWAP ExclusionCELF2 Exclusion CELF3, TNRC4 Inclusion PTBP2 InclusionPSF Exclusion miRNAs Target SFEffect on  E10  miR-9 PTBP1 Exclusion miR-124 PTBP1 ExclusionmiR-132 PTBP2 Exclusion Kinases Target SFEffect on  E10  CLK2 Exclusion PKA 9G8 InclusionTable 1.",Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
408 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
409 http://bmbreports.org BMB Reportsthought to increase the risk of PSP and CBD by increasing  exon 10 splicing (73-76).,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
"410 BMB Reports http://bmbreports.orgACKNOWLEDGEMENTS This research was supported by a grant of the Korea Health  Technology R&D Project through the Korea Health Industry  Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1943).",Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
411 http://bmbreports.org BMB Reports30.,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
412 BMB Reports http://bmbreports.org63.,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
413 http://bmbreports.org BMB Reports759-764 95.,Non-OADS,/arxiv_data1/oa_pdf/49/83/BMB-49-405.PMC5070727.pdf
"Young-Gyu Ko, Tel: +82-2-3290-3453; Fax:  +82-2-3290-4144; E-mail: ygko@korea.ac.kr, Jianjie Ma, Tel: +1- 614-292-2636; Fax: +1-614-247-7799; E-mail: Jianjie.Ma@osumc.edu http://dx.doi.org/10.5483/BMBRep.2016.49.8.079Received 9 May 2016Keywords: MG53, TRIM72, E3 ligase, Muscular Dystrophy,  Membrane Repair, Insulin Resistance ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Dual function of MG53 in membrane repair and insulin  signaling Tao Tan1, Young-Gyu Ko2,* & Jianjie Ma1,* 1Department of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH  43210, USA, 2Division of Life Sciences, Korea University, Seoul 02841, Korea MG53 is a member of the TRIM-family protein that acts as a  key component of the cell membrane repair machinery.",Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
415 http://bmbreports.org BMB Reportstherapeutic value of targeting MG53-mediated cell membrane  repair in regenerative medicine.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
416 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
417 http://bmbreports.org BMB Reportsmembrane repair in muscle physiology and disease.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
"418 BMB Reports http://bmbreports.orginjury (18), and acute kidney injury (22) in rodent and large  animal models of these diseases.",Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
"419 http://bmbreports.org BMB Reportsabrogates MG53-induced IRS-1 ubiquitination, indicating that  MG53 induces IRS-1 ubiquitination with the help of E2 ligase UBE2H (25).",Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
420 BMB Reports http://bmbreports.orgof the transgenic mouse model.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
421 http://bmbreports.org BMB Reports653-668 7.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
"422 BMB Reports http://bmbreports.orgfeedback regulator of myogenesis, is transcriptionally  activated by the synergism of MyoD (or myogenin) and MEF2.",Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
423 http://bmbreports.org BMB ReportsRecent progress toward understanding the molecular  mechanisms that regulate skeletal muscle mass.,Non-OADS,/arxiv_data1/oa_pdf/70/6a/BMB-49-414.PMC5070728.pdf
"Tel: +82-42-629-8785; Fax: +82-42-629-  8769; E-mail: leeja@hnu.kr http://dx.doi.org/10.5483/BMBRep.2016.49.8.081Received 10 May 2016, Revised 3 June 2016, Accepted 29 June 2016Keywords: ATG8, Autophagy, GABARAP , GABARAPL, LC3 ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Role of the mammalian ATG8/LC3 family in autophagy:  differential and compensatory roles in the spatiotemporal regulation of autophagy You-Kyung Lee & Jin-A Lee * Department of Biological Sciences and Biotechnology, College of Life Sciences and Nanotechnology, Hannam University, Daejeon 34 054,  Korea Autophagy, an evolutionarily conserved cellular degradation  pathway of the lysosome, is associated with many physiological and pathological processes.",Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
425 http://bmbreports.org BMB Reports,Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
Mammalian ATG8 family proteins in autophagy You-Kyung Lee and Jin-A Lee 426 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
Mammalian ATG8 family proteins in autophagy You-Kyung Lee and Jin-A Lee 427 http://bmbreports.org BMB Reportsidentification of new molecular targets that are important in  modulating autophagy in several human diseases.,Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
Mammalian ATG8 family proteins in autophagy You-Kyung Lee and Jin-A Lee 428 BMB Reports http://bmbreports.orgcellular compartments.,Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
Mammalian ATG8 family proteins in autophagy You-Kyung Lee and Jin-A Lee 429 http://bmbreports.org BMB Reportspathway (38).,Non-OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
"Mammalian ATG8 family proteins in autophagy You-Kyung Lee and Jin-A Lee 430 BMB Reports http://bmbreports.orgpatterns, and chromosome localization of three human  and two mouse homologues of GABA(A) receptor- associated protein.",OADS,/arxiv_data1/oa_pdf/fc/ba/BMB-49-424.PMC5070729.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.8.021Received 2 February 2016, Revised 29 February 2016,  Accepted 5 March 2016 Keywords: E7 oncoprotein, Human papillomavirus (HPV), Intrinsi- cally disordered protein (IDP), Molecular dynamics (MD) simu-lation, Nuclear magnetic resonance (NMR), Pre-structured moti f  (PreSMo) ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Structural investigation on the intrinsically disordered  N-terminal region of HPV16 E7 protein Chewook Lee1,#, Do-Hyoung Kim1,#, Si-Hyung Lee1, Jiulong Su1,2 & Kyou-Hoon Han1,2,* 1Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, 2Department of  Bioinformatics, University of Science and Technology, Daejeon 34113, Korea Human papillomavirus (HPV) is the major cause of cervical  cancer, a deadly threat to millions of females.",Non-OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
432 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
433 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
434 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
"435 http://bmbreports.org BMB Reportsprevious CD and NMR studies, show that the N-terminal half  of E7, either N-E7 (this study) or the 40-residue N-terminal fragment (29), is disordered and contains two helical PreSMos  that mediate binding of N-E7 with partners; the first PreSMo is  an E2F-mimic motif and the second encompasses the LXCXE motif allowing the binding of E7 with the retinoblastoma  tumor suppressor protein, pRB (38).",Non-OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
436 BMB Reports http://bmbreports.orgbetween the p62/Tfb1 subunit of TFIIH and the activation  domain of p53.,OADS,/arxiv_data1/oa_pdf/d2/b6/BMB-49-431.PMC5070730.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.8.020Received 1 February 2016, Revised 16 February 2016,  Accepted 10 March 2016 Keywords: Akt, Basic fibroblast growth factor, Mitogen-activated  protein kinase, Neuronal differentiation, Phosphatidylinositide3-kinase, Protein L-isoaspartyl methyltransferase ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Critical role of protein L-isoaspartyl methyltransferase in basic  fibroblast growth factor-mediated neuronal cell differentiation To Thi Mai Dung1,#, Young-Su Yi1,2,#, Jieun Heo1, Woo Seok Yang1, Ji Hye Kim1, Han Gyung Kim1, Jae Gwang Park1,  Byong Chul Yoo3, Jae Youl Cho1,* & Sungyoul Hong1,* 1Department of Genetic Engineering, Sungkyunkwan University, Suwon 16419, 2Department of Pharmaceutical Engineering, Cheongju  University, Cheongju 28503, 3Colorectal Cancer Branch, Research Institute, National Cancer Center, Goyang 10408, Korea We aimed to study the role of protein L-isoaspartyl methyl- transferase (PIMT) in neuronal differentiation using basic fibroblast growth factor (bFGF)-induced neuronal differentiation,  characterized by cell-body shrinkage, long neurite outgrowth,  and expression of neuronal differentiation markers light and medium neurofilaments (NF).",Non-OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
438 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
439 http://bmbreports.org BMB Reports  Fig.,Non-OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
440 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
441 http://bmbreports.org BMB Reportsregulating MEK1/2 and ERK1/2 activities in the MAPK and Akt  signaling pathways (Fig.,OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
"442 BMB Reports http://bmbreports.orgFGFR-1, MAPK/ERK, and transcription factor AP-1.",OADS,/arxiv_data1/oa_pdf/e2/fa/BMB-49-437.PMC5070731.pdf
"Tel: +82-2-740-8254; Fax: +82-2-744-  4534; E-mail: minjlee@snu.ac.kr http://dx.doi.org/10.5483/BMBRep.2016.49.8.087Received 26 May 2016, Revised 17 June 2016,  Accepted 21 June 2016 Keywords: Arginylation, ATE1, G protein signaling, N-end rule,  Neural tube ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Ablation of Arg-tRNA-protein transferases results in defective  neural tube development Eunkyoung Kim1,2, Seonmu Kim1, Jung Hoon Lee1,2, Yong Tae Kwon2 & Min Jae Lee1,2,3,* 1Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, 2Department of Biomedical Sciences,  Seoul National University Graduate School, 3Neuroscience Research Institute, Seoul National University College of Medicine, Seoul 03080,  Korea The arginylation branch of the N-end rule pathway is a  ubiquitin-mediated proteolytic system in which post-transla-tional conjugation of Arg by ATE1 -encoded Arg-tRNA-protein  transferase to N-terminal Asp, Glu, or oxidized Cys residues  generates essential degradation signals.",Non-OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
444 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
445 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
446 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
"447 http://bmbreports.org BMB Reportsmolecular mechanisms have yet to be determined, these data  strongly suggest that the ATE1-RGS circuit is implicated in normal development of the neural tube during embryogenesis.",OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
"448 BMB Reports http://bmbreports.orgQuantification of NO metabolites For measurement of nitrite (NO 2−) and nitrate (NO 3−) levels in  whole embryos and embryonic brains, tissue samples from wild-type and ATE1 −/− mice were homogenized in a buffer  consisting of 25 mM Tris-HCl (pH 7.5), 0.5 M EDTA, and 0.5  M EGTA and were centrifuged at 14,000 × g for 15 min.",OADS,/arxiv_data1/oa_pdf/ff/8a/BMB-49-443.PMC5070732.pdf
"http://dx.doi.org/10.5483/BMBRep.2016.49.8.090Received 3 June 2016, Revised 14 June 2016, Accepted 21 June 2016Keywords: NRG2, RNA granules, Stress granules, Stress signaling,  Translation ISSN: 1976-670X (electronic edition) Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular Biology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/li- censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the ori ginal work is properly cited.Identification of Neuregulin-2 as a novel stress granule  component Jin Ah Kim1,#, Aravinth Kumar Jayabalan1,#, Vinoth Kumar Kothandan1, Ramesh Mariappan1, Younghoon Kee2  & Takbum Ohn1,* 1Department of Cellular & Molecular Medicine, College of Medicine, Chosun University, Gwangju 61452, Korea, 2Department of Cell  Biology, Microbiology, and Molecular Biology, College of Arts and Sciences, University of South Florida, Tampa, Florida 33620, USA Stress Granules (SGs) are microscopically visible, phase dense  aggregates of translationally stalled messenger ribonucleo-protein (mRNP) complexes formed in response to distinct  stress conditions.",Non-OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
450 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
451 http://bmbreports.org BMB Reports Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
452 BMB Reports http://bmbreports.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
453 http://bmbreports.org BMB Reportsactive tertiary structure have been demonstrated to be  involved in phase separation and formation of membrane-less compartments inside cell.,Non-OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
"Thus, we checked whether any  disordered region resides in NRG2 using the web server  (http://iupred.enzim.hu/) and surprisingly most of the C- terminal region was found to be completely disordered (28).",OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
454 BMB Reports http://bmbreports.orgwas measured at 570 nm.,OADS,/arxiv_data1/oa_pdf/72/00/BMB-49-449.PMC5070733.pdf
This  is  an  open access article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.09.043 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"Van  Nostrand,  The  applied  anatomy  of  thyroglossal  tract remnants, Laryngoscope  87  (1977)  765–770,  http://dx.doi.org/10.1002/lary.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"197 (2015)  29–37,  http://dx.doi.org/10.1016/j.aanat.2014.09.001 .",OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"48  (2015)  15–27,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"71  (2007)  1731–1735,  http://dx.doi.org/10.1016/j.ijporl.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"26 (2015) 75–79, http://dx.doi.org/ 10.1007/s12022-015-9354-y .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"33  (2005)  365–369, http://dx.doi.org/10.1002/dc.20346 .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"48  (2012)  179,  http://dx.doi.org/10.4068/cmj.2012.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"115  (2006)  850–856,  http://dx.doi.org/10.1177/ 000348940611501110 .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"Venkatesan,  P.  Gupta,  Complications  associated  with  the sistrunk  procedure,  Laryngoscope  111  (2001)  119–123,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"79  (2002)  134–139,  http://dx.doi.org/10.1002/jso.10059 .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"(2016)  1–6,  http://dx.doi.org/10.1007/s00423-016-1460-x .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"23  (2014)  161–166,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"Tuttle,  L.  Wartofsky,  American Thyroid  Association Management  Guidelines  for  adult  patients  with  thyroid nodules  and  differentiated  thyroid  cancer:  The  American  Thyroid  Association Guidelines  Task  Force  on  Thyroid  Nodules  and  Differentiated  Thyroid  Cancer, Thyroid 26 (2015)  1–133,  http://dx.doi.org/10.1089/thy.2015.0020 .",Non-OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"(2016), http://dx.doi.org/10.1016/j.ijsu.2016.08.014 .",OADS,/arxiv_data1/oa_pdf/3c/12/main.PMC5070838.pdf
"To viewa copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/4.0/ Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)Combined mismatch repair and proofreading defect AML Jansen et al 1092 European Journal of Human Genetics",Non-OADS,/arxiv_data1/oa_pdf/7c/fe/ejhg2015252a.PMC5070903.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/de/ca/main.PMC5070923.pdf
http://dx.doi.org/10.1016/j.btre.2016.03.002 2215-017X/ ã  2016  The  Authors.,OADS,/arxiv_data1/oa_pdf/de/ca/main.PMC5070923.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Biotechnology  Reports  10  (2016)  29–37 Contents  lists  available  at  ScienceDirect Biotechnology  Reports journal  homepage:  www.else  vie  r.com/locat  e/btre,Non-OADS,/arxiv_data1/oa_pdf/de/ca/main.PMC5070923.pdf
Available from  http://www.fda.gov/AboutFDA/WhatWeDo.,OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from  http://www.finance.senate.gov/release/ grassley-baucus-release-committee-   report-on-avandia.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from http://www.fda.gov/ohrms/ dockets/ac/08/minutes/2008-4368m-Final.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from http://www.fda.gov/Drugs/ DrugSafety/ucm476466.htm.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from http://www.fda.gov/ downloads/Drugs/NewsEvents/UCM436369.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from http://www.novonordisk.,OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from http://en.sanofi.com/ Images/33756_20130912_lixisenatide_ en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available at http://www.fda.gov/Drugs/ NewsEvents/ucm433971.htm.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available  from https://www.ncdr.com/WebNCDR/ Diabetes/publicpage.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available from  http://www.mini-sentinel.org.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
Available at https://t1dexchange.org/pages.,Non-OADS,/arxiv_data1/oa_pdf/1d/7b/173.PMC5070965.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ © The Author(s) 2016Epigenetics and bipolar disorder B Ludwig and Y Dwivedi 1498 Molecular Psychiatry (2016), 1490 –1498",Non-OADS,/arxiv_data1/oa_pdf/57/30/mp2016123a.PMC5071130.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2e/a9/main.PMC5071539.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.08.007,OADS,/arxiv_data1/oa_pdf/2e/a9/main.PMC5071539.pdf
http://www.caremorectc.eu .,Non-OADS,/arxiv_data1/oa_pdf/2e/a9/main.PMC5071539.pdf
This is an open access article under the CCBY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9c/6a/main.PMC5071540.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.09.002,OADS,/arxiv_data1/oa_pdf/9c/6a/main.PMC5071540.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/62/main.PMC5071541.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.08.009,OADS,/arxiv_data1/oa_pdf/51/62/main.PMC5071541.pdf
The theme of the 2015 Annual Meeting of the International Society of Exposure Science (ISES) —Exposures in an Evolving Environment —brought this issue to the fore (meeting abstracts are available at http://isesweb.org/ Meetings/Docs/ISES2015_AbstractBook%20FINAL.pdf).,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
8New computational and analytical tools are being rapidly developed that will facilitate more ef ﬁcient and tractable assessments of chemical safety (http://www2.epa.gov/research/ chemical-safety-sustainability-strategic-research-action-plan-2016-2019) and are therefore a means to address this uncertainty.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
"With proper planning and communication, it is likely thatnew monitoring networks will be established within the US andworldwide within the next decade (see, e.g., the NORMAN Network: http://www.norman-network.net/).",Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
"For the 2014 –2015 season, over 12,000 birders across the US and Canada submitted checklists (Personal Communication, Anne Marine Johnson, Project Assistant, Project FeederWatch, Cornell Lab of Ornithology, 159 Sapsucker Woods Road, Ithaca, NY14850, http://feederwatch.org, 607-254-2416).",Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
(https://webcache.googleusercontent.com/search?q=cache:kSPEVJkYmNEJ or https://www.niehs.nih.gov/health/materials/a_human_health_perspective_on_- climate_change_full_report_508.pdf+&cd=1&hl=en&ct=clnk&gl=us).,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://dx.doi.org/10.7930/J0R49NQX.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://ipcc-wg2.gov/SREX/images/uploads/SREX-All_FINAL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
"Available at: http://www.for.gov.bc.ca/hfd/ pubs/rsi/fsp/Misc/Misc071.pdf, 2006.",Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://nca2014.globalchange.gov/report/ sectors/human-health.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://pdf.wri.org/connection_between_climate_change_and_extreme_weather.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://www.c2es.org/publications/extreme- weather-and-climate-change.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://www.epa.gov/oppt/existingchemicals/pubs/tscain ventory/index.html.,OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://www.birds.cor- nell.edu/citscitoolkit/about/de ﬁnition.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at:http://www.fws.gov/southeast/economicImpact/pdf/2011-BirdingReport--FINAL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://feederwatch.org/wp-content/uploads/2015/04/2015- News-Note.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
Available at: http://feederwatch.org/wp-content/uploads/2014/04/2014-News-Note.pdf.,Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ © The Author(s) 2016Exposure science in an age of changing climate LaKind et al 538 Journal of Exposure Science and Environmental Epidemiology (2016), 529 –538",Non-OADS,/arxiv_data1/oa_pdf/86/da/41370_2016_Article_BFjes201635.PMC5071542.pdf
"However, the same congruent targets with correct case markers would reduce lateralized negativity under the shallow semantic condition becauseReceived: 31 January 2016 Revised: 26 May 2016 Accepted: 11 October 2016 Heliyon 2 (2016) e00180 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"For instance, we know that it is moreinformative and grammatically rigid to have a subject in a sentence, but in Article No~e00180 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"Based on this ERP distinction, the present study aimed to examine the influence of grammatical congruency (i.e., correct/incorrect use of function words) on simple Article No~e00180 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"Both groups were matched for sex (SHL: 8 men, 5 women; DP: 10 men, 3women; Fisher ’s exact test, p= 0.673), age [SHL: mean ± standard deviation, 21.6 ± 3.7 years; DP: 20.7 ± 2.3 years; t (24)= 0.757, p= 0.456], handedness [laterality quotient: SHL, 0.95 ± 0.07; DP: 0.93 ± 0.10; t(24)= 1.120, p= 0.274] [30], short- term verbal working memory [reading span: SHL, 3.1 ± 1.1; DP: 3.2 ± 0.9; t(24)= 0.198, p= 0.845] [31], and long-term verbal memory [estimated vocabulary transformed into z-scores: SHL, −0.151 ± 1.179; DP: 0.151 ± 0.853; t(24)= 0.075, p= 0.46; vocabulary test: http://www.kecl.ntt.co.jp/icl/mtg/goitokusei/goi-test.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Both semantic tasks have been Article No~e00180 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Prime noun Congruent target verb Incongruent target verb Japanese English Japanese English Japanese English 1 雨戸 Shutter 開ける Open 冷ます Cool 2 意見 Opinion 述べる State 建てる Build 3 遺産 Inheritance 分ける Divide 閉める Shut 4 遺体 Corpse 埋める Bury 鳴らす Sound 5 植木 Garden plant 枯らす Wither 受ける Take 6 獲物 Game 逃がす Lose 溶かす Melt 7 落葉 Leaves 燃やす Burn 交わす Exchange 8 会社 Company 辞める Leave 惜しむ Spare 9 会話 Conversation 交わす Exchange 染める Dye 10 片目 One eye 閉じる Close 済ます Finish 11 楽器 Instrument 鳴らす Sound 過ごす Spend 12 危険 Danger 避ける Avoid 降ろす Unload 13 期限 Deadline 延ばす Extend 埋める Bury 14 基準 Standard 満たす Satisfy 浮かす Save 15 休暇 Holiday 過ごす Spend 着せる Dress 16 疑惑 Doubt 晴らす Dispel 分ける Divide 17 故人 Deceased 惜しむ Spare 下げる Lower 18 国旗 National flag 揚げる Fly 入れる Take 19 御飯 Dinner 食べる Eat 燃やす Burn 20 財布 Wallet 落とす Lose 述べる State 21 座席 Seat 空ける Leave 果たす Accomplish 22 砂糖 Sugar 溶かす Melt 伸ばす Straighten 23 資金 Money 貯める Earn 逃がす Lose 24 試験 Examination 受ける Take 借りる Rent 25 事件 Incident 起こす Cause 替える Change 26 事実 Truth 告げる Tell 空ける Leave 27 下着 Underwear 替える Change 終える Finish 28 上位 Higher rank 占める Occupy 開ける Open 29 食費 Food expenses 浮かす Save 避ける Avoid 30 白髪 Grey hair 染める Dye 上げる Make 31 新居 New house 建てる Build 晴らす Dispel 32 背筋 Back 伸ばす Straighten 止める Cease 33 煙草 Smoking 止める Cease 満たす Satisfy 34 貯金 Savings 増やす Increase 揚げる Fly 35 戸棚 Cupboard 閉める Shut 散らす Throw (Continued ) Article No~e00180 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Individual-averaged ERP waveforms were produced for each condition after baseline correction withthe mean potential of the 200 ms before target onset and artifact rejection (peak-to- Article No~e00180 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"The group differences in amplitude strength mightalso yield apparent topographical differences between the two task groups, even Article No~e00180 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
No significant differences were observed in the accuracy among the conditions and task groups Article No~e00180 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"As the maximal (max) statistical values across the four time windows indicated in the overall ANOVAs, the main and interaction effects according to the condition factors were significant in the lateral [condition (max): 500 –600 ms, Article No~e00180 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"The potential maps that are shown against the light-green background indicate significanteffects ( p<0.05, corrected) of the multiple comparisons between the SI condition and each of the three Article No~e00180 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 17 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
A parsimonious interpretation of the findings is that case markers function differently under the SHL and DP semantic conditions after spreading the Article No~e00180 18 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 19 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
"For example, the prime “Shutter ”activates related features, including “Open, ”which is consistent with the “STATE ”slot in the causative Article No~e00180 20 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 21 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 22 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 23 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 24 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 25 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 26 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
Article No~e00180 27 http://dx.doi.org/10.1016/j.heliyon.2016.e00180 2405-8440/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/64/0c/main.PMC5071545.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: White matterMRIBrainHypertensionBlood pressureHeritability 1.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/j.nicl.2016.10.0012213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.0000129643.77045.10 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/j.neuroimage.2010.09.025 .,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.17.6.1090 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"Twin research and human genetics: the of ﬁcial journal of the International Society for Twin Studies 15, 351– 371. http://dx.doi.org/10.1017/thg.",Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.29.6.1177 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"Psychiatry 70, 9 –14.http://dx.doi.org/10.1136/ jnnp.70.1.9 .",Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1093/brain/125.4.765 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.11 61/01.STR.0000125859.71051.83 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.30.8.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1007/s12021-007-9003-9 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/j.neuroimage.2010.07.033 Atlas: http:// www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009.,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1375/ 136905202320906318 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1002/gps.2087 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.31.6.1263 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1111/j.1552-6569.2006.00047.x .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1375/183242705774310123 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/S0197- 4580(01)00217-2 .,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1007/s13365-011-0032-7 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.STR.27.12.2230 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"Neurology 76, 1879– 1885. http://dx.doi.org/10.1212/WNL.0b013e31821d753f .",Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/STROKEAHA.109.565390 .744 C. Fennema-Notestine et al.,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"Aging 33, 1 –8.http://dx.doi.org/10.1016/j.neurobiolaging.2010.02.007 .",OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1002/ajmg.b.32162 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1109/42.563664 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05336 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1093/ajh/hpt271 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1093/ ajh/hpu134 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"Psychi- atry (Abingdon, England) 25, 738– 747. http://dx.doi.org/10.3109/09540261.2013.",Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1198/004017001316975880 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"(Lond) 34, 29 –40.http://dx.doi.org/10.1038/ijo.2009.177 .",OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1111/j.1467-9280.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
"35, 55 –62.http://dx.doi.org/10.3174/ajnr.A3612 .",Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1161/01.hyp.0000145857.98904.20 .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1097/ HJH.0b013e32801449fb .,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.1016/S1474-4422(13)70124-8 .,OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/13/98/main.PMC5071546.pdf
This is an open access article under the CCBY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0e/cc/main.PMC5071549.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.09.004,OADS,/arxiv_data1/oa_pdf/0e/cc/main.PMC5071549.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ rThe Author(s) 2016 Supplementary Information accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)Spermidine modulates macrophages to ameliorate EAE Q Yang et al 1861 Cell Death and Differentiation",Non-OADS,/arxiv_data1/oa_pdf/d3/83/cdd201671a.PMC5071574.pdf
https://www.eurotransplant.org/cms/mediaobject.php?file=ar_2014.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/b4/3e/KITP-13-28406.PMC5071584.pdf
Australian Donation And Transplantation Activity Report 2015. http://www.donatelife.gov.au/sites/default/files/Australian%20Donation%20and%20Transplantation%20Activity%20Report%202015.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/b4/3e/KITP-13-28406.PMC5071584.pdf
All  directives are available in various languages to download  from the EC website: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=CONSLEG:1993L0042:20071011:en:PDF .,Non-OADS,/arxiv_data1/oa_pdf/9a/0a/KITP-13-28413.PMC5071591.pdf
"The CEV is a living  process, consisting of a few steps, repeated when neces- sary, starting before obtaining the CE mark and continuing after placing the device on the market, in the latter case as part of the post-market surveillance system (for details on CEV see MEDDEV 2.7.1 CLINICAL EVALUATION: A GUIDE FOR  MANUFACTURERS AND NOTIFIED BODIES (http://ec.europa.eu/growth/sectors/medical-devices/guidance_en).",Non-OADS,/arxiv_data1/oa_pdf/9a/0a/KITP-13-28413.PMC5071591.pdf
"https://3dprint.com/91580/3d-printed-pelvic-implant/,  2015, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"2. http://www.notimpossible.com/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprintingindustry.com/news/3d-printing-enables-medical- models-with-blood-guts-all-44186/, 2015, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"4. http://envisiontec.com/trends-in-3d-printing-of-customized-medical-de-vices/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.youtube.com/watch?v=P2 peq82e8is, 2013, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://en.wikipedia.org/wiki/3D_printing, accessed 26 Febr.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.theengineer.co.uk/issues/24-may-2010/the-rise-of-additive-manufacturing/, 2010, ac-cessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"9. https://zortrax.pl/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"10. https://www.3dhubs.com/trends, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.khouse.org/arti-cles/2012/1078/, 2012, accessed 4 March 2013.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Stereolithography, accessed  11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Photopolymers, accessed 11  Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprint.com/65466/reflections-alain-le-mehaute/, 2015, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.primante3d.com/inventeur, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Chuck_Hull, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/3D_Systems, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.google.com/patents/uS4575330, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/STL_%28file_format%29, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Computer_aided_design, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/3D_scanner#  Hand-held_laser_scanners, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Photogrammetry, accessed  11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.sculpteo.com/en/3d-printing/3d-printing-and-traditional-manufacturing-processes/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprinting.com/what-is-3d-printing/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.kickstarter.com/projects/polymaker/polysmooth-and-polysher-3d-prints-without-lay-ers, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"Rifkin J. http://www.thethirdindustrialrevolution.com/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.gartner.com/newsroom/id/3117917, accessed 14 Aug.  2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/99905/3d-printing-to-safeguard-stetfetus/, 2015, ac-cessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"39. http://www.parsee.org/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprint.com/95097/project-glia-gaza-strip/, 2015, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprintingindustry.com/news/classic-books-made-tangible- blind-3d-printing-66332/, 2016, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.livescience.com/53477-shape-shifting-4d-printed-objects.html?li_source=LI&li_medium=more-from-livescience, 2016, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.washingtonpost.com/news/innovations/wp/2016/03/07/3-ways-in-which-a-3d-printer-may-one-day-save-your-life/, 2016, accessed  11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"Sharma R. http://www.forbes.com/sites/rakeshsharma/2013/07/08/the-3d-printing-revolution-you-have-not-heard-about/#959ebaa21e12, 2013, acces-sed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"46. http://www.materialise.com/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"47. http://envisiontec.com/3d-printing-industries/hearing-aid/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.3ders.org/articles/20130103-3d-printing-helps-develop-the-world- smallest-hearing-aid.html, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.hearingreview.com/2016/02/starkey-innovations-expo-focus- es-technology-marketing-purpose/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://whc.ifps.org.pl/2015/01/warsztaty-szkoleniowe-z-zakresu- chirurgii-implantow-slimakowych-xix-window-approach-workshop-waw-w- kajetanach/, accessed 19 Sept. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"52. https://www.dentalproductsreport.com/3d-printing/11614, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"53. http://www.dentalproductsreport.com/dental/article/10-things-you-need-know-about-3d-printing, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"The top 5 dental lab trends of 2015. https://www.dentalproductsreport.com/lab/article/top-5-dental-lab-trends-2015, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.dentalprod-uctsreport.com/lab/article/stratasys-debuts-new-3d-printer-larger-labs, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.dentalprod-uctsreport.com/dental/article/fda-approves-3d-printable-denture-base-material, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.stratasys.com/industries/dental/objet30-orthodesk, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"58. http://www.zenith3d.co.kr/eng/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"59. http://envisiontec.com/3d-printing-industries/dental/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
http://www.dentalproductsreport.,Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.stra- tasys.com/resources/case-studies/dental/guide3d, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"Five of the Top Drug & Device Developments  in 2015. http://www.faegrebd.com/five-of-the-top-drug-device-develop- ments-in-2015, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.business- week.com/articles/2012-05-03/how-about-them-gams-3d-printing-cus- tom-legs, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://dealingwithdifferent.com/3d-printing-prosthetics/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://theroboarm.com/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"67. http://enablingthefuture.org/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://enablingthefuture.org/2014/03/13/our-visual-tree/, accessed 4 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://healthtechinsider.com/  2015/06/08/bionic-leg-produces-normal-gait-video/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.gizmag.com/exo-prosthetic-leg-3d-printing/35297/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"71. http://andiamo.io/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.dezeen.com/2013/11/26/3d-printed-prosthetic-eyes/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"73. http://www.openbionics.com/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://qz.com/600405/kids-are-designing-their-own-3d-printed-superhero-cyborg-prosthetic-arms/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.telegraph.co.uk/news/  9962798/How-doctors-printed-my-new-face.html, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.eit-spine.de/cms/en/first_cervical__individualized_ cage_implanted1/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.popsci.com/science/article/2013-03/get-brand-new-skull-3-d-printing, accessed 11 Aug.  2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprintingindustry.com/2014/11/13/3000-3d-printed-spi-nal-implants/?utm_source=3D+Printing+Industry+Update&utm_mediu- m=email&utm_campaign=f73b7c15b9-RSS_EMAIL_CAMPAIGN&utm_ter - m=0_695d5c73dc-f73b7c15b9-64443961, 2014, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.bbc.com/ news/technology-16907104, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.mayfield- clinic.com/PE-CT.htm, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.bruker.com/imaging-blog/3d-printing-of-ct-data/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.instructables.com/id/3D- Printing-from-MRI-data-in-5-steps/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprinting.com/medical/researchers-develop-3d-printed-scaffolds- to-cure-type-1-diabetes/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/132467/pfizer-makerbot-arthri- tis, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"90. https://www.slicer.org/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://lodz.wyborcza.pl/lodz/1,3513 6,14561601,Przeszczepili_fragment_czaszki_narysowany_w.html, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.miastoinnowacji.lodz.pl/kosci-zamienne_16,561.html, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://naukawpolsce.pap.pl/aktualnosci/news,384581,prace-nad-wirtualna-sekcja-zwlok-w- technoparku.html, accessed 23 Sept. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.fiercepharma.com/animal-health/3d-systems-   preps-for-global-launch-of-printed-knee-implants-for-dogs, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.biuletyn.pw.edu.pl/Od- powiedzialna-uczelnia/Z-zycia-spolecznosci-PW/Bero-juz-chodzi-na-czte-rech-lapach, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/49992/fasotec-3d-print- wet-model/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://ko.3dsystems.com/blog/2015/11/virtual-surgical-planning-assists-full- face-transplant, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.dawca.pl/aktualnosci/24768,pierwszy-w-polsce-przeszczep-twarzy-przeprowadzono-w-gliwicach, accessed 11 Aug. 2016.100.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.guysandstthomas.nhs.uk/news-and-events/2016-news/january/20160125-Worldfirst3Dprintingusedinlife-changingkidneytrans- plant.aspx, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"First ever kidney transplant using 3D printing changes life of n orthern  Ireland toddler, Lucy, http://www.3ders.org/articles/20160126-first-kidney- transplant-using-3d-printing-changes-life-of-northern-ireland-toddler-lucy.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/67530/3d-printed-kid-ney-tumor/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.mirror.co.uk/news/world-news/conjoined-twins-separated-ground-breaking-7509052, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"107. http://www.malopolskieusg.pl/en/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.healthyskinportal.com/articles/3D-Printing-Technology-Leads-to-n ew-Varicose-Vein-Treatment/753/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"The First Ever Medical Winch – Zortrax M200 Contribution to Varicose Vein Surgery https://www.youtube.com/watch?v=d799V44IsX8#xsivd, ac-cessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"110. http://poland.pl/science/achievements-science/polish-product-future/, accessed 19 Sept. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
111. https://www.sculpteo.com/blog/2011/12/08/oyoglasses-make-eyewear-3d-printing-challenges-for-customized-glasses-companies/ 112.,Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.instructables.com/id/How-to-design-3d-printed-glasses/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.technologyre-view.com/s/540926/3-d-printing-breaks-the-glass-barrier/, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.fiercemedicaldevices.com/story/fda-clears-3-d-printed-device-mini-mally-invasive-foot-surgery/2015-02-02, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.wired.com/2013/07/is-this-cast-the-future-of-healing-broken-bones/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"116. http://www.fucco3d.com/#!druk-3d/ju363, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.bioinformant.com/what-if-3d-printing-was-100x-or-1000x- faster/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://app.getresponse.com/click.html?x=a62b&lc=2b3ru&mc=IM&s=Qs D1cn&st=BfNWv5&u=H83W&y=T&, 2016, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"123. http://www.cellink.eu/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"124. http://www.roosterbio.com/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.3ders.org/articles/20130815- how-do-they-3d-print-kidney-in-china.html, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://thediplomat.com/2013/08/chinese-scientists-are-3d-print- ing-ears-and-livers-with-living-tissue/, 2013, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.popularmechanics.com/science/health/a19443/3d-printer- bone-cartilidge-and-muscle/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/134070/3d-print-cartilage-replacement/, accessed 11 Aug. 2013.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://3dprint.com/58602/3d-printed-heart-organoid/, 2015, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://www.youtube.com/watch?v=tyGq4nLgqaE, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.nature.com/news/scientists-print-self-assembling-living-tissue-1.12743, 2015, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.bbc.com/news/technology-21614176, 2013, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.marketwatch.com/story/organovo-announces-commercial-release-of-the-exvive3dtm-human-liver-tissue-2014-11-18, ac-cessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://dx.doi.org/10.1371/journal.pone.0158674, 2016, accessed  14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.bbc.com/news/technology- 32795169, accessed 11 Aug. 2016.141.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://media.uow.edu.au/news/uOW162803.html, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"(143)  http://thediplomat.com/2013/08/chinese-scientists-are-3d-print- ing-ears-and-livers-with-living-tissue/, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.futuristspeaker.com/busi- ness-trends/inventing-the-3d-pill-printer/, 2012, accessed 11 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.chemistryviews.org/ details/ezine/5736441/Whats_n ew_in_3D_Printing.html, 2014, accessed  14 Aug. 2016.",OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"Mearian L. http://www.computerworld.com/article/3048823/3d-printing/ this-is-the-first-3d-printed-drug-to-win-fda-approval.html, 2016, accessed  14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://www.fiercepharma.com/regulatory/company-builds-plant-for-3dp-pill-making-as-it-nails-first-fda-approval, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"https://en.wikipedia.org/wiki/Personalized_medi-cine, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://3dprint.nih.gov/about, accessed 14 Aug. 2016.",OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"http://blogs.gartner.com/pete-basiliere/2015/12/02/gart-ner-predicts-2016-3d-printing-disrupts-healthcare-and-manufacturing/, 2015, accessed 14 Aug. 2016.",Non-OADS,/arxiv_data1/oa_pdf/d7/f2/KITP-13-28425.PMC5071603.pdf
"Date: 21-23.09.2016, Jastarnia, Poland Information: www.torakoneptunalia.pl  Thoracic Surgery Workshops – VATS Lobectomy Date: 26-28.09.2016, Warsaw, Poland Information: www.ptkt.pl/events 30 th EACTS Annual Meeting Date: 1-5.10.2016, Barcelona, Spain Information: www.eacts.org  3rd Annual Advances in Thoracic Surgical Oncology Date: 7-8.10.2016, New York, NY, USA Information: https://mskcc.cloud-cme.com  Acute Cardiovascular Care 2016 Date: 15-17.10.2016, Lisbon, PortugalInformation: https://www.escardio.org/Congresses-&--Events/Upcoming-congresses/Acute-Cardiovascular-Care/Acute-Cardiovascular-CareThird European Congress on eCardiology and eHealthDate: 26-28.10.2016, Berlin, GermanyInformation: http://www.e-cardiohealth.com/ EACTS Academy: 11 th European Mechanical Circulatory  Support Summit (EUMS) Date: 3-5.11.2016, Berlin, Germany Information: http://www.eacts.org/academy/2016-pro- gramme/ X Conference of the Polish Group of Lung Cancer Date: 18-19.11.2016, Warsaw, PolandInformation: www.rakpluca10.pl  X Symposium “Advances in immunosuppression in organ  transplantation vascularized” Date: 15-17.12.2016, Krakow, Poland Information: www.p-t-t.org  STS 53 rd Annual Meeting and STS/AATS Tech-Con 2017 Date: 21-25.01.2017, Houston, TX, USA Information: www.sts.org  Complications in vascular surgery and endovascular   – IV Conference of scientific training Date: 9-11.03.2017, Warsaw, PolandInformation: www.naczyniowka.pl 32 nd EACTA Annual Congress 2017 Date: 19-21.04.2017, Berlin, Germany Information: http://www.eacta.org/congress-events/  calendar-of-events/ 25th European Conference on General Thoracic Surgery Date: 28-31.05.2017, Innsbruck, Austria Information: www.ests.org",Non-OADS,/arxiv_data1/oa_pdf/d3/02/KITP-13-28483.PMC5071604.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.004 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
Available at: 〈https://cddep.org/sites/default/ ﬁles/swa_2015_ ﬁnal.pdf 〉.,OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
Available at: 〈http://apps.who.int/iris/ bitstream/10665/112642/1/9789241564748_eng.pdf 〉.,OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
Available at: 〈http://ecdc.europa.eu/en/publications/ Publications/antimicrobial-resistance-europe-2014.pdf 〉.,Non-OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
Available at: 〈http://www.cdc.gov/drugre sistance/pdf/ar-threats-2013-508.pdf 〉.,OADS,/arxiv_data1/oa_pdf/f1/5e/main.PMC5071619.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.002 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/71/e3/main.PMC5071621.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/e3/main.PMC5071621.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.001 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/22/22/main.PMC5071622.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/22/22/main.PMC5071622.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.016 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/94/0d/main.PMC5071623.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/94/0d/main.PMC5071623.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.015 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/c5/af/main.PMC5071626.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/af/main.PMC5071626.pdf
Available from 〈http://www.fao.org/ ﬁleadmin/user_upload/agns/ pdf/CTA_Advantame_77.pdf 〉.,OADS,/arxiv_data1/oa_pdf/c5/af/main.PMC5071626.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.013 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Abbreviations: ADP, adenosine diphosphate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ASIC1a, acid-sensing ion channel 1a; BDNF, brain-derived neurotrophic factor; CFDA, the China Food and Drug Administration; CNTF, ciliary neurotrophic factor; GDNF, glial cell line – derived neurotrophic factor; iGluRs, ionotropic glutamate receptors; MHRA, Medicine and Healthcare Products Regulatory Agency; NBP, butylphtha lide/3- n-butylphthalide; NGF, nerve growth factor; NMDA, N-methyl- D-aspartate; rt-Pas, recombinant tissue plasminogen activators; TCM, traditional Chinese medicine; TRP, transient receptor potential; TRPC, transient receptor potential canonical; TRPM, transient receptor potential melastatin; TRPV , transient receptor potential vanilloid nCorresponding author at: Department of Molecular and Cellular Pharmacology, State Key Laboratory of Natural and Biomimetic Drugs, Peking University School of Pharmaceutical Sciences, Beijing 100191, China.",Non-OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01929096?,Non-OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
Available from: 〈https://clinicaltrials.gov/ct2/show/NCT02430350?,Non-OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
Available from: 〈https://clinicaltrials.gov/ct2/show/ NCT01790997?term ¼NCT01790997&rank ¼1〉.,OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
Available from: 〈https://clinicaltrials.gov/ct2/show/ NCT02133521?term ¼NCT02133521&rank ¼1〉.,OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
Available from: 〈https://clinicaltrials.gov/ct2/show/ NCT02594995?term ¼NBP&rank ¼1〉.,OADS,/arxiv_data1/oa_pdf/b2/d4/main.PMC5071630.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.009 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/97/33/main.PMC5071632.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/97/33/main.PMC5071632.pdf
"Expasy.ch/tools/protparam.html ), and the SWISS-MODEL27–30 (http://swissmodel.Expasy.org/ ) predicted the protein secondary structure and analyzed the molecular modeling of SgCYP450-4.SignalP 4.0 Server ( http://www.Cbs.Dtu.dk/services/SignalP/ ) and TargetP 1.1 Server ( http://www.Cbs.Dtu.dk/services/TargetP/ ) were used to predict the signal peptide.",OADS,/arxiv_data1/oa_pdf/97/33/main.PMC5071632.pdf
v1.0 31(http:// www.bioinfo.tsinghua.edu.cn/SubLoc/ ) and TMHMM Server v.2.0 (http://www.Cbs.Dtu.dk/services/TMHMM/ ) were used to predict the protein subcellular localization and transmembrane region.,OADS,/arxiv_data1/oa_pdf/97/33/main.PMC5071632.pdf
Conserved domains were analyzed by Blastp and ExPASyPROSITE ( http://www.Expasy.ch/prosite/ ).,OADS,/arxiv_data1/oa_pdf/97/33/main.PMC5071632.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.06.010 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/15/3d/main.PMC5071633.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/15/3d/main.PMC5071633.pdf
"The TargetScan database ( http://www.targetscan.org/ ) predicts thatCol1a2 (Collagen, type 1, α2) is a potential target of miR-26a.",OADS,/arxiv_data1/oa_pdf/15/3d/main.PMC5071633.pdf
Available from: http://dx.doi.org/10.1111/jcmm.,Non-OADS,/arxiv_data1/oa_pdf/15/3d/main.PMC5071633.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.012 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/0f/9a/main.PMC5071634.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0f/9a/main.PMC5071634.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.o rg/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.005 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/6e/e0/main.PMC5071635.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6e/e0/main.PMC5071635.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.04.002 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/12/13/main.PMC5071636.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/12/13/main.PMC5071636.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.001 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/d8/c5/main.PMC5071637.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d8/c5/main.PMC5071637.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.006 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/d8/63/main.PMC5071638.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d8/63/main.PMC5071638.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Chinese Pharmaceutical Association Institute of Materia Medica, Chinese Academy of Medical Sciences www.elsevier.com/locate/apsb www.sciencedirect.comActa Pharmaceutica Sinica B http://dx.doi.org/10.1016/j.apsb.2016.05.009 2211-3835 &2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.",Non-OADS,/arxiv_data1/oa_pdf/67/c1/main.PMC5071639.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/67/c1/main.PMC5071639.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"2 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"Reference mass spectrum from Gracilibacillus massiliensis strain Awa-1Tspectra.Table salt microbiota Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"4 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"These evidence codes are from the Gene Ontologyproject (38).Table salt microbiota Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"6 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"Nucleotide content and gene count levels of the genome Attribute Value % of totala Size (bp) 4,207,226 100 G/C27C content (bp) 1,516,759 36.05 Coding region (bp) 3,579,496 85.07Total genes 3,908 100RNA genes 69 1.76Protein-coding genes 3,839 98.23Genes with function prediction 2,647 68.95 Genes assigned to COGs 2,455 63.94 Genes with peptide signals 430 11.20Genes with transmembrane helices 1,063 27.68 aThe total is based on either the size of the genome in base pairs or the total number of protein coding genes in the annotatedgenome.Table salt microbiota Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"8 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"Number of genes associated with the 25 general COG functional categories Code Value% value Description J 206 5.36 Translation A 0 0 RNA processing and modificationK 205 5.33 TranscriptionL 90 2.34 Replication, recombination, and repairB 1 0.026 Chromatin structure and dynamicsD 51 1.32 Cell cycle control, mitosis, and meiosis Y 0 0 Nuclear structure V 65 1.69 Defense mechanismsT 140 3.64 Signal transduction mechanismsM 125 3.25 Cell wall/membrane biogenesisN 53 1.38 Cell motilityZ 0 0 CytoskeletonW 9 0.23 Extracellular structuresU 32 0.83 Intracellular trafficking and secretion O 105 2.73 Posttranslational modification, protein turnover, and chaperones X 46 1.19 Mobilome: prophages and transposonsC 138 3.59 Energy production and conversionG 328 8.54 Carbohydrate transport and metabolismE 208 5.41 Amino acid transport and metabolismF 87 2.26 Nucleotide transport and metabolismH 148 3.85 Coenzyme transport and metabolism I 97 2.52 Lipid transport and metabolism P 144 3.75 Inorganic ion transport and metabolismQ 70 1.82 Secondary metabolites biosynthesis, transport, and catabolism R 244 6.35 General function prediction onlyS 191 4.97 Function unknown /C1 1,384 36.05 Not in COGsTable salt microbiota Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"10 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"GM, Gracilibacillus massiliensis Awa-1T; HH, Halobacillus halophilus DSM 2266; AJ, Amphibacillus jilinensis Y1; HT, Halobacillus trueperi HT-01; GH, Gracilibacillus halophilus YIM-C55.5T; GB, Gracilibacillus boraciitolerans JCM 21714.Table salt microbiota Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"12 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 32049 - http://dx.doi.org/10.3402/mehd.v27.32049",Non-OADS,/arxiv_data1/oa_pdf/b1/12/MEHD-27-32049.PMC5071648.pdf
"[accessed October 5, 2015] http://www.cdc.gov/ injury/wisqars/leading_causes_death.html 2.",Non-OADS,/arxiv_data1/oa_pdf/ad/f5/AJAD-25-221.PMC5071651.pdf
Available from URL: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6043a4.htm?s_cid ¼mm6043a4_w# ﬁg2.,OADS,/arxiv_data1/oa_pdf/ad/f5/AJAD-25-221.PMC5071651.pdf
Oct 2006. https://www.health.ny.,Non-OADS,/arxiv_data1/oa_pdf/ad/f5/AJAD-25-221.PMC5071651.pdf
"Image Analyses Image processing was performed using FSL software (http://www.fmrib.ox.ac.uk/fsl, Oxford University).Structural images Cerebral gray and white matter volumes were estimated using the optimized voxel-based morphometry (VBM)[Good et al., 2001] protocol FSL-VBM (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM) [Douaud et al., 2007], carried out with FSL 5.0 [Smith et al., 2004].",OADS,/arxiv_data1/oa_pdf/d9/86/HBM-37-2736.PMC5071657.pdf
"[*]S.Manna, Dr.A.P.Antonchi ck Abteilung Chemisc heBiologie Max-Planck -Institut f(o[z[rMolekulare Physiologie Otto-Hah n-Strasse 11,44227 Dortmund (Germany ) and Fakult(o[[wt Chemie undChemisc heBiologie Technische Universit(o[[wt Dortmund Otto-Hah n-Strasse 4a,44227 Dortmund (Germany ) E-mail :andrey .antonchi ck@mpi-dortm und.mpg.de Supportin ginformation forthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016008 07.",Non-OADS,/arxiv_data1/oa_pdf/c2/fb/ANIE-55-5290.PMC5071660.pdf
"The marginal bone levels at the mesial and distal sides of the implant were considered the primary outcome measures and obtained by one investigator at each centre, and analysed and validated by an inde- pendent person using ImageJ 1.44 (http://imagej.nih.gov/ij/) to measure the distance from the implant shoul-der to the ﬁrst visible bone contact (DIB).",OADS,/arxiv_data1/oa_pdf/59/37/JCPE-43-374.PMC5071662.pdf
Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.,OADS,/arxiv_data1/oa_pdf/a3/aa/IJC-139-322.PMC5071665.pdf
Available at: http://www.bfs.admin.ch/bfs/portal/de/index/infothek/erhebungen__quellen/blank/blank/cod/02.html 32.,Non-OADS,/arxiv_data1/oa_pdf/a3/aa/IJC-139-322.PMC5071665.pdf
"Nineteen homologous members were identi ﬁed; however, seven of them did not have transcripts in any tissueaccording to expressed sequence tag (EST) information(http://www.maizegdb.org/ ).",OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
Type IV and Type V VPPs both have a signal peptide predicted online ( http://www.cbs.dtu.,Non-OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
ZmVPP5 is expressed in multiple tissues The analysis of expression data ( http://www.maizeGDB.org ) for ZmVPP5 (GRMZM2G435818) revealed that the ZmVPP5 gene is expressed in multiple tissues.,OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
"ZmVPP5 is localized to the plasma membrane, vacuolar membrane, and nucleiTo determine the subcellular localization of the ZmVPP5protein, YFP-ZmVPP5 fusion protein was constructed.The predicted localization of ZmVPP5 is the plasma mem-brane ( http://wolfpsort.org/ ).",Non-OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
Speci ﬁc primers for ZmVPP5 and ubiquitin were designed online ( http://www.quantprime.de/ ) and are listed in Table S1.,OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
CD3-975 and CD3-1007 were bought from tair(http://www.arabidopsis.org/ ).,Non-OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
"Primers used in this study Speci ﬁc primers for qPCR were designed online ( http://www.quantprime.de/ ), and the other primers were designed using the Primer 5.0 software.",OADS,/arxiv_data1/oa_pdf/a0/dd/JIPB-58-518.PMC5071666.pdf
"We accessed the catalog of published GWAS liter- ature from the National Human Genome Research Insti- tute (NHGRI) and considered hundreds of T2DM-associated studies (http://www.genome.gov/gwastudies/, March 2014).",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"(Note: Because of this this study, the NHGRI GWAS catalog has been moved to the European Molecular Biology Laboratory-European Bioinformatics Institute [EMBL-EBI] at http://www.ebi.ac.uk/gwas, which features a new search interface and updated content.)",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"T o map genes to path- ways, we used the Kyoto Encyclopedia of Genes and Genomes (KEGG), “a collection of manually curated databases deal- ing with genomes, biological pathways, diseases, drugs, and chemical substances” [Kanehisa & Goto, 2000] and Reac- t o m e ,a“ f r e e ,o p e n - s o u r c e ,c u r a t e da n dp e e rr e v i e w e dp a t h - way database” (http://www.reactome.org/).",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"More than half of T2DM patients have signs of cardiovascular disease complications at di- agnosis (http://www.diabetes.co.uk/diabetes-complications/ heart-disease.html, July 2014) and patients with T2DM are at least two times more susceptible to myocardial infarction [Scherrer et al., 2011].",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
http://doi.org/10.1373/clinchem.2010.157016 Anderberg MR. 2014.,Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/http://dx.doi.org/10.1016/j.cell.2012.02.010 Bellanne-Chantelot C, Clauin S, Chauveau D, Collin P, Daumont M, Douillard C, Dubois-Laforgue D, Dusselier L, Gautier J, Jadoul M, Laloi-Michelin M, Genetic Epidemiology, Vol.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://linkinghub.elsevier.com/ retrieve/pii/S1471491410000973 Chan JCN, Malik V, Jia W, Kadowaki T, Y ajnik CS, Y oon K-H, Hu FB.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1001/jama.2009.726 Chen R, Corona E, Sikora M, Dudley JT, Morgan AA, Moreno-Estrada A, .",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1371/journal.pgen.1002621 C h e n gX ,S h iL ,N i eS ,W a n gF ,L iX ,X uC ,W a n gP ,Y a n gB ,L iQ ,P a nZ ,a n do t h e r s .",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.2337/db10-0185 Cho YS, Chen C-H, Hu C, Long J, Hee Ong RT, Sim X, Seielstad M. 2012.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ng.1019 C o n r a dD F ,J a k o b s s o nM ,C o o pG ,W e nX ,W a l lJ D ,R o s e n b e r gNa ,P r i t c h a r dJ K .",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
http://doi.org/10.1038/ng1911 Consortium TST 2 D. 2014.,Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/nature12828 Darabos C, Desai K, Cowper-Sallari R, Giacobini M, Graham BE, Lupien M, Moore JH.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://www.ncbi.nlm.nih.gov/pubmed/24297546 Darabos C, Leung D, Moore JH.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://www.geneticepi.org/iges-2014/ Darabos C, White MJ, Graham BE, Leung DN, Williams SM, Moore JH.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
BioData Mining 7(1):1. http://doi.org/10.1186/1756-0381-7-1 Forman D. 2009.,Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1093/hmg/ddl191 Gardner DS, Tai ES.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.2147/DMSO.S23353 Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabasi A-L. 2007.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1093/hmg/ddt399 Heckman MG, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon JA, Ross OA.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1002/mds.25600 Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Stefansson K. 2008.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ng.72 Hu T, Pan Q, Andrew AS, Langer JM, Cole MD, Tomlinson CR, Karagas MR, Moore JH.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"BioData Min 7(1):5. http://doi.org/10.1186/1756-0381-7-5 Ichihara S, Y amamoto K, Asano H, Nakatochi M, Sukegawa M, Ichihara G, Y okota M. 2013.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1161/CIRCGENETICS.111.000027 Jorde LB, Wooding SP.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1007/BF02221682 Kettunen J, Tukiainen T, Sarin A-P, Ortega-Alonso A, Tikkanen E, Lyytikainen L-P, Ripatti S. 2012.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ng.1073 Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W, Shridhar V. 2013.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1002/cncr.27706 Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
http://doi.org/10.2337/dc08-2175 Longabaugh WJR.,Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"BMC Bioinform 13:275. http://doi.org/10.1186/1471- 2105-13-275 Ma RCW, Chan JCN.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1111/nyas.12098 Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Hockett R. 2010.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1177/0091270009355161 Marigorta UM, Navarro A.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/73735 Nakagome S, Takeyama Y, Mano S, Sakisaka S, Matsui T, Kawamura S, Oota H. 2010.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
http://doi.org/10.1111/j.1469-1809.2010.00567.x Newman M. 2010.,Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ng.2742 Samuel VT, Shulman GI.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1016/j.cell.2012.02.017 Scherrer JF, Garﬁeld LD, Chrusciel T, Hauptman PJ, Carney RM, Freedland KE, Lustman PJ.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.2337/ dc11-0031 Serrano M ´A, Bogu ˜n´a M, Vespignani A.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://linkinghub.elsevier.com/retrieve/pii/S016882270900432X?showall =true Sim X, Ong RT-H, Suo C, Tay W-T, Liu J, Ng DP-K, .",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1371/journal.pgen.1001363 Sun X, Yu W, Hu C. 2014.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1371/journal.pcbi.1000662 Teo YY, Small KS, Fry AE, Wu Y, Kwiatkowski DP, Clark TG.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1002/gepi.20366 Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, Maeda S. 2008.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1038/ng.208 Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, McCarthy MI.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ng.609 Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Gerszten RE.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/nm.2307 302 Genetic Epidemiology, Vol.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"JA mM e dA s s o c 310(9):948– 959. http://doi.org/10.1001/jama.2013.168118 Y amauchi T, Hara K, Maeda S, Y asuda K, Takahashi A, Horikoshi M, Kadowaki T. 2010.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://dx.doi.org/10.1038/ ng.660Yuan J, Jin C, Qin H-D, Wang J, Sha W, Wang M, Shugart YY.",OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1371/journal.pone.0058785 Zhao D, Zhao F, Li Y, Zheng Z.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"http://doi.org/10.1007/s11886-011-0227-9 Zhou X, Menche JJ, Barabasi A-L, Sharma A.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
"Nat Commun 5:4212. http://doi.org/10.1038/ncomms5212 Genetic Epidemiology, Vol.",Non-OADS,/arxiv_data1/oa_pdf/d3/75/GEPI-40-293.PMC5071667.pdf
Available from URL: http://www.nan-byou.or.jp/entry/1356 6.,Non-OADS,/arxiv_data1/oa_pdf/d4/27/CEN3-7-158.PMC5071668.pdf
Available from URL: http://www.iryohoken.go.jp/shinryohoshu/searchMenu/doSearchInputBp 8.,Non-OADS,/arxiv_data1/oa_pdf/d4/27/CEN3-7-158.PMC5071668.pdf
Available from URL: http://www.e-stat.go.jp/SG1/estat/List.do?lid=000001127463 10.,OADS,/arxiv_data1/oa_pdf/d4/27/CEN3-7-158.PMC5071668.pdf
Available from URL: http://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken03/01.html 11.,Non-OADS,/arxiv_data1/oa_pdf/d4/27/CEN3-7-158.PMC5071668.pdf
Available from URL: http://www.mhlw.go.jp/stf/shingi/0000023522.html Supporting information Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:Figure S1.,Non-OADS,/arxiv_data1/oa_pdf/d4/27/CEN3-7-158.PMC5071668.pdf
"Treatment After a screening phase, amisulpride tablets (50 mg/ tablet) were administered orally for 8 weeks; dosing and titration were in accordance with the approvedChinese labeling (http://drugs.medlive.cn/drugref/ html/15330.shtml.",Non-OADS,/arxiv_data1/oa_pdf/dc/20/APPY-8-241.PMC5071681.pdf
"Correspondence to: Y. Li and D. HanReceived 19 October 2015; Revision received 24 February 2016; Accepted 4 March 2016Accepted manuscript online 8 March 2016; Article ﬁrst published online 28 March 2016 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/bit.25976/abstract).DOI 10.1002/bit.25976ARTICLE 2088 Biotechnology and Bioengineering, V ol.",Non-OADS,/arxiv_data1/oa_pdf/28/55/BIT-113-2088.PMC5071682.pdf
"[*]S.Seifert, Dr.K.Shoyama, Dr.D.Schmidt ,Prof.Dr.F.W(o[z[rthner Universit (o[[wtW(o[z[rzburg, Institut f(o[z[rOrganisch eChemie andCenterfor Nanosys tems Chemistry AmHublan d,97074 W(o[z[rzburg (Germa ny) E-mail :wuerthner@ch emie.uni-wuerz burg.de Supportin ginformation forthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016014 33.",Non-OADS,/arxiv_data1/oa_pdf/aa/8a/ANIE-55-6390.PMC5071686.pdf
"One ofthefirst feats ofchemistry that bore onallof science wastheestablishment ofthelawoftheconservation ofmass.Although itsur-form canbefound already inthe work ofLomonosov ,itwasputonafirmfooting bythe accurate experiments ofAntoine Lavoisier and hiswife, Marie-Anne ,shown inFigure 1inad ouble portrait[*]by[*]Prof. Dr.B.Friedrich Fritz-Haber- Institut derMax-Plan ck-Gesellscha ft Faradayweg 4–6, 14195 Berlin (Germany ) E-mail :bretislav .friedrich@ fhi-berlin.m pg.de Homepag e:http://www .fhi-berlin.m pg.de/mp/f riedrich TheORCID identifica tionnumber fortheauthor ofthisarticle canbe found under http://dx.do i.org/10.1002 /anie.201509 260.",Non-OADS,/arxiv_data1/oa_pdf/1b/3a/ANIE-55-5378.PMC5071687.pdf
2014. http://www.USRDS.ORG/ 2012/VIEW/DEFAULT.ASPX?ZOOM_HIGHLIGHT = ATLAS.,Non-OADS,/arxiv_data1/oa_pdf/25/af/CPDD-5-216.PMC5071690.pdf
1998. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/- Guidances/ucm072127.pdf.,Non-OADS,/arxiv_data1/oa_pdf/25/af/CPDD-5-216.PMC5071690.pdf
Note for guidance on the evaluation of the pharmacokinetics of medicinal prod-uctswithimpairedrenalfunction.2004.http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/25/af/CPDD-5-216.PMC5071690.pdf
2010. http://www.fda.,Non-OADS,/arxiv_data1/oa_pdf/25/af/CPDD-5-216.PMC5071690.pdf
Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094495.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e7/bd/PHAR-36-317.PMC5071694.pdf
http://dx.doi.org/10.1016/S0140-6736(15)01281-7.,OADS,/arxiv_data1/oa_pdf/e7/bd/PHAR-36-317.PMC5071694.pdf
http://poster-submission.com/ecc2015.,Non-OADS,/arxiv_data1/oa_pdf/e7/bd/PHAR-36-317.PMC5071694.pdf
Available from http://poster-submission.com/ecc2015.,Non-OADS,/arxiv_data1/oa_pdf/e7/bd/PHAR-36-317.PMC5071694.pdf
Available from http://poster-submission.com/ecc2015.,Non-OADS,/arxiv_data1/oa_pdf/e7/bd/PHAR-36-317.PMC5071694.pdf
"Available from: http://www.who.int/mediacentre/factsheets/fs311/ en/, accessed on August 11, 2015.",Non-OADS,/arxiv_data1/oa_pdf/80/9d/OBY-24-1162.PMC5071698.pdf
"Available from: http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en/,accessed on August 11, 2015.",Non-OADS,/arxiv_data1/oa_pdf/80/9d/OBY-24-1162.PMC5071698.pdf
"Dr.R.Cao Department ofChemist ry,Renmin University ofChina Beijing 100872 (China) E-mail :wenzhenlai@r uc.edu.cn ruicao@ruc.ed u.cn Prof. Dr.R.Cao School ofChemist ryandChemica lEngineering Shaanxi Normal Universi ty Xi’an 710119 (China) Dr.H.Y.Fang, H.Z.Jing College ofChemist ryandMolecu larEngineeri ng,Peking University Beijing 100871 (China) Supportin ginformation forthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2015100 01.",Non-OADS,/arxiv_data1/oa_pdf/b2/ce/ANIE-55-5457.PMC5071703.pdf
Retrieved from http://www.praat.org/ 2014.,Non-OADS,/arxiv_data1/oa_pdf/e6/0e/DEV-58-724.PMC5071706.pdf
"http://doi.org/10.1007/s10329-006-0033-y Feldman, R., & Eidelman, A. I.",OADS,/arxiv_data1/oa_pdf/e6/0e/DEV-58-724.PMC5071706.pdf
"Physiology & Behavior, 120, 203–210.http://doi.org/10.1016/j.physbeh.2013.07.003 Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.(1996).",Non-OADS,/arxiv_data1/oa_pdf/e6/0e/DEV-58-724.PMC5071706.pdf
Theaccountable average rates vary from 15 EUR to 100 EUR per hour depending on the instrument type and mode of operation and were published by the DFG in2011 (http://www.dfg.de/formulare/55_04/55_04_de.pdf).,OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
Readers who are inter-ested in further information on this topic can visit theGerBI wikipage: http://www.germanbioimaging.org/wiki/index.php/Manufacturers.,Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"We also suggest to con- sult a paper from colleagues at Friedrich Miescher Institut for Biomedical Research in Basel (Switzer-land), who developed a complex user management sys-tem for their facilities: http://www.imaging-git.com/science/protocols/enhancing-efﬁciency-resource-use.",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"A convenient and simple way to ensure thatusers have minimum background knowledge are man-datory online classes and tests, like those provided bythe Australian Microscopy and Microanalysis ResearchFacility (AMMRF; http://li155-94.members.linode.com/myscope/).",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"Such a universal standard is given by the Bio-Formats project (Open Microscopy Environment (OME), http://www.openmicroscopy.org/site/products/ bio-formats) which addresses most of the commonlyused image ﬁle formats.",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
List of selected software tools and respective online sources Tool URL [1] NITRC http://www.nitrc.org / [2] FSL http://fsl.fmrib.ox.ac.uk/fsl/fslwiki / [3] “I do Imaging” http://www.idoimaging.com / [4] AMIRA http://www.fei.com/software/amira-3d-for-life-sciences / [5] Arivis http://vision.arivis.com/en / [6] Imaris http://www.bitplane.com/imaris [7] Image-Pro Plus http://www.mediacy.com / [8] Leica LAS http://www.leica-microsystems.com/products/microscope-soft ware/software-for-materials-sciences/details/product/leica-las-image-analysis / [9] MetaMorph http://www.moleculardevices.com/systems/metamorph-research-imaging[10] NIS-Elements http://www.nikoninstruments.com/en_DE/Products/Software/ NIS-Elements-Advanced-Research/NIS-Elements-Viewer [11] SlideBook https://www.intelligent-imaging.com/slidebook[12] Velocity 3D http://www.perkinelmer.com/pages/020/cellularimaging/products/volocity.xhtml[13] Zeiss Zen http://www.zeiss.com/microscopy/en_de/products/microscope-software/zen.html[14] ImageJ http://imagej.nih.gov/ij/index.html[15] VTK http://www.vtk.org / [16] Fiji http://ﬁji.sc/Fiji [17] CellProﬁler http://www.cellproﬁler.org / [18] Ilastik http://ilastik.org / [19] KNIME https://www.knime.org / [20] OMERO http://www.openmicroscopy.org/site[21] BISQUE http://bioimage.ucsb.edu/bisque[22] FARSight http://farsight-toolkit.ee.uh.edu/wiki/Main_Page[23] BioImageXD http://www.bioimagexd.net / [24] Icy http://icy.bioimageanalysis.org / [25] Huygens - Deconvolution http://www.svi.nl/HomePage[26] AutoQuant - Deconvolution http://www.mediacy.com/index.aspx?page 5Home [27] ImageJ - Deconvolution http://bigwww.epﬂ.ch/algorithms/deconvolutionlab/#soft476 FERRANDO-MAY ET AL.,Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"Ideally, this is part of the institutional policy (e.g., http://www.embl.de/ services/library/open-access-information/BMC_pre_pay_ scheme1/IP-63—EMBL-Publication-Policy.pdf).",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"by EMBO (www.embo.org), the Royal Microscopy Society (RMS; www.rms.org.uk)or GerBI (http://www.germanbioimaging.org/wiki/ index.php/Calendar:Courses).",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"The GerBI Job Shadowing pro-gram, for example, promotes visits of CF staff members to other CFs to learn about their operation procedures or teaching activities as well as about speciﬁc imaging or image processing techniques (http://www.german- bioimaging.org/wiki/index.php/GerBI_Educational_Pro gramme).",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"GerBI has advocated the need for permanent positions for facility leaders (http://www.germanbioi- maging.org/wiki/images/c/ca/ IF-Professur-Positionspap- ier.pdf, in German language only).",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
"List of Master study programs worldwide with a focus on bioimaging University and type of program URL Boston University: Master of Science in Bioimaging http://www.bumc.bu.edu/mbi/ ETH Z €urich: Master in Biomedical Engineering, Track Bioimaginghttp://www.master-biomed.ethz.ch/education/focus/Bioimaging2 Universities Turku and Abo Akademi: Biomedical Imaging http://www.bioimaging.ﬁ/program/ University of Bordeaux: Master Biologie sant /C19e, sp /C19ecialit /C19e Bioimageriehttp://www.u-bordeaux.fr/formation/PRMASB_171/master-biologie- sante-specialite-bioimagerie Imperial College London: Master in Bioimaging Sciences http://www3.imperial.ac.uk/chemicalbiology/mresbioimagingParis Institute of Technology: Master BioMedical Engineering, Track BioImaginghttp://www.bme-paris.com/en/article/26 University of Iowa: Master Biomedical Engineering, Bioimag- ing Trackhttp://www.engineering.uiowa.edu/bme/undergraduate-program/ bme-tracks/bioimaging-track-bme University of California Davis: Master Biomedical Engineer- ing, Biomedical Imaginghttp://bme.ucdavis.edu/graduate/research/biomedical-imaging/ University of California Davis: Master Biomedical Engineer- ing, Biophotonics and Bioimaginghttp://bme.ucdavis.edu/graduate/student-info/designated-emphasis- in-biophotonics/ University of Singapure: CBIS BioImaging Training Programmehttp://cbis.nus.edu.sg/graduate-studies/ University College Dublin: MSc Imaging and Microscopy http://www.ucd.ie/graduatestudies/courseﬁnder/taughtprogrammes/ msc-imaging-and-microscopy / University of Amsterdam: MSc Biomedical Sciences, Track Cell Biology and Advanced Microscopyhttp://gss.uva.nl/masters-programmes/content18/study-programme/ cell-biology-and-advanced-microscopy.html University of Sydney: Master of Science in Microscopy and Microanalysishttp://sydney.edu.au/handbooks/archive/2012/science/postgraduate/ coursework/microscopy_microanalysis.shtml478 FERRANDO-MAY ET AL.",Non-OADS,/arxiv_data1/oa_pdf/31/cd/JEMT-79-463.PMC5071710.pdf
Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/App rovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM350239.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5e/19/ACEM-23-466.PMC5071715.pdf
http://seer.cancer.gov/statfacts/html/colorect.html.,Non-OADS,/arxiv_data1/oa_pdf/92/1b/IJC-139-177.PMC5071720.pdf
Erbitux (cetuximab) prescribing information 2013.Available at: http://www.drugs.com/pro/erbitux.html.,Non-OADS,/arxiv_data1/oa_pdf/92/1b/IJC-139-177.PMC5071720.pdf
http://www.clinicaltrials.gov/ct2/show/NCT01611857?term 5NCT01611857&rank 51.,Non-OADS,/arxiv_data1/oa_pdf/92/1b/IJC-139-177.PMC5071720.pdf
http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/92/1b/IJC-139-177.PMC5071720.pdf
"Recruitment of adult ADHD patients was conducted at three sites within an international multi-center persistent ADHD collaboration (IMpACT, http://www.impactadhdgenomics.com): Germany, Norway, and Spain.",OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
"For gene-set pathway analysis, we exam-ined structural categories of gene ontology (GO, http://geneontology.org), with respect to cellular function, biologicalprocess and cellular compartments.",OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
"We assembled a list of previously reported candidate GWA loci associated with aggressive behavior bysystematic literature search the catalog of published genome-wide association studies provided by National Human GenomeResearch Institute (NHGRI) (https://www.genome.gov/26525384), using key words of “aggression,” “anger,” “violence,” as well as “conduct disorder” and “antisocial personality disorder.” Eachidentiﬁed candidate GWA locus was then looked up in meta-analyzed aADHD sample.",OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
"As determined inthe TRANSFAC database implemented in the SNPinfo serverof the National Institute of Environmental Health Sciences(http://snpinfo.niehs.nih.gov), rs34588147 and rs35665773 (GWAP-values of 3.59E-06 and 3.25E-06, respectively, Supplementary Table SI) are transcription factor binding sites (TFBS) (Fig.",OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
"Notably, differential expressionofNTM between two major brain regions linked to aggression subtypes—prefrontal cortex and amygdala—was observed inearly prenatal stage of human brain development ( P¼0.015, http://www.brainspan.org).",Non-OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
The dataset used for the analyses described in thismanuscript were obtained from the database of Genotypes andPhenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gapthrough dbGaP accession number #20726-2.,OADS,/arxiv_data1/oa_pdf/ed/f6/AJMG-171-733.PMC5071721.pdf
"18In expression quantitative trait loci (eQTL) analysisusing the Gtex Portal (http://www.gtexportal.org/home/), both rs1126671 and rs1800759 have beenfound to have a signiﬁcant correlation to the tran-script levels of ADH4 .",OADS,/arxiv_data1/oa_pdf/e8/1e/HEAD-56-835.PMC5071723.pdf
"With our sample size and a minor allele frequencyof 0.33 (http://www.ncbi.nlm.nih.gov/projects/SNP/),we are able to detect true odds ratios (OR) for CH below 0.64 or above 1.51, respectively.",Non-OADS,/arxiv_data1/oa_pdf/e8/1e/HEAD-56-835.PMC5071723.pdf
Available at: http://www.cochrane-handbook.org Last accessed 1 January 2016.,OADS,/arxiv_data1/oa_pdf/bd/bf/DME-33-1035.PMC5071725.pdf
"9 TheReportsofTheSpecialCommitteefor theSafetyofProteinHydrolysatesin Cosmetics,bytheJapaneseSocietyof Allergology.Availableat:http://www.jsaweb.jp/modules/news_topics/index.php?page=article&storyid=114(lastaccessed26December 2014).",Non-OADS,/arxiv_data1/oa_pdf/e2/0d/COD-74-346.PMC5071728.pdf
"This study is registered at https://clinicaltrials.gov/ct2/show/ NCT02415777.Review criteria We gathered the information for the review via research database (such as PubMed, Ovid, Medline) and search engine (such as Google©).",OADS,/arxiv_data1/oa_pdf/66/39/IJCP-70-302.PMC5071730.pdf
"The dates ofpatients’ deaths were obtained from their medical records or from the Social Security Death Index (available at: http://ssdi.genealogy.rootsweb.com/, accessed March,2015).",OADS,/arxiv_data1/oa_pdf/6c/9a/CNCR-122-1836.PMC5071733.pdf
Available at: http://www.unodc.org/docs/treatment/ overdose.pdf (accessed 30 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
(Archieved at http://www.webcitation.org/6fXHKy7Iz on 24 February 2016.),Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
Available at: http://apps.who.int/iris/ bitstream/10665/137462/1/9789241548816_eng.pdf?,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
(Archieved athttp://www.webcitation.org/6fXI8tymn on 24 February 2016.),Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
Available at: https://theconversation.com/should-naloxone-be-used-to-reduce-opioid-overdoses-19896#comment_262515 (accessed 28 November 2013).,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
(Archieved at http://www.webcitation.org/6fXIOH8yA on 24 February 2016.),Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
Available at: http://www.emcdda.europa.eu/publications/emcdda-pa-pers/naloxone-effectiveness (accessed 1 June 2015 ).,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
Availableat: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76f7eee1-d524-43a4-a868-ffa9f29638a6.,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
Available at: http://www.atoda.org.au/wp- content/uploads/Summary-of- Interim-Findings-summary-for -release-2.pdf (accessed 1 April 2015) (Archieved at http://www.webcitation.org/6fXJbYN7kon 24 February 2016).,Non-OADS,/arxiv_data1/oa_pdf/41/b2/ADD-111-1177.PMC5071734.pdf
NOTES ahttp://www.tbi.univie.ac.at/RNA/ bhttp://nhjy.hzau.edu.cn/kech/swxxx/jakj/dianzi/Bioinf4/ miRNA/miRNA1.htm chttp://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form ACKNOWLEDGMENTS Adeline Berger received a PhD fellowship from Association Française contre les Myopathies (AFM) and Séver- ine Maire is currently supported by a PhD fellowship from DIM-Biothérapies.,Non-OADS,/arxiv_data1/oa_pdf/34/52/WRNA-7-487.PMC5071737.pdf
http://www.ema.europa.eu/docs/en_ GB/document_libr ary/EPAR_-_Prod- uct_Information/human/002445/WC500140401.pdf.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Byetta® (exenatide) Summary of Product Characteristics.http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Prod- uct_Information/human/000698/WC500051845.pdf.,OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Victoza® (liraglutide) Summary of Product Characteristics.http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Prod- uct_Information/human/001026/WC500050017.pdf.,OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Esperzan® (albiglutide) Summary of Product Characteristics.http://www.ema.eur opa.eu/docs/en_ GB/document_library/EPAR_-_Prod- uct_Information/human/002735/WC500165117.pdf.,OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
"Brief- ing document: Liraglutide injection, 3 mg. http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAd-visoryCommittee/UCM413317.pdf.Last accessed 3 February 2015.",Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Avail-able from: http://clinicaltrials.gov/ show/NCT01147250.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Available from: http://clinicaltrials.gov/show/ NCT01179048.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Avail- able from: http://clinicaltrials.gov/ show/NCT01144338.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
Available from:https://clinicaltrials.gov/show/ NCT01768559.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
http://bidocs.boehringer-ingelheim.,Non-OADS,/arxiv_data1/oa_pdf/fc/e3/DMRR-32-497.PMC5071744.pdf
"Statistics were run on S IGMASTATsoftware (Systat Soft- ware Inc., San Jose, CA) for Windows Version 11.0 and onhttp://vassarstats.net/fisher2x3.html.",OADS,/arxiv_data1/oa_pdf/a1/4d/TAN-87-356.PMC5071754.pdf
http://www.who.int/ growthref/who2007_bmi_for_age/en/index.html.,OADS,/arxiv_data1/oa_pdf/f7/35/ERV-24-366.PMC5071769.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/94/99/euv344.PMC5072134.pdf
http://www.inahta.org/HTA .,Non-OADS,/arxiv_data1/oa_pdf/94/99/euv344.PMC5072134.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/12/euv426.PMC5072135.pdf
"All analyses were performed with R for windows version 3.1 (The R foundation statistical computing,http://cran.r-project.org ).",OADS,/arxiv_data1/oa_pdf/37/12/euv426.PMC5072135.pdf
"The  patient  was  then  transferred  to  the  SICU  intubated  where resuscitation was continued  with  massive  transfusion  protocol, http://dx.doi.org/10.1016/j.ijscr.2016.10.022 2210-2612/© 2016  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/4c/a8/main.PMC5072138.pdf
This  is  an  open access article under the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c7/44/main.PMC5072139.pdf
No  ascites  were  observed  and based  on  the  ﬁndings  a  decision  was  made  for  total  excision  of http://dx.doi.org/10.1016/j.ijscr.2016.10.011 2210-2612/© 2016  The  Authors.,OADS,/arxiv_data1/oa_pdf/c7/44/main.PMC5072139.pdf
This  is  an  open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/36/cb/main.PMC5072140.pdf
"By  means of  histopathologic  examination  of  the  explanted  aneurysm,  the http://dx.doi.org/10.1016/j.ijscr.2016.10.008 2210-2612/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/36/cb/main.PMC5072140.pdf
"(2016), http://dx.doi.org/10.1016/j.ijsu.2016.08.014  [Epub  ahead  of print] pii:  S1743-9191(16)30303-X.",Non-OADS,/arxiv_data1/oa_pdf/36/cb/main.PMC5072140.pdf
This  is  an  open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a1/a4/main.PMC5072142.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.10.005 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/a4/main.PMC5072142.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor http://dx.doi.org/10.1016/j.gore.2016.10.003 2352-5789/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
"BMC Cancer 14, 784. http://dx.doi.org/10.1186/1471-2407-14-784 .",Non-OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
"40 (4), 373. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
"Case Rep. 6, 22–24.http://dx.doi.org/10.1016/j.gynor.2013.07.003 .21 L.B.",OADS,/arxiv_data1/oa_pdf/53/f4/main.PMC5072143.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/10/72/main.PMC5072144.pdf
